https://lymphoma-stg.clarovantdigital.com/library/chemotherapy-free-management-of-follicular-and-marginal-zone-lymphoma/2024-01-15T22:57:58+00:00https://lymphoma-stg.clarovantdigital.com/library/a-comprehensive-retrospective-cohort-study-of-the-journey-of-b-cell-lymphoma-in-taiwan/2024-01-15T22:56:57+00:00https://lymphoma-stg.clarovantdigital.com/library/post-traumatic-stress-symptoms-seen-in-pediatric-hodgkin-lymphoma-survivors/2024-01-15T22:55:46+00:00https://lymphoma-stg.clarovantdigital.com/library/loncastuximab-tesirine-in-relapsed-or-refractory-dlbcl-results-from-a-phase-ii-trial/2024-01-15T22:54:41+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-and-outcomes-of-older-patients-with-mantle-cell-lymphoma-in-an-asian-population/2024-01-15T22:53:33+00:00https://lymphoma-stg.clarovantdigital.com/library/antibody-therapies-for-large-b-cell-lymphoma/2024-01-15T22:52:04+00:00https://lymphoma-stg.clarovantdigital.com/library/age-is-the-most-important-predictor-of-survival-in-diffuse-large-b-cell-lymphoma-patients-achieving-event-free-survival-at-24-months-a-swedish-population-based-study/2024-01-15T22:50:57+00:00https://lymphoma-stg.clarovantdigital.com/library/myocardial-infarction-in-diffuse-large-b-cell-lymphoma-patients-a-population-based-matched-cohort-study/2024-01-15T22:50:00+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-plus-brentuximab-vedotin-shows-efficacy-for-patients-with-mediastinal-gray-zone-lymphoma/2026-01-15T13:55:32+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-organ-function-based-clinical-trial-eligibility-criteria-in-patients-with-diffuse-large-b-cell-lymphoma-who-gets-left-behind/2022-02-03T20:01:52+00:00https://lymphoma-stg.clarovantdigital.com/library/data-from-the-captivate-study-umrd-cohort-suggest-role-for-fixed-duration-therapy-in-cll-sll/2026-01-14T21:31:48+00:00https://lymphoma-stg.clarovantdigital.com/library/cure-rate-in-the-elderly-patients-with-diffuse-large-b-cell-lymphoma-deteriorates-after-the-age-of-80-results-from-a-single-center-survey/2022-02-03T20:01:53+00:00https://lymphoma-stg.clarovantdigital.com/library/cytokine-release-syndrome-and-neurological-event-costs-in-lisocabtagene-maraleucel-treated-patients-in-the-transcend-nhl-001-trial/2024-01-29T21:24:37+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-a-novel-bivalent-cd20-targeting-t-cell-engaging-bispecific-antibody-induces-durable-complete-remissions-in-relapsed-or-refractory-b-cell-lymphoma-a-phase-i-trial/2024-01-29T21:14:09+00:00https://lymphoma-stg.clarovantdigital.com/library/subsequent-malignant-neoplasms-among-children-with-hodgkin-lymphoma-a-report-from-the-childrens-oncology-group/2024-01-29T21:07:37+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-and-budget-impact-analyses-of-tisagenlecleucel-in-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-from-singapores-private-insurance-payers-perspective/2025-12-15T22:18:42+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiovascular-disease-risks-in-younger-versus-older-adult-b-cell-nonhodgkins-lymphoma-survivors/2024-01-15T23:00:46+00:00https://lymphoma-stg.clarovantdigital.com/library/preliminary-results-from-phase-i-studies-of-cd20-x-cd3-bispecific-antibodies-in-r-r-b-cell-non-hodgkin-lymphoma/2026-01-14T19:46:10+00:00https://lymphoma-stg.clarovantdigital.com/library/cosmic-chemotherapy-plus-ofatumumab-at-standard-or-mega-dose-in-chronic-lymphocytic-leukaemia-a-phase-ii-randomised-study/2024-01-15T21:55:06+00:00https://lymphoma-stg.clarovantdigital.com/library/chronos-3-copanlisib-plus-rituximab-in-patients-with-relapsed-indolent-nonhodgkin-lymphoma/2026-01-06T21:12:52+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-oncology-trial-results-reporting-over-a-10-year-period/2024-01-15T21:48:13+00:00https://lymphoma-stg.clarovantdigital.com/library/cd24-contributes-to-treatment-effect-in-abc-dlbcl-patients-with-r-chop-resistance/2024-01-15T21:41:15+00:00https://lymphoma-stg.clarovantdigital.com/library/os-and-time-to-richter-transformation-linked-with-age-in-adolescent-and-young-adults-with-cll/2024-01-15T21:40:18+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-single-center-data-for-lenalidomide-plus-rituximab-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-and-transformed-follicular-lymphoma/2026-01-15T13:55:12+00:00https://lymphoma-stg.clarovantdigital.com/library/single-hit-tp53-associated-with-prolonged-os-and-pfs-vs-multi-hit-tp53-in-ibrutinib-treated-cll/2024-01-15T21:35:46+00:00https://lymphoma-stg.clarovantdigital.com/library/study-suggests-unsatisfactory-survival-in-elderly-patients-after-attenuated-therapy-for-mantle-cell-lymphoma/2024-01-15T21:28:04+00:00https://lymphoma-stg.clarovantdigital.com/library/cirmtuzumab-ibrutinib-therapy-well-tolerated-in-both-cll-mcl/2024-01-15T21:26:32+00:00https://lymphoma-stg.clarovantdigital.com/library/atypical-covid-19-dynamics-in-a-patient-with-mantle-cell-lymphoma-exposed-to-rituximab/2024-01-15T21:24:14+00:00https://lymphoma-stg.clarovantdigital.com/library/first-results-of-a-head-to-head-trial-of-acalabrutinib-versus-ibrutinib-in-patients-with-high-risk-cll/2024-01-15T21:23:10+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-tisagenlecleucel-tisa-cel-in-adult-patients-pts-with-relapsed-refractory-follicular-lymphoma-r-r-fl-primary-analysis-of-the-phase-2-elara-trial/2024-01-15T21:21:40+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-car-t-cell-therapy-in-r-r-large-b-cell-lymphoma-demonstrates-efficacy-signals/2024-01-15T21:18:54+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-viral-hepatitis-hiv-infection-and-non-hodgkin-lymphomas-in-west-africa-a-case-control-study/2024-01-15T21:15:49+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-plus-rituximab-continues-to-improve-pfs-with-manageable-safety-in-lymphoma-subtypes/2026-01-15T13:54:37+00:00https://lymphoma-stg.clarovantdigital.com/library/maintenance-with-rituximab-for-mcl-prolongs-time-to-next-treatment/2024-01-15T21:11:18+00:00https://lymphoma-stg.clarovantdigital.com/library/relapsed-refractory-follicular-lymphoma-car-t-cell-therapy-shows-promise/2024-01-15T21:09:18+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-pola-rituximab-r-lenalidomide-len-in-patients-pts-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-primary-analysis-of-a-phase-1b-2-trial/2026-01-15T13:54:08+00:00https://lymphoma-stg.clarovantdigital.com/library/impaired-humoral-response-in-lymphoma-patients-surviving-the-acute-phase-of-covid-19/2024-01-15T20:48:47+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-disease-treatment-on-the-outcome-of-patients-with-chronic-lymphocytic-leukemia-cll-with-covid-19-a-multicenter-study-on-behalf-of-gellc/2024-01-15T20:08:40+00:00https://lymphoma-stg.clarovantdigital.com/library/multicenter-retrospective-analysis-of-risk-factors-for-mortality-of-covid-19-infection-in-patients-with-lymphoma/2024-01-15T20:05:30+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-spectrum-of-infections-among-hiv-aids-patients-with-lymphoma-during-chemotherapy/2025-12-15T19:14:56+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-venetoclax-for-first-line-treatment-of-chronic-lymphocytic-leukemia-a-nonrandomized-phase-2-trial-2/2024-01-15T20:02:43+00:00https://lymphoma-stg.clarovantdigital.com/library/chemotherapy-followed-by-autologous-stem-cell-transplantation-shows-promise-as-first-line-treatment-for-t-cell-non-hodgkin-lymphoma/2024-01-15T20:01:18+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-rituximab-in-patients-with-diffuse-large-b-cell-lymphoma-in-malawi-a-prospective-single-arm-non-randomised-phase-1-2-clinical-trial/2024-01-15T19:59:57+00:00https://lymphoma-stg.clarovantdigital.com/library/copanlisib-regimen-improves-outcomes-in-pretreated-follicular-marginal-zone-lymphoma/2023-12-18T22:29:38+00:00https://lymphoma-stg.clarovantdigital.com/library/updates-in-the-treatment-of-peripheral-t-cell-lymphomas/2025-12-15T19:46:08+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-study-of-naratuximab-emtansine-plus-rituximab-in-diffuse-large-b-cell-lymphoma/2023-12-18T22:13:19+00:00https://lymphoma-stg.clarovantdigital.com/library/first-interim-analysis-of-alpine-study-results-of-a-phase-3-randomized-study-of-zanubrutinib-vs-ibrutinib-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/2025-03-03T21:06:38+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-zanubrutinib-versus-rituximab-based-chemoimmunotherapy-in-waldenstrom-macroglobulinemia-matching-adjusted-indirect-comparisons/2023-12-18T22:08:44+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-monotherapy-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-34-month-follow-up-results/2023-12-18T22:03:57+00:00https://lymphoma-stg.clarovantdigital.com/library/how-does-covid-19-impact-patients-with-lymphoma-receiving-b-cell-depleting-immunotherapy/2023-12-18T22:02:08+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-for-the-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma/2023-12-18T22:00:29+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-consolidation-after-autologous-stem-cells-transplantation-for-hodgkin-lymphoma-a-real-life-experience-by-fondazione-italiana-linfomi-fil/2023-12-18T21:57:28+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-challenge-cll-in-adolescents-and-young-adults/2023-12-18T21:56:22+00:00https://lymphoma-stg.clarovantdigital.com/library/progression-free-survival-at-24-months-as-a-landmark-after-autologous-stem-cell-transplant-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2023-12-18T21:52:32+00:00https://lymphoma-stg.clarovantdigital.com/library/durable-responses-seen-with-tafasitamab-lenalidomide-combo-in-dlbcl/2023-12-18T21:51:19+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-for-patients-with-mcl-reveals-discrepancy-between-actual-care-and-clinical-trial-recommendations/2023-12-18T21:49:39+00:00https://lymphoma-stg.clarovantdigital.com/library/celltrion-releases-first-real-world-data-for-its-rituximab-biosimilar-in-dlbcl/2023-12-18T21:48:38+00:00https://lymphoma-stg.clarovantdigital.com/library/matrix-provides-excellent-long-lasting-survival-in-primary-cns-lymphoma/2023-12-18T21:47:15+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-results-of-a-phase-2-study-from-geltamo-investigating-the-combination-of-ibrutinib-with-r-gemox-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2023-12-18T21:45:56+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-plus-obinutuzumab-prolongs-pfs-not-os-in-chronic-lymphocytic-leukemia/2026-01-14T21:31:07+00:00https://lymphoma-stg.clarovantdigital.com/library/epigenetics-in-the-pathogenesis-and-treatment-of-cutaneous-t-cell-lymphoma/2023-12-18T21:32:26+00:00https://lymphoma-stg.clarovantdigital.com/library/what-is-the-optimal-frontline-immunochemotherapy-for-primary-mediastinal-b-cell-lymphoma/2026-01-15T16:45:37+00:00https://lymphoma-stg.clarovantdigital.com/library/physical-activity-during-and-after-haematological-cancer-treatment-a-cross-sectional-survey-of-haematology-healthcare-professionals-in-the-united-kingdom/2023-12-18T21:27:25+00:00https://lymphoma-stg.clarovantdigital.com/library/effect-of-time-to-relapse-on-overall-survival-os-in-mantle-cell-lymphoma-mcl-patients-pts-following-frontline-high-dose-therapy-and-autologous-hematopoietic-cell-transplantation-autohct/2023-12-18T21:25:32+00:00https://lymphoma-stg.clarovantdigital.com/library/toxicities-of-high-dose-chemotherapy-and-autologous-hematopoietic-cell-transplantation-in-older-patients-with-lymphoma/2025-12-19T15:18:48+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-trial-of-pembrolizumab-plus-gemcitabine-vinorelbine-and-liposomal-doxorubicin-as-second-line-therapy-for-relapsed-or-refractory-classical-hodgkin-lymphoma/2023-12-18T20:56:27+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-iii-echelon-1-study-updated-results-of-brentuximab-vedotin-chemotherapy-for-untreated-chl/2023-12-18T20:54:34+00:00https://lymphoma-stg.clarovantdigital.com/library/lymphoma-hub-satellite-symposium-2021-summary-and-roundtable-discussion/2023-12-18T20:52:13+00:00https://lymphoma-stg.clarovantdigital.com/library/fertility-analysis-in-male-patients-long-surviving-by-hodgkin-lymphoma/2023-12-18T20:49:34+00:00https://lymphoma-stg.clarovantdigital.com/library/current-progress-in-investigating-mature-t-and-nk-cell-lymphoma-gene-aberrations-by-next-generation-sequencing-ngs/2023-12-18T20:09:44+00:00https://lymphoma-stg.clarovantdigital.com/library/feasibility-of-combining-the-phosphatidylinositol-3-kinase-inhibitor-copanlisib-with-rituximab-based-immunochemotherapy-in-patients-with-relapsed-indolent-b-cell-lymphoma/2023-12-18T20:07:09+00:00https://lymphoma-stg.clarovantdigital.com/library/the-prove-study-us-real-world-experience-with-chlormethine-mechlorethamine-gel-in-combination-with-other-therapies-for-patients-with-mycosis-fungoides-cutaneous-t-cell-lymphoma/2023-12-18T20:03:45+00:00https://lymphoma-stg.clarovantdigital.com/library/evolving-therapeutic-landscape-in-follicular-lymphoma-a-look-at-emerging-and-investigational-therapies/2026-01-14T19:45:44+00:00https://lymphoma-stg.clarovantdigital.com/library/a-pet-adapted-approach-for-the-treatment-of-early-stage-bulky-classic-hodgkin-lymphoma/2023-12-18T19:59:17+00:00https://lymphoma-stg.clarovantdigital.com/library/axi-cel-provides-durable-responses-in-higher-risk-follicular-lymphoma-and-mzl-regardless-of-pod24-status/2023-12-18T19:58:00+00:00https://lymphoma-stg.clarovantdigital.com/library/monitoring-of-circulating-tumor-dna-improves-early-relapse-detection-after-axicabtagene-ciloleucel-infusion-in-large-b-cell-lymphoma-results-of-a-prospective-multi-institutional-trial/2023-12-18T19:56:46+00:00https://lymphoma-stg.clarovantdigital.com/library/how-do-cell-of-origin-and-molecular-features-influence-outcomes-in-r-r-dlbcl/2023-12-18T19:54:49+00:00https://lymphoma-stg.clarovantdigital.com/library/bacterial-infection-and-non-hodgkin-b-cell-lymphoma-interactions-between-pathogen-host-and-the-tumor-environment/2023-12-18T19:47:35+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-related-to-fdg-pet-ct-response-in-patients-with-hodgkin-lymphoma-treated-with-brentuximab-vedotin-at-relapse-or-consolidation/2024-04-04T18:39:27+00:00https://lymphoma-stg.clarovantdigital.com/library/identification-of-key-mutations-in-central-nervous-diffuse-large-b-cell-lymphoma-dlbcl-by-comprehensive-analysis-between-sequencing-and-tcga-database/2023-12-18T19:43:15+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-with-fixed-duration-venetoclax-obinutuzumab-for-previously-untreated-chronic-lymphocytic-leukemia-results-from-the-randomized-phase-3-cll14-trial/2023-12-18T19:42:02+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-and-associated-risk-factors-for-neutropenia-with-venetoclax-and-obinutuzumab-in-the-treatment-of-chronic-lymphocytic-leukemia/2023-12-18T19:40:42+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-chimeric-antigen-receptor-t-cell-therapy-for-b-cell-non-hodgkin-lymphoma/2023-12-18T19:39:17+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-ibrutinib-venetoclax-elicits-durable-responses-in-cll-with-undetectable-mrd/2026-01-14T21:30:30+00:00https://lymphoma-stg.clarovantdigital.com/library/the-mutational-profile-of-immune-surveillance-genes-in-diagnostic-and-refractory-relapsed-dlbcls/2023-12-18T19:33:40+00:00https://lymphoma-stg.clarovantdigital.com/library/resolution-of-one-year-persisting-covid-19-pneumonia-and-development-of-immune-thrombocytopenia-in-a-follicular-lymphoma-patient-with-preceding-rituximab-maintenance-therapy-a-follow-up-report-and-li/2023-12-18T19:31:44+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-among-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-treated-with-single-agent-selinexor-in-the-sadal-study/2023-12-18T19:30:15+00:00https://lymphoma-stg.clarovantdigital.com/library/progress-in-molecular-feature-of-smoldering-mantle-cell-lymphoma/2023-12-18T19:26:48+00:00https://lymphoma-stg.clarovantdigital.com/library/how-have-radiotherapy-fractionation-schemes-evolved-for-the-treatment-of-indolent-lymphomas/2025-05-27T12:16:15+00:00https://lymphoma-stg.clarovantdigital.com/library/temporary-cessation-of-ibrutinib-results-in-reduced-grade-3-4-infections-and-durable-remissions-interim-analysis-of-an-on-off-repeat-phase-1b-2-study-in-patients-with-chronic-lymphocytic-leukemia/2023-12-18T19:24:01+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-six-versus-eight-cycles-of-standard-regimen-in-patients-with-diffuse-large-b-cell-lymphoma-propensity-score-matching-analysis/2023-12-18T19:22:29+00:00https://lymphoma-stg.clarovantdigital.com/library/btk-inhibitors-in-chronic-lymphocytic-leukemia-biological-activity-and-immune-effects/2025-04-14T21:11:33+00:00https://lymphoma-stg.clarovantdigital.com/library/hiv-associated-burkitt-lymphoma-outcomes-from-a-us-uk-collaborative-analysis/2023-12-18T19:20:33+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-following-myocardial-infarction-in-young-adult-survivors-of-hodgkin-lymphoma-the-young-mi-registry/2023-12-18T19:15:15+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-plus-chemotherapy-compared-with-rituximab-plus-chemotherapy-in-previously-untreated-italian-patients-with-advanced-follicular-lymphoma-at-intermediate-high-risk-a-cost-effectiveness-anal/2023-12-18T19:13:32+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-mogamulizumab-by-patient-baseline-blood-tumour-burden-a-post-hoc-analysis-of-the-mavoric-trial/2023-12-18T19:12:01+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnostic-features-of-nodular-lymphocyte-predominant-hodgkin-lymphoma/2023-12-18T19:07:43+00:00https://lymphoma-stg.clarovantdigital.com/library/current-situation-of-proton-therapy-for-hodgkin-lymphoma-from-expectations-to-evidence/2023-12-18T19:02:25+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-a-dna-oligonucleotide-therapy-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2023-12-18T19:00:36+00:00https://lymphoma-stg.clarovantdigital.com/library/real-time-remote-symptom-monitoring-during-chemotherapy-for-cancer-european-multicentre-randomised-controlled-trial-esmart/2023-12-18T18:58:38+00:00https://lymphoma-stg.clarovantdigital.com/library/ivac-with-or-without-rituximab-for-relapsed-or-refractory-b-cell-non-hodgkin-lymphomas-real-world-experience-in-the-modern-era/2023-12-18T18:56:49+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-versus-ibrutinib-in-previously-treated-chronic-lymphocytic-leukemia-results-of-the-first-randomized-phase-iii-trial/2023-12-18T18:54:07+00:00https://lymphoma-stg.clarovantdigital.com/library/significance-of-initial-interim-and-end-of-therapy-18f-fdg-pet-ct-for-predicting-transformation-risk-in-follicular-lymphoma/2023-12-18T18:52:54+00:00https://lymphoma-stg.clarovantdigital.com/library/prediction-and-characterization-of-diffuse-large-bcell-lymphoma-cell-of-origin-subtypes-using-targeted-sequencing/2023-12-18T18:51:56+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-of-ibrutinib-in-classic-and-variant-hairy-cell-leukemia/2023-12-18T18:48:37+00:00https://lymphoma-stg.clarovantdigital.com/library/early-relapse-in-first-line-follicular-lymphoma-a-review-of-the-clinical-implications-and-available-mitigation-and-management-strategies/2023-12-18T18:44:09+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-in-combination-with-standard-chemotherapy-for-pediatric-patients-with-newly-diagnosed-alk-alcl/2023-12-18T18:42:35+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-best-supportive-care-chop-or-r-chop-for-treatment-of-diffuse-large-b-cell-lymphoma-in-malawi-a-cost-effectiveness-analysis/2023-12-18T18:38:16+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-r-chop-dose-intensity-on-survival-outcomes-in-diffuse-large-b-cell-lymphoma-a-systematic-review/2023-12-18T18:30:11+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-prophylactic-high-dose-mtx-in-high-risk-dlbcl-a-treatment-intent-based-analysis/2023-12-18T18:28:57+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-central-nervous-system-lymphoma-may-be-treated-by-methotrexate-outside-clinical-trials/2023-12-18T18:26:54+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-among-patients-with-mantle-cell-lymphoma-and-comparison-of-healthcare-resource-utilization-and-costs-among-relapsed-refractory-patients-treated-with-ibrutinib-or-chemoimmunotherapy/2023-12-18T18:21:32+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-diffuse-large-b-cell-lymphoma-of-the-urinary-tract-a-population-based-analysis/2023-12-18T18:19:50+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-venetoclax-plus-rituximab-for-relapsed-cll-five-year-follow-up-of-continuous-or-limited-duration-therapy/2023-12-18T18:18:14+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-camidanlumab-tesirine-in-patients-with-r-r-classical-hodgkin-lymphoma/2023-12-18T18:05:59+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-characteristics-and-outcome-of-patients-treated-with-single-agent-ibrutinib-for-chronic-lymphocytic-leukemia-in-spain-ibrors-llc-study/2023-12-18T18:06:38+00:00https://lymphoma-stg.clarovantdigital.com/library/improvement-of-outcomes-of-an-escalated-high-dose-methotrexate-based-regimen-for-patients-with-newly-diagnosed-primary-central-nervous-system-lymphoma-a-real-world-cohort-study/2023-12-18T18:03:38+00:00https://lymphoma-stg.clarovantdigital.com/library/lack-of-intrafollicular-memory-cd4t-cells-is-predictive-of-early-clinical-failure-in-newly-diagnosed-follicular-lymphoma/2023-12-18T18:02:30+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-rituximab-biosimilars-on-overall-survival-in-diffuse-large-b-cell-lymphoma-a-dutch-population-based-study/2023-12-18T18:01:23+00:00https://lymphoma-stg.clarovantdigital.com/library/statin-use-and-survival-in-16-098-patients-with-non-hodgkin-lymphoma-or-chronic-lymphocytic-leukaemia-treated-in-the-rituximab-era/2023-12-18T18:00:21+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-rituximab-shows-efficacy-in-indolent-mantle-cell-lymphoma/2023-12-18T17:59:08+00:00https://lymphoma-stg.clarovantdigital.com/library/increased-levels-of-the-cardiovascular-disease-risk-biomarkers-gdf15-and-myostatin-in-patients-with-chronic-lymphocytic-leukemia/2023-12-18T17:46:04+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-burkitt-lymphoma-with-central-nervous-system-involvement/2023-12-18T17:44:56+00:00https://lymphoma-stg.clarovantdigital.com/library/pd1-gene-deletions-associated-with-worse-prognoses-of-cutaneous-t-cell-lymphomas/2023-12-18T17:43:55+00:00https://lymphoma-stg.clarovantdigital.com/library/cutaneous-squamous-cell-carcinoma-in-patients-with-chronic-lymphocytic-leukemia-a-systematic-review-of-the-literature/2023-12-18T17:43:01+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-use-and-acceptance-of-biosimilar-monoclonal-antibodies-of-rituximab-in-oncology-practice-in-the-usa/2025-12-19T18:41:29+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-in-patients-with-multi-hit-tp53-chronic-lymphocytic-leukemia-treated-with-ibrutinib/2023-12-18T17:40:10+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-in-combination-with-nivolumab-in-relapsed-or-refractory-hodgkin-lymphoma-3-year-study-results/2023-12-18T17:38:32+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-or-mrd-guided-venetoclax-maintenance-treatment-in-patients-with-cll-unfit-for-first-line-fcr-results-from-hovon-139-give-trial/2023-12-18T17:36:17+00:00https://lymphoma-stg.clarovantdigital.com/library/9-year-follow-up-of-patients-with-relapsed-follicular-lymphoma-after-nonmyeloablative-allogeneic-stem-cell-transplant-and-autologous-transplant/2023-12-18T17:34:38+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-shows-encouraging-tolerability-activity-in-btk-inhibitor-intolerant-b-cell-malignancies/2023-12-18T17:32:53+00:00https://lymphoma-stg.clarovantdigital.com/library/standardized-guidelines-support-management-strategies-of-car-t-cell-therapy-related-toxicities/2023-12-18T17:30:41+00:00https://lymphoma-stg.clarovantdigital.com/library/expression-pattern-and-role-of-circular-rnas-in-the-prognosis-of-mantle-cell-lymphoma-in-younger-patients/2023-12-18T17:28:20+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-induces-durable-disease-control-in-frontline-cll-at-4-years/2023-12-18T17:27:04+00:00https://lymphoma-stg.clarovantdigital.com/library/loncastuximab-tesirine-and-ibrutinib-combination-shows-promise-in-r-r-dlbcl-and-mcl/2023-12-18T17:25:24+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-solidifies-role-of-fixed-duration-venetoclax-plus-rituximab-in-relapsed-refractory-cll/2023-12-18T17:19:04+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathological-and-prognostic-features-of-hepatitis-b-virus-associated-diffuse-large-b-cell-lymphoma-a-single-center-retrospective-study-in-china/2023-12-18T16:44:17+00:00https://lymphoma-stg.clarovantdigital.com/library/targeting-the-tumor-microenvironment-in-b-cell-lymphoma-challenges-and-opportunities/2023-11-30T17:35:56+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-progression-free-survival-for-bulky-and-non-bulky-advanced-stage-diffuse-large-b-cell-lymphoma-with-consolidative-radiation-therapy-a-bi-institutional-analysis/2023-11-30T17:34:31+00:00https://lymphoma-stg.clarovantdigital.com/library/balancing-the-car-t-perspectives-on-efficacy-and-safety-of-car-t-cell-therapy-in-hematologic-malignancies/2023-11-30T17:30:52+00:00https://lymphoma-stg.clarovantdigital.com/library/activity-of-mrna-covid-19-vaccines-in-patients-with-lymphoid-malignancies/2023-11-30T17:29:40+00:00https://lymphoma-stg.clarovantdigital.com/library/predicted-risks-of-cardiovascular-disease-following-chemotherapy-and-radiotherapy-in-the-uk-ncri-rapid-trial-of-positron-emission-tomography-directed-therapy-for-early-stage-hodgkin-lymphoma/2023-11-30T17:26:38+00:00https://lymphoma-stg.clarovantdigital.com/library/clonal-hematopoiesis-in-patients-receiving-chimeric-antigen-receptor-t-cell-therapy/2023-11-30T17:24:12+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-car-t-cell-products-axicabtagene-ciloleucel-tisagenlecleucel-and-lisocabtagene-maraleucel-for-the-treatment-of-hematologic-malignancies-a-systematic-review-and-meta-analysis/2023-11-30T17:23:05+00:00https://lymphoma-stg.clarovantdigital.com/library/assessing-and-management-of-neurotoxicity-after-car-t-therapy-in-diffuse-large-b-cell-lymphoma/2023-11-30T17:20:44+00:00https://lymphoma-stg.clarovantdigital.com/library/healthy-lifestyle-may-lower-cancer-incidence-among-individuals-with-high-genetic-risk/2023-11-30T17:17:04+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-elicits-high-durable-responses-in-multiply-relapsed-follicular-lymphoma/2023-11-30T17:13:56+00:00https://lymphoma-stg.clarovantdigital.com/library/astct-cibmtr-and-ebmt-clinical-practice-recommendations-for-transplant-and-cellular-therapies-in-mantle-cell-lymphoma/2023-11-30T17:04:54+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-and-outcomes-of-1845-patients-with-follicular-lymphoma-a-real-world-multicenter-experience-in-china/2023-11-30T17:03:55+00:00https://lymphoma-stg.clarovantdigital.com/library/late-effects-in-pediatric-hodgkin-lymphoma-survivors-after-uniform-treatment-with-abvd-with-or-without-radiotherapy/2023-11-30T17:02:15+00:00https://lymphoma-stg.clarovantdigital.com/library/benzene-exposure-and-non-hodgkin-lymphoma-a-systematic-review-and-meta-analysis-of-human-studies/2023-11-30T17:01:00+00:00https://lymphoma-stg.clarovantdigital.com/library/idelalisib-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-results-from-a-nordic-lymphoma-group-phase-ii-trial/2023-11-30T17:00:13+00:00https://lymphoma-stg.clarovantdigital.com/library/conditional-survival-and-annual-hazard-estimates-of-classical-hodgkin-lymphoma/2023-11-30T16:58:19+00:00https://lymphoma-stg.clarovantdigital.com/library/development-of-a-novel-prognostic-scoring-system-for-risk-stratification-of-patients-with-angioimmunoblastic-t-cell-lymphoma/2023-11-30T16:55:49+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-survival-of-patients-with-mantle-cell-lymphoma-after-autologous-haematopoietic-stem-cell-transplantation-in-first-remission-a-post-hoc-analysis-of-an-open-label-multicentre-randomised-ph/2023-11-30T16:53:49+00:00https://lymphoma-stg.clarovantdigital.com/library/antibody-responses-after-first-and-second-covid-19-vaccination-in-patients-with-chronic-lymphocytic-leukaemia/2023-11-30T16:52:41+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-ct-p10-versus-rituximab-in-untreated-low-tumour-burden-follicular-lymphoma-final-results-of-a-randomised-phase-3-study/2023-11-30T16:51:17+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-of-central-nervous-system-relapses-in-patients-with-dlbcl-treated-with-lenalidomide-as-maintenance-after-r-chop/2023-11-30T16:47:50+00:00https://lymphoma-stg.clarovantdigital.com/library/combining-ixazomib-with-subcutaneous-rituximab-and-dexamethasone-in-relapsed-or-refractory-waldenstroms-macroglobulinemia-final-analysis-of-the-phase-i-ii-hovon124-ecwm-r2-study/2023-11-30T16:46:07+00:00https://lymphoma-stg.clarovantdigital.com/library/waldenstroms-macroglobulinemia-an-exploration-into-the-pathology-and-diagnosis-of-a-complex-b-cell-malignancy/2023-11-30T16:44:13+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-patients-with-relapsed-or-refractory-non-hodgkin-lymphoma-treated-with-venetoclax-in-a-phase-i-first-in-human-study/2023-11-30T16:42:04+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-and-correlative-analysis-of-two-phase-ii-trials-of-rituximab-and-lenalidomide-followed-by-continuous-lenalidomide-in-untreated-and-relapsed-refractory-indolent-lymphoma/2023-11-30T16:40:55+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-profiling-in-diffuse-large-b-cell-lymphoma-why-so-many-types-of-subtypes/2023-11-30T16:39:34+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiovascular-risk-associated-with-ibrutinib-use-in-chronic-lymphocytic-leukemia-a-population-based-cohort-study/2023-11-30T16:34:18+00:00https://lymphoma-stg.clarovantdigital.com/library/cll-045-long-term-follow-up-up-to-7-years-in-the-resonate-2-study-of-first-line-ibrutinib-treatment-for-chronic-lymphocytic-leukemia-cll/2023-11-30T16:32:38+00:00https://lymphoma-stg.clarovantdigital.com/library/mrd-status-not-associated-with-pfs-in-chronic-lymphocytic-leukemia-patients-on-ibrutinib/2026-01-14T21:29:36+00:00https://lymphoma-stg.clarovantdigital.com/library/racial-and-ethnic-differences-in-the-utilization-of-autologous-transplantation-for-lymphoma-in-the-united-states/2023-11-30T16:24:27+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-the-bnt162b2-mrna-covid-19-vaccine-in-patients-with-b-cell-non-hodgkin-lymphoma/2025-12-15T22:11:12+00:00https://lymphoma-stg.clarovantdigital.com/library/upward-trend-in-follicular-lymphoma-among-the-korean-population-10-year-experience-at-a-large-tertiary-institution/2026-04-24T19:52:54+00:00https://lymphoma-stg.clarovantdigital.com/library/an-overview-of-lenalidomide-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-follicular-lymphoma-the-evidence-to-date/2023-11-30T16:17:11+00:00https://lymphoma-stg.clarovantdigital.com/library/antibody-response-to-sars-cov-2-vaccines-in-patients-with-hematologic-malignancies/2026-01-15T16:44:56+00:00https://lymphoma-stg.clarovantdigital.com/library/the-echelon-2-trial-5-year-results-of-a-randomized-double-blind-phase-3-study-of-brentuximab-vedotin-and-chp-achp-versus-chop-in-frontline-treatment-of-patients-with-cd30-positive-peripheral-t-c-2/2023-11-30T16:00:43+00:00https://lymphoma-stg.clarovantdigital.com/library/high-dose-methotrexate-is-effective-for-prevention-of-isolated-cns-relapse-in-diffuse-large-b-cell-lymphoma/2023-11-30T15:56:34+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-venetoclax-plus-rituximab-for-relapsed-cll-5-year-follow-up-of-continuous-or-limited-duration-therapy/2023-11-30T17:39:28+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-radiation-therapy-after-high-dose-chemotherapy-and-autologous-hematopoietic-stem-cell-transplantation-in-patients-with-relapsed-refractory-lymphomas/2025-05-27T12:16:52+00:00https://lymphoma-stg.clarovantdigital.com/library/tisagenlecleucel-demonstrates-efficacy-in-relapsed-refractory-follicular-lymphoma/2023-11-30T15:28:56+00:00https://lymphoma-stg.clarovantdigital.com/library/patients-on-trials-supporting-drug-approvals-are-younger-than-real-world-patients/2023-11-30T15:18:06+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-refractory-follicular-lymphoma-a-poor-outcome-entity-with-high-risk-of-transformation-to-aggressive-b-cell-lymphoma/2023-11-30T15:14:14+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-monotherapy-for-patients-with-treatment-naive-chronic-lymphocytic-leukemia-and-17p-deletion/2023-11-30T15:03:30+00:00https://lymphoma-stg.clarovantdigital.com/library/matching-adjusted-indirect-treatment-comparison-of-liso-cel-versus-axi-cel-in-relapsed-or-refractory-large-b-cell-lymphoma/2023-11-30T14:57:59+00:00https://lymphoma-stg.clarovantdigital.com/library/cause-of-death-in-patients-with-newly-diagnosed-chronic-lymphocytic-leukemia-cll-stratified-by-the-cll-international-prognostic-index/2023-11-30T14:55:54+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapies-show-similar-efficacy-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2023-11-30T15:04:17+00:00https://lymphoma-stg.clarovantdigital.com/library/lack-of-biomarker-testing-in-cll-sll-may-lead-to-suboptimal-treatment/2025-03-03T21:04:49+00:00https://lymphoma-stg.clarovantdigital.com/library/orelabrutinib-and-mil62-combination-therapy-well-tolerated-for-patients-with-relapsed-refractory-b-cell-non-hodgkin-lymphoma/2026-01-15T16:44:18+00:00https://lymphoma-stg.clarovantdigital.com/library/targeting-brutons-tyrosine-kinase-in-cll/2023-11-27T23:16:20+00:00https://lymphoma-stg.clarovantdigital.com/library/u2-plus-pembrolizumab-shows-continued-efficacy-at-5-years-in-cll-and-richters-transformation/2023-11-27T23:15:20+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-indicators-of-survival-in-sinonasal-diffuse-large-b-cell-lymphoma-a-national-cancer-database-analysis/2023-11-27T23:13:45+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-in-patients-with-relapsed-refractory-mantle-cell-lymphoma/2023-11-27T23:12:54+00:00https://lymphoma-stg.clarovantdigital.com/library/longitudinal-changes-in-cognitive-function-in-a-nationwide-cohort-study-of-patients-with-lymphoma-treated-with-chemotherapy/2025-12-15T21:18:48+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-responses-deepen-over-time-in-relapsed-refractory-cll/2023-11-27T23:09:21+00:00https://lymphoma-stg.clarovantdigital.com/library/superior-efficacy-with-copanlisib-plus-rituximab-vs-placebo-plus-rituximab-in-patients-with-relapsed-marginal-zone-lymphoma/2023-11-27T23:08:33+00:00https://lymphoma-stg.clarovantdigital.com/library/dose-escalation-of-subcutaneous-epcoritamab-in-patients-with-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-an-open-label-phase-1-2-study/2026-01-14T18:13:21+00:00https://lymphoma-stg.clarovantdigital.com/library/more-pronounced-muscle-loss-during-immunochemotherapy-is-associated-with-worse-clinical-outcomes-in-newly-diagnosed-patients-with-diffuse-large-b-cell-lymphoma-with-unfavorable-features/2023-11-27T23:05:02+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-venetoclax-and-obinutuzumab-as-frontline-treatment-for-chronic-lymphocytic-leukaemia-a-single-arm-open-label-phase-2-study/2023-11-27T23:04:26+00:00https://lymphoma-stg.clarovantdigital.com/library/how-can-we-select-the-best-targeted-agent-for-patients-with-cll/2025-05-13T13:44:26+00:00https://lymphoma-stg.clarovantdigital.com/library/high-rates-of-covid-19-mortality-seen-in-patients-with-hematological-malignancies/2023-11-27T23:01:06+00:00https://lymphoma-stg.clarovantdigital.com/library/the-mtor-inhibitor-temsirolimus-added-to-rituximab-combined-with-dexamethasone-cytarabine-and-cisplatinum-r-dhap-for-the-treatment-of-patients-with-relapsed-or-refractory-dlbcl-results-from-the/2023-11-27T22:58:07+00:00https://lymphoma-stg.clarovantdigital.com/library/overall-survival-and-ezh2-expression-in-mantle-cell-lymphoma/2023-11-27T22:55:48+00:00https://lymphoma-stg.clarovantdigital.com/library/r-chop-with-added-genetic-subtype-based-targeted-therapy-improves-cr-rates-in-newly-diagnosed-dlbcl/2023-11-27T22:55:02+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukaemia-clones-are-detectable-decades-before-diagnosis/2023-11-27T22:53:45+00:00https://lymphoma-stg.clarovantdigital.com/library/the-beneficial-effect-of-escalated-r-chop-21-for-the-treatment-of-diffuse-large-b-cell-lymphoma-in-elderly-male-patients-a-propensity-matched-cohort-study/2023-11-27T22:52:39+00:00https://lymphoma-stg.clarovantdigital.com/library/dose-adjusted-etoposide-doxorubicin-and-cyclophosphamide-with-vincristine-and-prednisone-plus-rituximab-therapy-in-children-and-adolescents-with-primary-mediastinal-b-cell-lymphoma-a-multicenter-ph/2023-11-27T22:51:45+00:00https://lymphoma-stg.clarovantdigital.com/library/the-pretreatment-platelet-count-predicts-survival-outcomes-of-diffuse-large-b-cell-lymphoma-an-analysis-of-1007-patients-in-the-rituximab-era/2023-11-27T22:50:00+00:00https://lymphoma-stg.clarovantdigital.com/library/trends-in-use-of-anti-infective-prophylaxis-with-non-hodgkin-lymphoma-treatment/2023-11-27T22:49:11+00:00https://lymphoma-stg.clarovantdigital.com/library/willingness-to-travel-for-cellular-therapy-the-influence-of-follow-up-care-location-oncologist-continuity-and-race/2023-11-27T22:48:23+00:00https://lymphoma-stg.clarovantdigital.com/library/physician-considered-treatment-attributes-for-third-line-diffuse-large-b-cell-lymphoma-treatment-decision-making-physician-perspectives-from-a-survey-across-western-europe-and-us/2023-11-27T22:47:02+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-nivolumab-and-rituximab-shows-efficacy-with-manageable-safety-in-follicular-lymphoma/2023-11-27T22:03:52+00:00https://lymphoma-stg.clarovantdigital.com/library/should-undetectable-minimal-residual-disease-be-the-goal-of-chronic-lymphocytic-leukemia-therapy/2023-11-27T21:57:40+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-cell-of-origin-on-outcomes-after-autologous-hematopoietic-cell-transplant-in-diffuse-large-b-cell-lymphoma/2023-11-27T21:54:38+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-rituximab-versus-placebo-plus-rituximab-for-waldenstroms-macroglobulinemia-final-analysis-from-the-randomized-phase-iii-innovate-study/2023-11-27T21:53:34+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-and-allogeneic-hematopoietic-cell-transplantation-for-diffuse-large-b-cell-lymphoma-type-richter-syndrome/2023-11-27T21:51:23+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-venetoclax-for-first-line-treatment-of-chronic-lymphocytic-leukemia-primary-analysis-results-from-the-minimal-residual-disease-cohort-of-the-randomized-phase-ii-captivate-study/2023-11-27T21:44:28+00:00https://lymphoma-stg.clarovantdigital.com/library/quality-of-life-of-survivors-1-year-after-the-diagnosis-of-diffuse-large-b-cell-lymphoma-a-lysa-study/2023-11-27T21:43:19+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-in-t-cell-malignancies-is-success-a-low-hanging-fruit/2023-11-27T21:42:28+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-as-a-salvage-and-bridging-treatment-in-relapsed-or-refractory-large-b-cell-lymphomas/2026-01-15T14:17:29+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-dlbcl-in-patients-older-than-65-years-analysis-of-3-year-real-world-data-of-practice-patterns-and-outcomes-in-england/2023-11-27T21:36:59+00:00https://lymphoma-stg.clarovantdigital.com/library/gonadal-function-recovery-in-patients-with-advanced-hodgkin-lymphoma-treated-with-a-pet-adapted-regimen-prospective-analysis-of-a-randomized-phase-iii-trial-ahl2011/2023-11-27T21:35:47+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-after-first-line-immunochemotherapy-for-primary-mediastinal-b-cell-lymphoma-a-lysa-study/2023-11-27T21:34:40+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-venetoclax-monotherapy-on-the-quality-of-life-of-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-results-from-the-phase-3b-venice-ii-trial/2023-11-27T21:33:18+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiovascular-complications-associated-with-novel-agents-in-the-chronic-lymphocytic-leukemia-armamentarium-a-pharmacovigilance-analysis/2023-11-27T21:31:55+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-gastric-non-hodgkin-lymphomas-recent-advances-regarding-disease-pathogenesis-and-treatment/2023-11-27T21:25:56+00:00https://lymphoma-stg.clarovantdigital.com/library/umbralisib-demonstrates-favorable-long-term-safety-for-patients-with-r-r-lymphoid-malignancies/2023-11-27T21:23:03+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-results-of-the-treatment-of-hodgkin-lymphoma-in-a-resource-constrained-setting-real-world-data-from-a-single-center/2026-03-13T19:39:36+00:00https://lymphoma-stg.clarovantdigital.com/library/utility-of-mrd-testing-shown-for-select-cll-treatment-regimens/2025-05-13T13:42:47+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-monotherapy-in-relapsed-refractory-mantle-cell-lymphoma-a-pooled-analysis-of-two-clinical-trials/2023-11-27T21:19:05+00:00https://lymphoma-stg.clarovantdigital.com/library/crispr-edited-car-t-appears-safe-effective-for-advanced-large-b-cell-lymphoma/2023-11-27T21:18:13+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-what-is-the-evidence/2023-11-27T21:17:19+00:00https://lymphoma-stg.clarovantdigital.com/library/improving-risk-benefit-of-frontline-classical-hodgkin-lymphoma-treatment/2023-11-27T21:15:31+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-cll-sequentially-resistant-to-both-bcl2-and-btk-inhibition/2023-11-27T21:14:39+00:00https://lymphoma-stg.clarovantdigital.com/library/cancer-patients-have-impaired-antibody-responses-to-covid-19-mrna-vaccines/2023-11-27T21:12:15+00:00https://lymphoma-stg.clarovantdigital.com/library/consolidative-radiotherapy-remains-a-key-player-in-the-salvage-management-of-hodgkin-lymphoma/2026-01-15T14:16:57+00:00https://lymphoma-stg.clarovantdigital.com/library/predictors-of-neutralizing-antibody-response-to-bnt162b2-vaccination-in-allogeneic-hematopoietic-stem-cell-transplant-recipients/2023-11-27T21:09:54+00:00https://lymphoma-stg.clarovantdigital.com/library/frequent-mutated-b2m-ezh2-irf8-and-tnfrsf14-in-primary-bone-diffuse-large-b-cell-lymphoma-reflect-a-gcb-phenotype/2023-11-27T21:07:28+00:00https://lymphoma-stg.clarovantdigital.com/library/a-bigger-red-flag-for-car-ts-toll-on-the-heart-lungs/2024-07-30T20:40:04+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-htlv-1-carriers-with-diffuse-large-b-cell-lymphoma-a-single-center-retrospective-matched-cohort-study/2023-11-27T19:38:42+00:00https://lymphoma-stg.clarovantdigital.com/library/big-boom-radiation-treatment-rt-of-4-gy-single-fraction-is-it-an-acceptable-alternative-to-boom-boom-radiation-treatment-2-gyx2-fractions-for-non-hodgkin-lymphomas-nhl/2023-11-27T19:36:13+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-btk-inhibition-in-the-treatment-of-chronic-lymphocytic-leukemia-a-clinical-view/2023-11-27T19:34:47+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-dynamics-after-venetoclax-obinutuzumab-treatment-extended-off-treatment-follow-up-from-the-randomized-cll14-study/2023-11-27T19:31:39+00:00https://lymphoma-stg.clarovantdigital.com/library/parenthood-rates-and-use-of-assisted-reproductive-techniques-in-younger-hodgkin-lymphoma-survivors-a-danish-population-based-study/2023-11-27T19:30:31+00:00https://lymphoma-stg.clarovantdigital.com/library/nine-year-follow-up-of-patients-with-relapsed-follicular-lymphoma-after-nonmyeloablative-allogeneic-stem-cell-transplant-and-autologous-transplant/2026-01-15T13:53:37+00:00https://lymphoma-stg.clarovantdigital.com/library/concurrent-ibrutinib-plus-venetoclax-in-relapsed-refractory-mantle-cell-lymphoma-the-safety-run-in-of-the-phase-3-sympatico-study/2023-11-27T19:27:49+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcome-of-hyper-cvad-r-for-burkitt-leukemia-lymphoma-and-high-grade-b-cell-lymphoma-focus-on-cns-relapse/2023-11-27T19:25:34+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-monotherapy-for-treatment-of-chronic-lymphocytic-leukaemia-ace-cl-001-analysis-of-the-richter-transformation-cohort-of-an-open-label-single-arm-phase-1-2-study/2023-11-27T19:32:33+00:00https://lymphoma-stg.clarovantdigital.com/library/cell-in-cell-sheltering-may-have-implications-in-drug-resistance/2023-11-27T19:22:15+00:00https://lymphoma-stg.clarovantdigital.com/library/age-related-disease-risks-in-younger-versus-older-b-cell-non-hodgkins-lymphoma-survivors/2023-11-27T19:19:10+00:00https://lymphoma-stg.clarovantdigital.com/library/response-adapted-postinduction-strategy-in-patients-with-advanced-stage-follicular-lymphoma-the-foll12-study/2023-11-27T19:07:54+00:00https://lymphoma-stg.clarovantdigital.com/library/understanding-the-mutational-landscape-of-plasmablastic-lymphoma-a-genomic-analysis/2026-09-02T16:05:30+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-atezolizumab-lenalidomide-for-the-treatment-of-patients-with-relapsed-refractory-follicular-lymphoma-final-analysis-of-a-phase-ib-ii-trial/2023-11-27T19:04:40+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-magnolia-trial-efficacy-and-safety-of-zanubrutinib-in-marginal-zone-lymphoma/2023-11-27T19:00:01+00:00https://lymphoma-stg.clarovantdigital.com/library/geriatric-hematology-in-low-resource-settings-improving-care-for-older-people-through-the-implementation-of-geriatric-hematology-programs/2026-03-13T13:34:29+00:00https://lymphoma-stg.clarovantdigital.com/library/effect-of-ibrutinib-with-r-chop-chemotherapy-in-genetic-subtypes-of-dlbcl/2023-11-27T18:57:38+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-surveillance-imaging-after-curative-intent-radiotherapy-for-limited-stage-follicular-lymphoma/2025-05-27T12:17:23+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-lenalidomide-in-the-treatment-of-peripheral-t-cell-non-hodgkin-lymphomas/2023-11-24T15:10:35+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-remissions-in-patients-with-early-relapse-of-diffuse-large-b-cell-lymphoma-following-high-dose-chemotherapy-autologous-stem-cell-transplantation-and-radiotherapy-of-residual-disease/2023-11-24T15:09:23+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-risk-factors-associated-with-bleeding-and-thrombosis-following-chimeric-antigen-receptor-t-cell-therapy/2023-11-24T15:08:34+00:00https://lymphoma-stg.clarovantdigital.com/library/adoptive-t-cell-therapy-for-hodgkin-lymphoma/2026-09-02T16:04:46+00:00https://lymphoma-stg.clarovantdigital.com/library/synthetic-control-arms-in-studies-of-multiple-myeloma-and-diffuse-large-b-cell-lymphoma/2023-11-24T15:06:51+00:00https://lymphoma-stg.clarovantdigital.com/library/high-counts-of-cd68-and-cd163-macrophages-in-mantle-cell-lymphoma-are-associated-with-inferior-prognosis/2023-11-24T15:05:56+00:00https://lymphoma-stg.clarovantdigital.com/library/diesel-exhaust-exposure-and-risk-of-non-hodgkin-lymphoma-a-meta-analysis/2023-11-24T15:04:33+00:00https://lymphoma-stg.clarovantdigital.com/library/new-technique-may-lead-to-safer-stem-cell-transplants/2023-11-24T15:01:40+00:00https://lymphoma-stg.clarovantdigital.com/library/second-generation-brutons-tyrosine-kinase-inhibitors-simply-the-best-treatments-for-chronic-lymphocytic-leukemia/2023-11-24T15:00:33+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-study-to-assess-the-safety-and-efficacy-of-the-dual-mtorc1-2-and-pi3k-inhibitor-bimiralisib-pqr309-in-relapsed-refractory-lymphoma/2023-11-24T14:58:44+00:00https://lymphoma-stg.clarovantdigital.com/library/re-mind-comparing-tafasitamab-lenalidomide-l-mind-with-a-real-world-lenalidomide-monotherapy-cohort-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2026-01-15T14:16:27+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-second-primary-malignancies-in-patients-with-follicular-lymphoma-a-population-based-study-in-the-netherlands-1989-2018/2023-11-24T14:56:06+00:00https://lymphoma-stg.clarovantdigital.com/library/metagenomic-analysis-to-identify-novel-infectious-agents-in-systemic-anaplastic-large-cell-lymphoma/2023-11-21T22:05:34+00:00https://lymphoma-stg.clarovantdigital.com/library/overcoming-acquired-epigenetic-resistance-to-btk-inhibitors/2023-11-21T22:04:02+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-shows-promising-response-rate-in-relapsed-refractory-marginal-zone-lymphoma/2023-11-21T22:02:25+00:00https://lymphoma-stg.clarovantdigital.com/library/the-efficacy-and-safety-of-the-jak-1-2-inhibitor-ruxolitinib-in-tcl/2023-11-21T22:00:36+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-factors-predictive-of-pod24-a-robust-early-clinical-endpoint-of-poor-survival-in-patients-with-fl/2023-11-21T21:59:16+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-analysis-of-hepatosplenic-t-cell-lymphoma-a-population-based-study-using-seer/2023-11-21T21:58:26+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-perspectives-on-health-related-quality-of-life-in-diffuse-large-b-cell-lymphoma-treated-with-car-t-cell-therapy-a-qualitative-study/2023-11-21T21:57:40+00:00https://lymphoma-stg.clarovantdigital.com/library/hodgkin-lymphoma-arising-in-patients-with-chronic-lymphocytic-leukemia-outcomes-from-a-large-multi-center-collaboration/2023-11-21T21:55:27+00:00https://lymphoma-stg.clarovantdigital.com/library/identification-of-a-genetic-signature-enriching-for-response-to-ibrutinib-in-relapsed-refractory-follicular-lymphoma-in-the-dawn-phase-2-trial/2023-11-21T21:54:11+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-diagnosis-of-t-cell-lymphoma-a-correlative-study-of-pcr-based-t-cell-clonality-assessment-and-targeted-ngs/2023-11-21T21:46:05+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-in-previously-treated-waldenstrom-macroglobulinemia/2023-11-21T21:45:08+00:00https://lymphoma-stg.clarovantdigital.com/library/janus-kinases-restrain-chronic-lymphocytic-leukemia-cells-in-patients-on-ibrutinib-results-of-a-phase-ii-trial/2023-11-21T21:43:04+00:00https://lymphoma-stg.clarovantdigital.com/library/what-role-is-there-for-allogeneic-sct-in-the-treatment-of-hodgkin-lymphoma/2023-11-21T21:35:58+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristics-and-clinical-outcomes-of-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-who-received-at-least-3-lines-of-therapies/2026-01-15T13:52:59+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-with-rituximab-in-first-line-treatment-of-older-patients-with-mantle-cell-lymphoma/2023-11-21T19:42:46+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-cd30-and-pd-1-targeted-therapies-for-classical-hodgkin-lymphoma-2/2023-11-21T19:41:33+00:00https://lymphoma-stg.clarovantdigital.com/library/aitl-pathophysiology-diagnostic-challenges-and-current-and-future-treatment-of-a-rare-t-cell-lymphoma-subtype/2023-11-21T19:38:20+00:00https://lymphoma-stg.clarovantdigital.com/library/global-regional-and-national-cancer-incidence-and-death-for-29-cancer-groups-in-2019-and-trends-analysis-of-the-global-cancer-burden-1990-2019/2026-03-13T13:35:12+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-agents-may-be-preferable-to-chemotherapy-for-large-b-cell-lymphoma-progressing-after-cd19-car-t-a-multicenter-observational-study/2023-11-21T19:35:49+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-and-treatment-patterns-in-patients-with-aggressive-b-cell-lymphoma-after-failure-of-anti-cd19-car-t-cell-therapy/2023-11-21T19:34:36+00:00https://lymphoma-stg.clarovantdigital.com/library/mantle-cell-lymphoma-a-clinical-review-of-the-changing-treatment-paradigms-with-the-advent-of-novel-therapies-and-an-insight-into-indian-data/2023-11-21T19:33:34+00:00https://lymphoma-stg.clarovantdigital.com/library/intensified-treatment-of-patients-with-early-stage-unfavourable-hodgkin-lymphoma-long-term-follow-up-of-a-randomised-international-phase-3-trial-of-the-german-hodgkin-study-group-ghsg-hd14/2023-11-21T19:32:47+00:00https://lymphoma-stg.clarovantdigital.com/library/surgery-and-chemotherapy-versus-chemotherapy-only-in-older-persons-with-primary-intestinal-diffuse-large-b-cell-lymphoma/2023-11-21T19:29:26+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-relapsed-refractory-aggressive-b-cell-lymphoma-patients-relapsing-after-anti-cd19-car-t-cells-and-enrolled-in-the-descar-t-french-national-registry/2026-01-15T14:16:00+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-glofit-in-combination-with-polatuzumab-vedotin-pola-phase-ib-ii-preliminary-data-support-manageable-safety-and-encouraging-efficacy-in-relapsed-refractory-r-r-diffuse-large-b-cell-ly/2023-11-21T19:26:39+00:00https://lymphoma-stg.clarovantdigital.com/library/a-multi-center-retrospective-study-of-polatuzumab-for-patients-with-large-b-cell-lymphoma-relapsed-after-standard-of-care-car-t-cell-therapy/2023-11-21T19:25:09+00:00https://lymphoma-stg.clarovantdigital.com/library/the-polarix-study-polatuzumab-vedotin-with-rituximab-cyclophosphamide-doxorubicin-and-prednisone-pola-r-chp-versus-rituximab-cyclophosphamide-doxorubicin-vincristine-and-prednisone-r-chop-t/2023-11-21T19:23:15+00:00https://lymphoma-stg.clarovantdigital.com/library/a-multicenter-analysis-of-outcomes-toxicities-and-patterns-of-use-with-commercial-axicabtagene-ciloleucel-and-tisagenlecleucel-for-relapsed-refractory-aggressive-b-cell-lymphomas/2023-11-21T19:21:57+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-tisagenlecleucel-in-adult-patients-pts-with-high-risk-relapsed-refractory-follicular-lymphoma-r-r-fl-subgroup-analysis-of-the-phase-ii-elara-study/2023-11-21T19:20:07+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-compared-to-tisagenlecleucel-for-the-treatment-of-relapsed-or-refractory-large-b-cell-lymphoma-in-the-real-world-setting-in-spain/2023-11-21T19:18:42+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-not-recommended-over-watch-and-wait-in-asymptomatic-early-cll/2025-12-15T22:23:03+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-results-from-anti-cd19-car-t-cell-therapy-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-in-spain-and-comparison-with-previous-standard-of-care-a-geltamo-geth-study/2023-11-21T19:14:36+00:00https://lymphoma-stg.clarovantdigital.com/library/real-life-car-t-cell-treatment-in-large-b-cell-lymphomas-indicates-that-axi-cel-and-tisa-cel-have-similar-outcomes-but-long-term-cytopenia-is-an-emerging-problem/2023-11-21T19:12:28+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-comorbidities-on-outcomes-and-toxicity-in-patients-treated-with-car-t-cell-therapy-for-diffuse-large-b-cell-lymphoma-dlbcl-a-multicenter-rwe-study/2025-12-15T16:26:04+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-obinutuzumab-and-venetoclax-with-minimal-residual-disease-driven-discontinuation-in-previously-untreated-patients-with-chronic-lymphocytic-leukaemia-or-small-lymphocytic-lymphoma-a-mul/2025-03-03T21:03:26+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-severity-and-mortality-in-patients-with-cll-an-update-of-the-international-eric-and-campus-cll-study/2023-11-21T19:03:44+00:00https://lymphoma-stg.clarovantdigital.com/library/tisagenlecleucel-vs-standard-of-care-as-second-line-therapy-of-primary-refractory-or-relapsed-aggressive-b-cell-non-hodgkin-lymphoma-analysis-of-the-phase-iii-belinda-study/2023-11-21T18:51:57+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-of-patients-with-large-b-cell-lymphoma-treated-with-standard-of-care-axicabtagene-ciloleucel-results-from-the-us-lymphoma-car-t-cell-consortium/2023-11-21T18:50:21+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-analysis-of-zuma-5-a-phase-2-study-of-axicabtagene-ciloleucel-axi-cel-in-patients-with-relapsed-refractory-r-r-indolent-non-hodgkin-lymphoma-inhl/2023-11-21T18:45:53+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-analysis-of-zuma-7-a-phase-3-randomized-trial-of-axicabtagene-ciloleucel-axi-cel-versus-standard-of-care-therapy-in-patients-with-relapsed-refractory-large-b-cell-lymphoma/2025-12-15T16:23:20+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-4-year-and-5-year-overall-survival-os-by-12-and-24-month-event-free-survival-efs-an-updated-analysis-of-zuma-1-the-pivotal-study-of-axicabtagene-ciloleucel-axi-cel-in-patients-p/2023-11-21T18:46:49+00:00https://lymphoma-stg.clarovantdigital.com/library/the-magnolia-trial-zanubrutinib-a-next-generation-bruton-tyrosine-kinase-inhibitor-demonstrates-safety-and-efficacy-in-relapsed-refractory-marginal-zone-lymphoma/2023-11-21T18:38:34+00:00https://lymphoma-stg.clarovantdigital.com/library/bortezomib-consolidation-or-maintenance-following-immunochemotherapy-and-autologous-stem-cell-transplantation-for-mantle-cell-lymphoma-calgb-alliance-50403/2023-11-27T19:12:51+00:00https://lymphoma-stg.clarovantdigital.com/library/romidepsin-plus-chop-versus-chop-in-patients-with-previously-untreated-peripheral-t-cell-lymphoma-results-of-the-ro-chop-phase-iii-study/2023-11-21T18:28:31+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-analysis-of-zuma-12-a-phase-2-study-of-axicabtagene-ciloleucel-axi-cel-as-first-line-therapy-in-patients-with-high-risk-large-b-cell-lymphoma-lbcl/2023-11-21T18:26:20+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-outcomes-in-a-phase-3-randomized-open-label-study-evaluating-the-efficacy-of-axicabtagene-ciloleucel-axi-cel-versus-standard-of-care-therapy-in-patients-with-relapsed-refractory-l/2023-11-21T16:53:03+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-study-of-prophylactic-anakinra-to-prevent-crs-and-neurotoxicity-in-patients-receiving-cd19-car-t-cell-therapy-for-relapsed-or-refractory-lymphoma/2023-11-21T16:50:27+00:00https://lymphoma-stg.clarovantdigital.com/library/association-between-multimorbidity-and-socioeconomic-deprivation-on-short-term-mortality-among-patients-with-diffuse-large-b-cell-or-follicular-lymphoma-in-england-a-nationwide-cohort-study/2023-11-21T16:48:24+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-of-anti-cd-19-chimeric-antigen-receptor-t-cell-therapy-in-the-older-population-with-diffuse-large-b-cell-lymphoma-a-meta-analysis-2/2023-11-21T16:46:01+00:00https://lymphoma-stg.clarovantdigital.com/library/tp53-and-cd19-directed-chimeric-antigen-receptor-t-cell-car-t-therapy-in-large-b-cell-lymphoma/2023-11-21T16:33:33+00:00https://lymphoma-stg.clarovantdigital.com/library/pre-treatment-health-related-quality-of-life-parameters-have-prognostic-impact-in-patients-65-years-with-newly-diagnosed-mantle-cell-lymphoma-the-nordic-lymphoma-group-mcl4-lena-berit-experience/2023-11-21T16:32:24+00:00https://lymphoma-stg.clarovantdigital.com/library/high-bacterial-abundances-of-dorea-and-pediococcus-in-the-gut-microbiome-linked-to-expansion-immune-checkpoint-expression-and-efficacy-of-cd19-directed-car-t-cells-in-patients-with-r-r-dlbcl/2023-11-21T16:31:20+00:00https://lymphoma-stg.clarovantdigital.com/library/barriers-to-enrollment-in-clinical-trials-in-patients-with-aggressive-b-cell-non-hodgkin-lymphoma-that-progressed-after-anti-cd19-cart-cell-therapy/2023-11-21T16:26:00+00:00https://lymphoma-stg.clarovantdigital.com/library/a-propensity-score-matched-comparison-of-axi-cel-and-tisa-cel-for-relapsed-refractory-diffuse-large-b-cell-lymphoma-in-real-life-a-lysa-study-from-the-descar-t-registry/2023-11-21T16:26:48+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-molecular-features-of-diffuse-large-b-cell-lymphoma-on-treatment-outcomes-with-anti-cd19-chimeric-antigen-receptor-car-t-cell-therapy/2023-11-21T16:27:28+00:00https://lymphoma-stg.clarovantdigital.com/library/antibody-response-after-one-and-or-two-doses-of-bnt162b2-anti-sars-cov-2-mrna-vaccine-in-patients-treated-by-car-t-cells-therapy/2023-11-21T16:28:21+00:00https://lymphoma-stg.clarovantdigital.com/library/response-to-bridging-therapy-as-a-predictor-of-outcomes-for-chimeric-antigen-receptor-therapy-in-large-b-cell-lymphoma/2026-01-15T16:43:46+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-toxicity-management-and-steroid-use-in-high-grade-b-cell-lymphoma-impact-on-real-world-survival-outcomes-in-the-uk-2/2023-11-21T16:29:02+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-efficacy-of-first-line-ibrutinib-treatment-for-chronic-lymphocytic-leukaemia-in-patients-with-tp53-aberrations-apooled-analysis-from-four-clinical-trials/2023-11-21T16:13:34+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-based-therapy-as-third-line-or-beyond-treatment-for-patients-with-dlbcl/2026-01-15T14:15:36+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-1-2-study-of-thiotepa-based-immunochemotherapy-in-relapsed-refractory-primary-cns-lymphoma-the-tier-trial/2023-11-21T16:10:55+00:00https://lymphoma-stg.clarovantdigital.com/library/accuracy-of-pathologic-diagnosis-in-patients-with-lymphoma-and-survival-a-prospective-analysis-from-botswana/2026-03-13T19:38:53+00:00https://lymphoma-stg.clarovantdigital.com/library/effective-central-nervous-system-cns-prophylaxis-chemotherapy-approach-in-high-risk-diffuse-large-b-cell-lymphoma-dlbcl-a-network-meta-analysis/2025-12-15T21:38:09+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-in-relapsed-or-refractory-indolent-non-hodgkin-lymphoma-zuma-5-a-single-arm-multicentre-phase-2-trial/2023-11-21T16:06:20+00:00https://lymphoma-stg.clarovantdigital.com/library/the-real-world-experience-with-single-agent-ibrutinib-in-relapsed-refractory-cll-2/2023-11-21T16:05:00+00:00https://lymphoma-stg.clarovantdigital.com/library/next-generation-sequencing-based-monitoring-of-circulating-tumor-dna-reveals-clonotypic-heterogeneity-in-untreated-ptcl/2023-11-21T16:03:32+00:00https://lymphoma-stg.clarovantdigital.com/library/epidemiology-of-diffuse-large-b-cell-lymphoma-dlbcl-and-follicular-lymphoma-fl-in-the-united-states-and-western-europe-population-level-projections-for-2020-2025/2023-11-21T16:01:47+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-efficacy-and-safety-outcomes-for-patients-with-relapsed-or-refractory-r-r-aggressive-b-cell-non-hodgkins-lymphoma-abnhl-treated-with-commercial-tisagenlecleucel-update-from-the-center/2023-11-21T16:00:26+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-liso-cel-a-cd19-directed-chimeric-antigen-receptor-car-t-cell-therapy-versus-standard-of-care-soc-with-salvage-chemotherapy-ct-followed-by-autologous-stem-cell-trans/2023-11-21T15:58:25+00:00https://lymphoma-stg.clarovantdigital.com/library/outreach-results-from-a-phase-2-study-of-lisocabtagene-maraleucel-liso-cel-administered-as-inpatient-inpt-or-outpatient-outpt-treatment-in-the-nonuniversity-setting-in-patients-pts-with-r-r-l/2023-11-15T21:42:12+00:00https://lymphoma-stg.clarovantdigital.com/library/two-year-follow-up-of-transcend-nhl-001-a-multicenter-phase-1-study-of-lisocabtagene-maraleucel-liso-cel-in-relapsed-or-refractory-r-r-large-b-cell-lymphomas-lbcl/2023-11-15T21:41:10+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-quality-of-life-qol-with-lisocabtagene-maraleucel-liso-cel-a-cd19-directed-chimeric-antigen-receptor-car-t-cell-therapy-compared-with-standard-of-care-soc-as-second-line-2l-treatm/2023-11-15T21:35:30+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-in-previously-untreated-diffuse-large-b-cell-lymphoma/2023-11-15T21:28:46+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-as-second-line-therapy-for-large-b-cell-lymphoma/2023-11-15T21:39:32+00:00https://lymphoma-stg.clarovantdigital.com/library/profiling-of-circulating-tumor-dna-for-noninvasive-disease-detection-risk-stratification-and-mrd-monitoring-in-patients-with-cns-lymphoma/2026-01-14T21:29:08+00:00https://lymphoma-stg.clarovantdigital.com/library/matching-adjusted-indirect-treatment-comparison-maic-of-acalabrutinib-alone-or-in-combination-with-obinutuzumab-versus-ibrutinib-or-venetoclax-plus-obinutuzumab-in-patients-with-treatment-naive-chro/2023-11-15T21:23:31+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-combined-with-obinutuzumab-and-chop-i-ochop-for-richter-transformation/2023-11-15T21:21:45+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-as-monotherapy-and-in-combination-with-obinutuzumab-induces-high-complete-response-rates-in-patients-pts-with-multiple-relapsed-or-refractory-r-r-follicular-lymphoma-fl/2023-11-15T21:19:59+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-monotherapy-provides-durable-responses-after-fixed-length-dosing-in-relapsed-refractory-r-r-non-hodgkin-lymphoma-nhl-patients-pts/2023-11-15T21:18:48+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evidence-of-brexucabtagene-autoleucel-for-the-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma/2023-11-15T21:17:44+00:00https://lymphoma-stg.clarovantdigital.com/library/brexucabtagene-autoleucel-for-relapsed-refractory-mantle-cell-lymphoma-real-world-experience-from-the-us-lymphoma-car-t-consortium/2023-11-15T21:16:47+00:00https://lymphoma-stg.clarovantdigital.com/library/analysis-of-outcomes-and-predictors-of-response-in-patients-with-relapsed-mantle-cell-lymphoma-treated-with-brexucabtagene-autoleucel/2023-11-15T21:14:22+00:00https://lymphoma-stg.clarovantdigital.com/library/final-results-from-a-phase-2-study-of-tipifarnib-in-subjects-with-relapsed-or-refractory-peripheral-t-cell-lymphoma/2023-11-15T21:13:06+00:00https://lymphoma-stg.clarovantdigital.com/library/relmacabtagene-autoleucel-cd19-cart-therapy-for-adults-with-heavily-pretreated-relapsed-refractory-large-b-cell-lymphoma-in-china/2023-11-15T21:10:23+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-clinical-response-of-relmacabtagene-autoleucel-in-adults-with-relapsed-refractory-follicular-lymphoma-r-r-fl-in-china/2023-11-15T21:09:26+00:00https://lymphoma-stg.clarovantdigital.com/library/the-combination-of-umbralisib-plus-ublituximab-is-active-in-patients-with-relapsed-or-refractory-marginal-zone-lymphoma-mzl-results-from-the-phase-2-global-unity-nhl-trial/2023-11-15T21:07:50+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-ublituximab-in-combination-with-umbralisib-u2-in-patients-with-chronic-lymphocytic-leukemia-cll-by-treatment-status-a-sub-analysis-of-the-phase-3-unity-cll-study/2023-11-15T21:06:50+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-umbralisib-ublituximab-u2-and-u2-plus-bendamustine-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-dlbcl/2023-11-15T21:04:32+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-evaluating-the-addition-of-ublituximab-and-umbralisib-u2-to-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia-cll-a-minimal-residual-disease-mrd-driven-time-limited-appro/2023-11-15T21:05:20+00:00https://lymphoma-stg.clarovantdigital.com/library/favorable-outcomes-for-patients-treated-with-u2-with-co-morbidities-or-concomitant-medications-a-retrospective-analysis-of-unity-cll-phase-3-trial/2023-11-15T21:01:55+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-monotherapy-is-an-effective-and-well-tolerated-treatment-option-for-patients-with-relapsed-refractory-r-r-follicular-lymphoma-fl-who-have-received-2-prior-lines-of-therapy-pivotal/2023-11-15T20:58:44+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-in-combination-with-lenalidomide-has-a-manageable-safety-profile-and-encouraging-activity-in-patients-with-relapsed-refractory-follicular-lymphoma-initial-results-from-a-phase-ib-study/2023-11-15T20:57:46+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-1b-2-study-of-vipor-venetoclax-ibrutinib-prednisone-obinutuzumab-and-lenalidomide-in-relapsed-refractory-and-untreated-mantle-cell-lymphoma-safety-efficacy-and-molecular-analysis/2023-11-15T20:56:15+00:00https://lymphoma-stg.clarovantdigital.com/library/time-limited-venetoclax-and-ibrutinib-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-r-r-cll-who-have-undetectable-mrd-primary-analysis-from-the-randomized-phase-ii-vision-ho14/2023-11-15T20:54:43+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-treatment-with-ibrutinib-ibr-plus-venetoclax-ven-for-chronic-lymphocytic-leukemia-cll-2-year-post-randomization-disease-free-survival-dfs-results-from-the-minimal-residual-disease/2023-11-15T20:52:28+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-iii-belinda-tisa-cel-vs-standard-of-care-as-second-line-treatment-of-aggressive-b-cell-lymphoma/2025-12-15T22:21:04+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-r-chp-vs-r-chop-for-frontline-treatment-of-dlbcl-results-from-the-phase-iii-polarix-trial/2023-11-14T22:27:34+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-non-hodgkins-lymphoma-of-the-orbit-treatment-outcomes-from-india/2023-11-14T22:26:26+00:00https://lymphoma-stg.clarovantdigital.com/library/initial-treatment-patterns-and-survival-outcomes-of-mantle-cell-lymphoma-patients-managed-at-chinese-academic-centers-in-the-rituximab-era-a-real-world-study/2023-11-14T22:25:37+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-severity-mortality-and-mrna-vaccine-responses-in-patients-with-cll/2023-11-14T22:24:55+00:00https://lymphoma-stg.clarovantdigital.com/library/successful-treatment-of-primary-cns-extranodal-nk-t-cell-lymphoma-with-surgery-and-chemotherapy-combined-with-sintilimab-a-case-report-and-literature-review/2023-11-14T22:23:01+00:00https://lymphoma-stg.clarovantdigital.com/library/lymphoma-cell-metabolism-may-provide-new-cancer-target/2023-11-14T22:21:29+00:00https://lymphoma-stg.clarovantdigital.com/library/impaired-neutralisation-of-sars-cov-2-delta-variant-in-vaccinated-patients-with-b-cell-chronic-lymphocytic-leukaemia/2026-01-15T16:43:09+00:00https://lymphoma-stg.clarovantdigital.com/library/helicobacter-pylori-caga-status-and-gastric-mucosa-associated-lymphoid-tissue-lymphoma-a-systematic-review-and-meta-analysis/2023-11-14T22:18:05+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-efficacy-of-tisagenlecleucel-and-lisocabtagene-maraleucel-among-adults-with-relapsed-refractory-large-b-cell-lymphomas-an-indirect-treatment-comparison/2023-11-14T22:16:13+00:00https://lymphoma-stg.clarovantdigital.com/library/geriatric-assessment-better-than-chronologic-age-for-measuring-health-related-quality-of-life-in-nhl/2023-11-14T22:14:23+00:00https://lymphoma-stg.clarovantdigital.com/library/socioeconomic-inequalities-in-treatment-and-relative-survival-among-patients-with-diffuse-large-b-cell-lymphoma-a-hong-kong-population-based-study/2023-11-14T22:12:40+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-landscape-of-relapsed-and-refractory-diffuse-large-b-cell-lymphoma-a-systemic-review-and-association-analysis-with-next-generation-sequencing/2023-11-14T22:11:53+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-for-treatment-naive-and-relapsed-refractory-chronic-lymphocytic-leukaemia-long-term-follow-up-of-the-phase-i-ii-au-003-study/2023-11-14T22:10:37+00:00https://lymphoma-stg.clarovantdigital.com/library/romidepsin-plus-choep-falls-short-in-newly-diagnosed-peripheral-t-cell-lymphoma/2023-11-14T22:09:28+00:00https://lymphoma-stg.clarovantdigital.com/library/targeted-treatment-of-chronic-lymphocytic-leukemia-clinical-utility-of-acalabrutinib/2023-11-14T22:07:46+00:00https://lymphoma-stg.clarovantdigital.com/library/burkitt-lymphoma-in-the-modern-era-real-world-outcomes-and-prognostication-across-30-us-cancer-centers/2023-11-14T22:06:34+00:00https://lymphoma-stg.clarovantdigital.com/library/healthcare-utilization-and-comorbidity-in-chronic-lymphocytic-leukemia/2023-11-14T22:05:38+00:00https://lymphoma-stg.clarovantdigital.com/library/prophylactic-tocilizumab-prior-to-anti-cd19-car-t-cell-therapy-for-non-hodgkin-lymphoma/2023-11-14T22:04:50+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-plus-ice-acceptable-salvage-for-relapsed-refractory-hodgkin-lymphoma/2026-01-15T14:14:59+00:00https://lymphoma-stg.clarovantdigital.com/library/development-and-testing-of-a-lymphoma-clinical-trials-specific-frailty-index-a-secondary-analysis-of-the-ly-12-clinical-trial/2023-11-14T21:51:38+00:00https://lymphoma-stg.clarovantdigital.com/library/bruton-tyrosine-kinase-inhibitors-in-b-cell-malignancies-their-use-and-differential-features/2023-11-14T21:48:13+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-obinutuzumab-and-atezolizumab-pd-l1-checkpoint-inhibitor-for-treatment-for-patients-with-richter-transformation/2023-11-14T21:47:06+00:00https://lymphoma-stg.clarovantdigital.com/library/three-year-follow-up-of-the-ascend-trial-acalabrutinib-vs-rituximab-plus-idelalisib-or-bendamustine-in-relapsed-refractory-chronic-lymphocytic-leukemia/2023-11-14T21:44:39+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-ibrutinib-rituximab-and-mini-chop-in-very-elderly-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma-primary-analysis-of-the-australasian-leukaemia-lymphoma-group-nhl29-study/2023-11-14T21:43:43+00:00https://lymphoma-stg.clarovantdigital.com/library/planned-interim-analysis-of-a-phase-2-study-of-loncastuximab-tesirine-plus-ibrutinib-in-patients-with-advanced-diffuse-large-b-cell-lymphoma-lotis-3/2023-11-14T21:39:59+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-responses-of-patients-with-relapsed-or-refractory-high-grade-b-cell-lymphoma-treated-with-loncastuximab-tesirine-in-the-lotis-2-clinical-trial/2023-11-14T21:38:11+00:00https://lymphoma-stg.clarovantdigital.com/library/the-anti-cd19-antibody-drug-conjugate-loncastuximab-tesirine-achieved-responses-in-patients-with-diffuse-large-b-cell-lymphoma-who-relapsed-after-anti-cd19-car-t-cell-therapy/2023-11-14T21:36:28+00:00https://lymphoma-stg.clarovantdigital.com/library/tafasitamab-plus-lenalidomide-versus-pola-br-r2-and-car-t-comparing-outcomes-from-re-mind2-an-observational-retrospective-cohort-study-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2026-01-06T20:54:32+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2a-study-of-the-dual-syk-jak-inhibitor-cerdulatinib-alxn2075-as-monotherapy-in-patients-with-relapsed-refractory-peripheral-t-cell-lymphoma/2023-11-14T21:32:27+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2a-study-of-the-dual-syk-jak-inhibitor-cerdulatinib-alxn2075-as-monotherapy-or-in-combination-with-rituximab-in-patients-with-relapsed-refractory-follicular-lymphoma/2023-11-14T21:31:25+00:00https://lymphoma-stg.clarovantdigital.com/library/prolonged-sars-cov-2-infection-in-patients-with-lymphoid-malignancies/2023-11-14T21:29:33+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-biologic-therapies-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-car-t-is-not-the-only-answer/2023-11-14T21:28:40+00:00https://lymphoma-stg.clarovantdigital.com/library/preliminary-safety-and-efficacy-from-a-multicenter-investigator-initiated-phase-ii-study-in-untreated-tp53-mutant-mantle-cell-lymphoma-with-zanubrutinib-obinutuzumab-and-venetoclax-boven/2023-11-14T21:26:57+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-obinutuzumab-and-venetoclax-in-chronic-lymphocytic-leukemia-early-mrd-kinetics-define-a-high-risk-patient-cohort-with-delayed-bone-marrow-undetectable-mrd-and-earlier-post-treatment-mr/2026-01-14T21:28:24+00:00https://lymphoma-stg.clarovantdigital.com/library/pooled-analysis-of-first-line-treatment-with-targeted-agents-in-patients-with-chronic-lymphocytic-leukemia-cll-aged-80-years-and-older/2023-11-14T21:25:05+00:00https://lymphoma-stg.clarovantdigital.com/library/breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl-data-based-on-the-lymphoma-study-association-lysa-registry-promising-results-of-brentuximab-vedotin-combined-with-cyclophosphami/2023-11-14T21:13:12+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-of-lenalidomide-plus-rituximab-versus-rituximab-monotherapy-in-patients-with-previously-treated-follicular-lymphoma-a-societal-view/2023-11-14T21:12:11+00:00https://lymphoma-stg.clarovantdigital.com/library/high-grade-b-cell-lymphoma-with-myc-bcl2-and-or-bcl6-rearrangements-unraveling-the-genetic-landscape-of-a-rare-aggressive-subtype-of-non-hodgkin-lymphoma/2023-11-14T21:10:22+00:00https://lymphoma-stg.clarovantdigital.com/library/follicular-lymphoma-a-summary-of-the-hot-topics-presented-at-the-63rd-american-society-of-hematology-annual-meeting-and-exposition/2023-11-14T21:07:54+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-in-combination-with-rituximab-for-indolent-clinical-forms-of-mantle-cell-lymphoma-imcl-2015-a-multicenter-open-label-single-arm-phase-ii-trial/2026-01-14T21:27:02+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-multicenter-single-arm-open-label-study-of-parsaclisib-a-pi3k-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-in-china/2023-11-14T21:03:23+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-parsaclisib-in-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-not-previously-treated-with-a-btk-inhibitor-primary-analysis-from-a-phase-2-study-citadel-205/2023-11-14T21:02:00+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-parsaclisib-in-patients-with-relapsed-or-refractory-marginal-zone-lymphoma-primary-analysis-from-a-phase-2-study-citadel-204/2023-11-14T19:43:14+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-parsaclisib-in-patients-with-relapsed-or-refractory-follicular-lymphoma-primary-analysis-from-a-phase-2-study-citadel-203/2023-11-14T19:41:07+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-patterns-and-review-of-hodgkin-lymphoma-in-the-republic-of-armenia/2023-11-14T19:37:50+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-cll-clonal-growth-rate-is-slower-following-venetoclax-rituximab-venr-results-from-a-minimal-residual-disease-mrd-model-from-the-randomized-phase-3-murano-trial/2026-01-14T21:26:24+00:00https://lymphoma-stg.clarovantdigital.com/library/chemo-free-combination-of-lenalidomide-rituximab-in-elderly-frail-patients-with-mcl-and-dlbcl/2023-11-27T19:13:59+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-rituximab-followed-by-r-hcvad-as-frontline-treatment-for-young-patients/2023-11-14T19:29:19+00:00https://lymphoma-stg.clarovantdigital.com/library/quality-of-life-analysis-of-pembrolizumab-vs-brentuximab-vedotin-for-relapsed-refractory-classical-hodgkin-lymphoma/2023-11-14T18:48:32+00:00https://lymphoma-stg.clarovantdigital.com/library/night-shift-work-and-lymphoma-results-from-an-italian-multicentre-case-control-study/2023-11-14T18:47:10+00:00https://lymphoma-stg.clarovantdigital.com/library/the-risk-of-malignancy-in-patients-with-igg4-related-disease-a-systematic-review-and-meta-analysis/2023-11-14T18:33:33+00:00https://lymphoma-stg.clarovantdigital.com/library/current-frontline-treatment-of-diffuse-large-b-cell-lymphoma/2025-12-15T19:20:12+00:00https://lymphoma-stg.clarovantdigital.com/library/limited-but-not-eliminated-excess-long-term-morbidity-in-stage-i-iia-hodgkin-lymphoma-treated-with-doxorubicin-bleomycin-vinblastine-and-dacarbazine-and-limited-field-radiotherapy/2023-11-14T18:35:11+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnosis-and-management-of-diffuse-large-b-cell-lymphoma-society-of-medical-oncology-pakistan-society-of-hematology-and-pakistan-society-of-clinical-oncology-joint-clinical-practice-guideline/2023-11-14T18:35:56+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-subcutaneous-rituximab-in-previously-untreated-patients-with-cd20-diffuse-large-b-cell-lymphoma-or-follicular-lymphoma-results-from-an-italian-phase-iiib-study/2023-11-14T18:26:52+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-manifestations-of-diffuse-large-b-cell-lymphoma-that-exhibits-initial-symptoms-in-the-maxilla-and-mandible-a-single-center-retrospective-study/2023-11-14T18:36:46+00:00https://lymphoma-stg.clarovantdigital.com/library/positron-emission-tomography-driven-strategy-in-advanced-hodgkin-lymphoma-prolonged-follow-up-of-the-ahl2011-phase-iii-lymphoma-study-association-study/2022-02-04T19:48:18+00:00https://lymphoma-stg.clarovantdigital.com/library/the-european-medicines-agency-review-of-tafasitamab-in-combination-with-lenalidomide-for-the-treatment-of-adult-patients-with-relapsed_refractory-diffuse-large-b-cell-lymphoma/2023-08-23T15:57:34+00:00https://lymphoma-stg.clarovantdigital.com/library/biological-features-and-prognostic-impact-of-bone-marrow-infiltration-in-patients-with-diffuse-large-b-cell-lymphoma/2023-08-23T14:49:17+00:00https://lymphoma-stg.clarovantdigital.com/library/predictive-impact-of-soluble-interleukin-2-receptor-and-number-of-extranodal-sites-for-identification-of-patients-at-very-high-risk-of-cns-relapse-in-diffuse-large-b-cell-lymphoma/2022-03-01T18:57:37+00:00https://lymphoma-stg.clarovantdigital.com/library/limited-but-not-eliminated-excess-long-term-morbidity-in-stage-i-iia-hodgkin-lymphoma-treated-with-doxorubicin-bleomycin-vinblastine-and-dacarbazine-and-limited-field-radiotherapy-2/2022-03-01T18:57:38+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-therapy-associated-with-frequent-reports-of-cardiopulmonary-aes/2023-11-14T18:07:43+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-tp53-genomic-alterations-in-large-b-cell-lymphoma-treated-with-cd19-chimeric-antigen-receptor-t-cell-therapy/2023-11-14T18:06:54+00:00https://lymphoma-stg.clarovantdigital.com/library/response-adapted-omission-of-radiotherapy-and-comparison-of-consolidation-chemotherapy-in-children-and-adolescents-with-intermediate-stage-and-advanced-stage-classical-hodgkin-lymphoma-euronet-phl-c1/2022-03-01T18:57:39+00:00https://lymphoma-stg.clarovantdigital.com/library/the-outcome-of-watchful-waiting-in-patients-with-previously-treated-follicular-lymphoma/2022-03-01T18:57:39+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-rituximab-followed-by-r-hcvad-shows-activity-safety-in-younger-patients-with-mcl/2023-11-14T18:02:02+00:00https://lymphoma-stg.clarovantdigital.com/library/what-is-the-rationale-behind-the-combination-of-glofitamab-polatuzumab-in-patients-with-r-r-dlbcl/2023-11-14T17:59:54+00:00https://lymphoma-stg.clarovantdigital.com/library/mrd-status-may-not-predict-pfs-for-patients-with-chronic-lymphocytic-leukemia-treated-with-ibrutinib/2026-01-14T21:25:48+00:00https://lymphoma-stg.clarovantdigital.com/library/duvelisib-in-patients-with-relapsed-refractory-peripheral-t-cell-lymphoma-from-the-phase-2-primo-trial-results-of-an-interim-analysis/2026-01-15T13:51:10+00:00https://lymphoma-stg.clarovantdigital.com/library/scoring-system-predicts-infection-risk-treatment-outcomes-after-car-t/2022-08-10T18:11:16+00:00https://lymphoma-stg.clarovantdigital.com/library/seeking-clarity-for-treatment-sequencing-with-car-t-in-follicular-lymphoma/2023-11-14T17:55:44+00:00https://lymphoma-stg.clarovantdigital.com/library/male-and-female-fertility-prevention-and-monitoring-hodgkin-lymphoma-and-diffuse-large-b-cell-lymphoma-adult-survivors-a-systematic-review-by-the-fondazione-italiana-linfomi/2022-03-01T18:57:40+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-analysis-of-first-line-treatment-of-43-cases-of-chronic-lymphocytic-leukemia-with-fludarabine-and-cyclophosphamide-combined-with-rituximab-fcr-regimen/2023-11-14T17:54:25+00:00https://lymphoma-stg.clarovantdigital.com/library/a-matching-adjusted-indirect-comparison-of-single-arm-trials-in-patients-with-relapsed-or-refractory-follicular-lymphoma-who-received-at-least-two-prior-systemic-treatments-tazemetostat-was-associate/2023-11-14T17:51:28+00:00https://lymphoma-stg.clarovantdigital.com/library/axi-cel-car-t-significantly-improves-efs-among-older-patients-with-non-hodgkin-lymphoma/2022-08-10T18:09:04+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-third-generation-cd20-targeted-car-t-mb-106-for-treatment-of-relapsed-refractory-b-nhl-and-cll/2026-01-14T22:36:17+00:00https://lymphoma-stg.clarovantdigital.com/library/overexpression-of-wild-type-rras2-without-oncogenic-mutations-drives-chronic-lymphocytic-leukemia/2023-11-14T17:42:03+00:00https://lymphoma-stg.clarovantdigital.com/library/prior-treatment-with-cancer-drug-likely-renders-covid-19-vaccine-ineffective-study-finds/2026-01-06T21:12:06+00:00https://lymphoma-stg.clarovantdigital.com/library/sgk1-mutation-status-can-further-stratify-patients-with-germinal-center-b-cell-like-diffuse-large-b-cell-lymphoma-into-different-prognostic-subgroups/2022-03-01T18:57:41+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-high-dose-therapy-and-autologous-blood-stem-cell-transplantation-in-patients-with-primary-central-nervous-system-non-hodgkin-lymphomas-a-single-centre-experience-in-61-patients/2023-11-14T17:39:27+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-checkpoint-blockade-for-the-treatment-of-hodgkin-lymphoma/2023-11-14T17:38:20+00:00https://lymphoma-stg.clarovantdigital.com/library/antibody-response-to-covid-19-vaccination-in-patients-with-lymphoma/2025-05-26T16:37:27+00:00https://lymphoma-stg.clarovantdigital.com/library/evolving-frontline-immunochemotherapy-for-mantle-cell-lymphoma-and-the-impact-on-survival-outcomes/2023-11-14T17:35:49+00:00https://lymphoma-stg.clarovantdigital.com/library/expression-and-prognostic-value-of-glucose-transporter-3-in-diffuse-large-b-cell-lymphoma/2022-03-01T18:57:42+00:00https://lymphoma-stg.clarovantdigital.com/library/mrd-growth-decelerated-with-venetoclax-combined-with-either-rituximab-or-obinutuzumab-in-patients-with-r-r-cll/2026-01-14T21:25:22+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-aspects-of-resistance-to-immunotherapies-advances-in-understanding-and-management-of-diffuse-large-b-cell-lymphoma/2023-11-14T17:31:11+00:00https://lymphoma-stg.clarovantdigital.com/library/vital-organ-sparing-with-proton-therapy-for-pediatric-hodgkin-lymphoma-toxicity-and-outcomes-in-50-patients/2022-03-01T18:57:43+00:00https://lymphoma-stg.clarovantdigital.com/library/new-approaches-for-treatment-of-advanced-extranodal-nk-t-cell-lymphoma/2023-11-14T17:29:40+00:00https://lymphoma-stg.clarovantdigital.com/library/ddx3x-loss-is-an-adverse-prognostic-marker-in-diffuse-large-b-cell-lymphoma-and-is-associated-with-chemoresistance-in-aggressive-non-hodgkin-lymphoma-subtypes/2022-03-01T18:57:43+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-low-burden-tp53-mutations-in-the-management-of-cll/2023-11-14T17:26:37+00:00https://lymphoma-stg.clarovantdigital.com/library/targeted-therapy-for-relapsed-refractory-follicular-lymphoma-focus-on-clinical-utility-of-tazemetostat/2023-11-14T17:25:44+00:00https://lymphoma-stg.clarovantdigital.com/library/what-does-the-first-line-data-for-polatuzumab-vedotin-tell-us-about-its-role-in-r-r-dlbcl/2023-11-14T17:24:50+00:00https://lymphoma-stg.clarovantdigital.com/library/burden-of-illness-and-treatment-patterns-in-second-line-large-b-cell-lymphoma/2022-03-01T18:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-phase-3-alcanza-study-of-brentuximab-vedotin-vs-physicians-choice-in-cutaneous-t-cell-lymphoma-final-data/2023-11-14T18:04:51+00:00https://lymphoma-stg.clarovantdigital.com/library/differences-in-health-technology-assessment-recommendations-among-european-jurisdictions/2022-03-01T19:57:27+00:00https://lymphoma-stg.clarovantdigital.com/library/to-hta-or-not-to-hta-identifying-the-factors-influencing-the-rapid-review-outcome-in-ireland/2022-03-01T20:31:09+00:00https://lymphoma-stg.clarovantdigital.com/library/health-technology-assessment-of-drugs-in-ireland-an-analysis-of-timelines/2022-03-01T20:42:19+00:00https://lymphoma-stg.clarovantdigital.com/library/economic-evaluation-for-pricing-and-reimbursement-of-new-drugs-in-spain/2023-08-23T16:55:02+00:00https://lymphoma-stg.clarovantdigital.com/library/review-of-hta-outcomes-and-timelines-in-australia-canada-and-europe-2014-2018/2022-03-01T21:22:45+00:00https://lymphoma-stg.clarovantdigital.com/library/development-of-health-technology-assessment-in-china-new-challenges/2022-03-01T21:48:48+00:00https://lymphoma-stg.clarovantdigital.com/library/expanding-access-to-healthcare-in-south-asia/2022-03-02T18:30:59+00:00https://lymphoma-stg.clarovantdigital.com/library/a-70-cut-off-for-myc-protein-expression-in-diffuse-large-b-cell-lymphoma-identifies-a-high-risk-group-of-patients/2023-08-23T14:48:16+00:00https://lymphoma-stg.clarovantdigital.com/library/classification-of-non-hodgkin-lymphoma-in-southeast-turkey-a-review-of-550-cases/2023-08-23T14:47:20+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-idelalisib-on-health-related-quality-of-life-in-patients-with-relapsed-chronic-lymphocytic-leukemia-in-a-phase-3-randomized-trial/2023-08-23T14:46:25+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-alterations-in-b-cell-lymphoma-subtypes-as-potential-biomarkers-for-noninvasive-diagnosis-prognosis-therapy-and-disease-monitoring/2023-08-23T14:43:37+00:00https://lymphoma-stg.clarovantdigital.com/library/the-prognostic-impact-of-comorbidities-in-patients-with-de-novo-diffuse-large-b-cell-lymphoma-treated-with-r-chop-immunochemotherapy-in-curative-intent/2023-08-23T14:42:30+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-treatment-beyond-progression-with-immune-checkpoint-blockade-in-hodgkin-lymphoma/2022-03-02T20:07:59+00:00https://lymphoma-stg.clarovantdigital.com/library/richter-transformation-of-chronic-lymphocytic-leukemia-in-the-era-of-novel-agents/2023-08-23T14:40:39+00:00https://lymphoma-stg.clarovantdigital.com/library/ighv-mutational-status-and-outcome-for-patients-with-chronic-lymphocytic-leukemia-upon-treatment-a-danish-nationwide-population-based-study/2023-08-23T14:37:18+00:00https://lymphoma-stg.clarovantdigital.com/library/kmt2d-mutations-and-tp53-disruptions-are-poor-prognostic-biomarkers-in-mantle-cell-lymphoma-receiving-high-dose-therapy-a-fil-study/2023-08-23T14:36:33+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-on-survival-through-consolidation-radiotherapy-for-diffuse-large-b-cell-lymphoma-a-comprehensive-meta-analysis/2022-03-02T21:55:14+00:00https://lymphoma-stg.clarovantdigital.com/library/relapsed-refractory-mantle-cell-lymphoma-beyond-btk-inhibitors/2023-08-29T20:30:44+00:00https://lymphoma-stg.clarovantdigital.com/library/tocilizumab-for-severe-sars-cov-2-infection-in-patients-with-lymphoma/2022-03-03T00:07:28+00:00https://lymphoma-stg.clarovantdigital.com/library/association-between-atopic-eczema-and-cancer-in-england-and-denmark/2022-03-03T00:11:57+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-pet-ct-in-patients-with-chronic-lymphocytic-leukemia-cll-treated-with-frontline-chemoimmunotherapy/2023-08-23T14:26:00+00:00https://lymphoma-stg.clarovantdigital.com/library/selinexor-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-sadal-a-single-arm-multinational-multicentre-open-label-phase-2-trial/2022-03-03T00:23:06+00:00https://lymphoma-stg.clarovantdigital.com/library/concurrent-tp53-and-cdkn2a-gene-aberrations-in-newly-diagnosed-mantle-cell-lymphoma-correlate-with-chemoresistance-and-call-for-innovative-upfront-therapy/2023-08-23T14:24:17+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-and-treatment-outcomes-of-children-with-anaplastic-large-cell-lymphoma/2022-03-03T19:25:51+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-toxicity-and-its-management/2026-01-14T22:00:33+00:00https://lymphoma-stg.clarovantdigital.com/library/longitudinal-health-related-quality-of-life-in-first-line-treated-patients-with-chronic-lymphocytic-leukemia-results-from-the-connect-cll-registry/2023-08-23T14:20:22+00:00https://lymphoma-stg.clarovantdigital.com/library/disease-flare-during-temporary-interruption-of-ibrutinib-therapy-in-patients-with-chronic-lymphocytic-leukemia/2023-08-23T14:19:09+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-factors-in-childhood-anaplastic-large-cell-lymphoma-long-term-results-of-the-international-alcl99-trial/2022-03-03T22:13:45+00:00https://lymphoma-stg.clarovantdigital.com/library/cd20-negative-nodular-lymphocyte-predominant-hodgkin-lymphoma/2022-03-03T22:22:42+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-efficacy-of-acalabrutinib-in-frontline-treatment-of-chronic-lymphocytic-leukemia-a-systematic-review-and-network-meta-analysis-2/2023-08-23T14:15:35+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-and-predictive-role-of-gene-mutations-in-chronic-lymphocytic-leukemia-results-from-the-pivotal-phase-iii-study-complement1/2023-08-23T14:13:23+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-myc-on-anti-tumor-immune-responses-in-aggressive-b-cell-non-hodgkin-lymphomas-consequences-for-cancer-immunotherapy/2025-12-15T21:50:26+00:00https://lymphoma-stg.clarovantdigital.com/library/nutrition-in-cancer-therapy-in-the-elderly-an-epigenetic-connection/2022-03-04T22:14:30+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-induced-humoral-immunosuppression-a-systematic-review/2023-08-23T14:04:47+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-therapies-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2023-08-23T14:03:56+00:00https://lymphoma-stg.clarovantdigital.com/library/current-treatment-of-refractory-relapsed-chronic-lymphocytic-leukemia-a-focus-on-novel-drugs/2023-08-23T13:52:34+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-systemic-treatment-for-malt-lymphoma-do-we-still-need-chemotherapy-real-world-data-from-the-medical-university-vienna/2023-08-23T13:50:50+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-clonal-hematopoiesis-with-angioimmunoblastic-t-cell-lymphoma-genetic-evidence-for-stem-cell-origin-etiology-and-prediction-of-secondary-hematologic-malignancy/2022-03-07T19:23:26+00:00https://lymphoma-stg.clarovantdigital.com/library/the-evolving-knowledge-on-t-and-nk-cells-in-classic-hodgkin-lymphoma-insights-into-novel-subsets-populating-the-immune-microenvironment/2024-04-02T17:56:39+00:00https://lymphoma-stg.clarovantdigital.com/library/npm-alk-a-driver-of-lymphoma-pathogenesis-and-a-therapeutic-target/2022-03-07T19:39:18+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-checkpoint-inhibitors-in-b-cell-lymphoma/2022-03-07T19:51:18+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-cause-specific-mortality-in-hodgkin-lymphoma-patients/2022-03-07T19:58:22+00:00https://lymphoma-stg.clarovantdigital.com/library/no-increased-bleeding-events-in-patients-with-relapsed-chronic-lymphocytic-leukemia-and-indolent-non-hodgkin-lymphoma-treated-with-idelalisib-2/2023-08-16T21:03:56+00:00https://lymphoma-stg.clarovantdigital.com/library/checkpoint-inhibition-therapy-in-transplant-ineligible-relapsed-or-refractory-classic-hodgkin-lymphoma-2/2022-03-07T20:30:40+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-stem-cell-transplantation-in-mantle-cell-lymphoma-in-the-era-of-new-drugs-and-car-t-cell-therapy/2023-08-16T21:01:02+00:00https://lymphoma-stg.clarovantdigital.com/library/detailed-long-term-follow-up-of-patients-who-relapsed-after-the-nordic-mantle-cell-lymphoma-trials-mcl2-and-mcl3/2022-03-07T21:20:20+00:00https://lymphoma-stg.clarovantdigital.com/library/copanlisib-in-the-treatment-of-relapsed-follicular-lymphoma-utility-and-experience-from-the-clinic/2023-08-16T21:00:02+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-relapsed-mantle-cell-lymphoma-patients-after-discontinuing-acalabrutinib/2023-08-16T20:55:42+00:00https://lymphoma-stg.clarovantdigital.com/library/extranodal-natural-killer-t-cell-lymphoma-nasal-type-diagnosis-and-treatment/2023-08-16T20:54:45+00:00https://lymphoma-stg.clarovantdigital.com/library/a-10-year-cohort-study-of-175-primary-gastrointestinal-lymphoma-cases-in-thailand-clinical-features-and-outcomes-in-the-immunochemotherapy-era/2023-11-09T14:43:59+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-targeted-agents-for-follicular-lymphoma/2023-08-16T20:50:52+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-factors-and-mortality-of-covid-19-in-patients-with-lymphoma-a-multicenter-study/2022-03-08T16:05:03+00:00https://lymphoma-stg.clarovantdigital.com/library/relapsed-mantle-cell-lymphoma-current-management-recent-progress-and-future-directions/2023-08-16T20:48:25+00:00https://lymphoma-stg.clarovantdigital.com/library/the-prognostic-significance-of-del6q23-in-chronic-lymphocytic-leukemia/2023-08-16T20:45:44+00:00https://lymphoma-stg.clarovantdigital.com/library/high-risk-of-cardiovascular-side-effects-after-treatment-of-hodgkins-lymphoma-is-there-a-need-for-intervention-in-long-term-survivors/2022-03-08T16:24:56+00:00https://lymphoma-stg.clarovantdigital.com/library/predictive-and-prognostic-molecular-factors-in-diffuse-large-b-cell-lymphomas/2023-08-16T20:44:09+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-containing-risk-adapted-treatment-strategy-in-nodular-lymphocyte-predominant-hodgkin-lymphoma-7-years-follow-up/2023-08-16T20:42:46+00:00https://lymphoma-stg.clarovantdigital.com/library/perspectives-on-outpatient-administration-of-car-t-cell-therapy-in-aggressive-b-cell-lymphoma-and-acute-lymphoblastic-leukemia/2026-01-14T21:59:39+00:00https://lymphoma-stg.clarovantdigital.com/library/autoimmune-complications-in-hematologic-neoplasms/2023-08-16T20:20:20+00:00https://lymphoma-stg.clarovantdigital.com/library/targeting-the-tumor-microenvironment-in-chronic-lymphocytic-leukemia/2023-08-16T20:18:41+00:00https://lymphoma-stg.clarovantdigital.com/library/myc-rearrangement-but-not-extra-myc-copies-is-an-independent-prognostic-factor-in-patients-with-mantle-cell-lymphoma/2023-08-16T20:17:28+00:00https://lymphoma-stg.clarovantdigital.com/library/the-evolving-landscape-of-chronic-lymphocytic-leukemia-on-diagnosis-prognosis-and-treatment/2023-08-16T20:15:32+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-in-dlbcl-are-we-past-the-cell-of-origin/2022-03-09T21:56:16+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-clinical-and-serum-biomarkers-in-diffuse-large-b-cell-lymphoma/2022-03-09T22:04:02+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-the-pathogenesis-of-ebv-associated-diffuse-large-b-cell-lymphoma/2022-03-09T22:12:33+00:00https://lymphoma-stg.clarovantdigital.com/library/the-value-of-bone-marrow-biopsy-for-staging-of-patients-with-primary-cns-lymphoma/2023-08-16T20:14:02+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-a-selective-bruton-tyrosine-kinase-inhibitor-for-the-treatment-of-b-cell-malignancies/2023-08-16T20:12:23+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-human-immunodeficiency-syndrome-with-non-hodgkins-lymphoma/2024-04-24T20:38:22+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-allogeneic-stem-cell-transplant-and-autologous-stem-cell-transplant-in-refractory-or-relapsed-peripheral-t-cell-lymphoma/2023-08-16T20:11:24+00:00https://lymphoma-stg.clarovantdigital.com/library/paracetamol-intake-and-hematologic-malignancies-a-meta-analysis-of-observational-studies/2022-03-14T18:54:56+00:00https://lymphoma-stg.clarovantdigital.com/library/fifteen-year-follow-up-of-relapsed-indolent-non-hodgkin-lymphoma-patients-vaccinated-with-tumor-loaded-dendritic-cells/2022-03-14T19:06:39+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-convalescent-plasma-therapy-with-survival-in-patients-with-hematologic-cancers-and-covid-19/2022-03-14T19:18:11+00:00https://lymphoma-stg.clarovantdigital.com/library/targeted-therapies-and-immune-checkpoint-inhibitors-in-primary-cns-lymphoma/2023-08-16T19:31:26+00:00https://lymphoma-stg.clarovantdigital.com/library/pitfalls-in-the-diagnosis-of-nodular-lymphocyte-predominant-hodgkin-lymphoma-variant-patterns-borderlines-and-mimics/2022-03-14T19:34:58+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-maintenance-versus-observation-after-immunochemotherapy-r-chop-r-mcpand-r-fcm-in-untreated-follicular-lymphoma-patients-a-randomized-trial-of-the-ostdeutsche-studiengruppe-hamatologie-u/2023-09-07T19:05:51+00:00https://lymphoma-stg.clarovantdigital.com/library/how-to-obtain-a-high-quality-ctdna-in-lymphoma-patients-preanalytical-tips-and-tricks/2023-08-16T19:25:25+00:00https://lymphoma-stg.clarovantdigital.com/library/the-incidence-and-treatment-response-of-double-expression-of-myc-and-bcl2-in-patients-with-diffuse-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis/2022-03-14T20:19:02+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-flow-cytometric-immunophenotyping-for-classic-hodgkin-lymphoma-in-small-biopsy-and-cytology-specimens/2022-03-14T20:37:37+00:00https://lymphoma-stg.clarovantdigital.com/library/review-of-treatment-options-for-the-management-of-advanced-stage-hodgkin-lymphoma/2023-08-16T19:23:39+00:00https://lymphoma-stg.clarovantdigital.com/library/non-coding-rnas-in-normal-b-cell-development-and-in-mantle-cell-lymphoma-from-molecular-mechanism-to-biomarker-and-therapeutic-agent-potential/2023-08-16T19:22:35+00:00https://lymphoma-stg.clarovantdigital.com/library/lymphoma-complicating-rheumatoid-arthritis-results-from-a-french-case-control-study/2022-03-14T20:55:37+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-transplant-versus-chimeric-antigen-receptor-t-cell-therapy-for-relapsed-dlbcl-in-partial-remission/2023-08-16T19:21:45+00:00https://lymphoma-stg.clarovantdigital.com/library/incorporating-novel-targeted-and-immunotherapeutic-agents-in-the-treatment-of-b-cell-lymphomas/2023-08-16T17:41:42+00:00https://lymphoma-stg.clarovantdigital.com/library/mri-versus-ct-and-pet-ct-in-the-preoperative-assessment-of-hodgkin-and-non-hodgkin-lymphomas/2022-03-14T21:17:17+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-radiotherapy-to-bulky-sites-of-advanced-hodgkin-lymphoma-treated-with-abvd-final-results-of-fil-hd0801-trial/2023-08-16T12:37:58+00:00https://lymphoma-stg.clarovantdigital.com/library/second-primary-malignancies-in-treated-and-untreated-patients-with-chronic-lymphocytic-leukemia/2023-09-29T20:02:00+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiovascular-adverse-events-in-patients-with-chronic-lymphocytic-leukemia-receiving-acalabrutinib-monotherapy-pooled-analysis-of-762-patients/2023-08-16T12:36:22+00:00https://lymphoma-stg.clarovantdigital.com/library/hodgkin-lymphoma-a-special-microenvironment-2/2023-08-16T12:34:28+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-clinical-outcomes-of-gastric-malt-lymphoma-a-nationwide-multicenter-study-in-korea/2022-03-14T21:52:57+00:00https://lymphoma-stg.clarovantdigital.com/library/trends-analysis-of-non-hodgkin-lymphoma-at-the-national-regional-and-global-level-1990-2019-results-from-the-global-burden-of-disease-study-2019/2022-03-14T21:58:45+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-treatment-intensity-with-survival-in-older-patients-with-hodgkin-lymphoma/2022-03-14T22:05:52+00:00https://lymphoma-stg.clarovantdigital.com/library/early-relapse-identifies-mcl-patients-with-inferior-survival-after-intensive-or-less-intensive-frontline-therapy/2022-03-14T22:10:49+00:00https://lymphoma-stg.clarovantdigital.com/library/does-immunohistochemically-cd5-positivity-matter-in-diffuse-large-b-cell-lymphoma-patients-turkish-multicenter-study/2022-03-14T22:15:23+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostication-and-treatment-of-burkitt-lymphoma-in-the-modern-era/2022-03-14T22:21:03+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-in-follicular-lymphoma/2026-01-14T20:54:57+00:00https://lymphoma-stg.clarovantdigital.com/library/influence-of-tp53-mutation-on-survival-of-diffuse-large-b-cell-lymphoma-in-the-car-t-cell-era/2022-08-15T19:35:45+00:00https://lymphoma-stg.clarovantdigital.com/library/an-international-analysis-evaluating-frontline-bendamustine-with-rituximab-in-extranodal-marginal-zone-lymphoma/2023-08-16T12:30:33+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-in-vaccinated-adult-patients-with-hematological-malignancies-preliminary-results-from-epicovideha/2022-10-13T19:10:28+00:00https://lymphoma-stg.clarovantdigital.com/library/how-to-diagnose-and-treat-cd5-positive-lymphomas-involving-the-spleen/2023-08-16T12:29:01+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacies-and-toxicities-of-seven-chemotherapy-regimens-for-advanced-hodgkin-lymphoma/2022-03-15T01:27:56+00:00https://lymphoma-stg.clarovantdigital.com/library/autoimmune-hemolytic-anemia-in-chronic-lymphocytic-leukemia-a-comprehensive-review/2023-08-16T12:27:52+00:00https://lymphoma-stg.clarovantdigital.com/library/second-primary-malignancies-in-chronic-lymphocytic-leukaemia-skin-solid-organ-haematological-and-richters-syndrome/2023-09-29T20:01:17+00:00https://lymphoma-stg.clarovantdigital.com/library/high-risk-subtypes-of-chronic-lymphocytic-leukemia-are-detectable-as-early-as-16-years-prior-to-diagnosis/2023-08-16T12:25:51+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-breast-lymphoma-of-childhood-a-case-report-and-review-of-literature/2023-08-16T12:24:36+00:00https://lymphoma-stg.clarovantdigital.com/library/association-between-multimorbidity-and-socioeconomic-deprivation-on-short-term-mortality-among-patients-with-diffuse-large-b-cell-or-follicular-lymphoma-in-england-a-nationwide-cohort-study-2/2022-03-15T02:14:35+00:00https://lymphoma-stg.clarovantdigital.com/library/transformed-lymphoma-is-associated-with-a-favorable-response-to-car-t-cell-treatment-in-dlbcl-patients/2026-01-14T21:58:57+00:00https://lymphoma-stg.clarovantdigital.com/library/cellular-and-humoral-immune-response-to-mrna-covid-19-vaccination-in-subjects-with-chronic-lymphocytic-leukemia/2023-08-16T12:17:42+00:00https://lymphoma-stg.clarovantdigital.com/library/american-society-of-transplantation-and-cellular-therapy-center-of-international-blood-and-marrow-transplant-research-and-european-society-for-blood-and-marrow-transplantation-clinical-practice-reco/2023-11-14T17:23:12+00:00https://lymphoma-stg.clarovantdigital.com/library/which-patients-with-aggressive-b-cell-nhl-do-not-qualify-for-car-t/2022-03-15T21:37:54+00:00https://lymphoma-stg.clarovantdigital.com/library/characterization-of-low-grade-arthralgia-myalgia-and-musculoskeletal-pain-with-ibrutinib-therapy-pooled-analysis-of-clinical-trials-in-patients-with-chronic-lymphocytic-leukemia-and-mantle-cell-lym/2023-11-14T17:21:24+00:00https://lymphoma-stg.clarovantdigital.com/library/begev-salvage-regimen-in-relapsed-refractory-classical-hodgkin-lymphoma-a-real-life-experience/2026-01-15T14:14:32+00:00https://lymphoma-stg.clarovantdigital.com/library/early-fdg-pet-response-predicts-car-t-failure-in-large-b-cell-lymphoma/2022-08-10T18:01:14+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-prognostic-understanding-with-health-care-use-among-older-adults-with-advanced-cancer-a-secondary-analysis-of-a-cluster-randomized-clinical-trial/2023-11-14T17:19:51+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-transplant-vs-chimeric-antigen-receptor-t-cell-therapy-for-relapsed-dlbcl-in-partial-remission/2023-11-14T17:16:16+00:00https://lymphoma-stg.clarovantdigital.com/library/granulocyte-colony-stimulating-factor-usage-in-recipients-of-chimeric-antigen-receptor-t-cell-immunotherapy/2023-11-14T17:14:46+00:00https://lymphoma-stg.clarovantdigital.com/library/hola-covid-19-study-evaluating-the-impact-of-caring-for-patients-with-covid-19-on-cancer-care-delivery-in-latin-america/2022-03-15T21:37:55+00:00https://lymphoma-stg.clarovantdigital.com/library/childrens-oncology-group-trial-aall1231-a-phase-iii-clinical-trial-testing-bortezomib-in-newly-diagnosed-t-cell-acute-lymphoblastic-leukemia-and-lymphoma/2022-03-15T21:37:55+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-cll-with-reed-sternberg-like-cells-vs-classic-hodgkin-lymphoma-transformation-of-cll-does-this-distinction-matter/2023-11-14T17:12:14+00:00https://lymphoma-stg.clarovantdigital.com/library/when-is-car-t-a-good-option-for-patients-with-follicular-and-marginal-zone-lymphomas/2022-08-10T17:57:34+00:00https://lymphoma-stg.clarovantdigital.com/library/tisagenlecleucel-not-superior-to-soc-as-2l-treatment-for-aggressive-b-cell-lymphoma/2023-11-14T17:10:30+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-sarcopenia-in-patients-with-diffuse-large-b-cell-lymphoma-treated-with-r-chop-a-systematic-review-and-meta-analysis/2022-03-15T21:37:56+00:00https://lymphoma-stg.clarovantdigital.com/library/mechanisms-of-resistance-to-noncovalent-brutons-tyrosine-kinase-inhibitors/2023-11-14T17:19:09+00:00https://lymphoma-stg.clarovantdigital.com/library/differences-in-cancer-incidence-by-broad-ethnic-group-in-england-2013-2017/2022-03-15T21:45:17+00:00https://lymphoma-stg.clarovantdigital.com/library/cd24-is-a-surrogate-for-immune-cold-phenotype-in-aggressive-large-b-cell-lymphoma/2023-11-14T17:09:06+00:00https://lymphoma-stg.clarovantdigital.com/library/sars-cov-2-neutralizing-antibody-treatment-in-covid-19-patients-with-immunodeficiency-due-to-b-cell-non-hodgkin-lymphoma/2023-08-16T12:16:46+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-pulmonary-b-cell-lymphoma-a-review-and-update/2022-03-15T22:01:06+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-activity-of-pembrolizumab-in-combination-with-rituximab-in-relapsed-or-refractory-follicular-lymphoma-2/2023-08-16T12:15:28+00:00https://lymphoma-stg.clarovantdigital.com/library/follicular-lymphoma-grade-3b-and-diffuse-large-b-cell-lymphoma-present-a-histopathological-and-molecular-continuum-lacking-features-of-progression-transformation/2023-08-16T12:12:08+00:00https://lymphoma-stg.clarovantdigital.com/library/results-of-a-uk-real-world-study-of-polatuzumab-vedotin-bendamustine-and-rituximab-for-relapsed-refractory-large-b-cell-lymphoma/2023-08-16T12:10:53+00:00https://lymphoma-stg.clarovantdigital.com/library/mucosa-associated-lymphoid-tissue-malt-lymphoma-in-the-gastrointestinal-tract-in-the-modern-era/2022-03-23T21:01:17+00:00https://lymphoma-stg.clarovantdigital.com/library/indirect-comparison-of-tisagenlecleucel-and-historical-treatments-for-relapsed-refractory-diffuse-large-b-cell-lymphoma/2026-01-14T21:48:16+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-time-trends-of-second-primary-malignancies-after-non-hodgkin-lymphoma-a-swedish-population-based-study/2023-09-29T20:00:35+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-analysis-of-axicabtagene-ciloleucel-vs-tisagenlecleucel-for-the-management-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-in-spain/2026-01-15T13:44:28+00:00https://lymphoma-stg.clarovantdigital.com/library/humoral-and-cellular-immunogenicity-of-sars-cov-2-vaccines-in-chronic-lymphocytic-leukemia-a-prospective-cohort-study/2023-08-16T12:07:01+00:00https://lymphoma-stg.clarovantdigital.com/library/key-considerations-in-the-health-technology-assessment-of-advanced-therapy-medicinal-products-in-scotland-the-netherlands-and-england/2022-03-24T21:02:33+00:00https://lymphoma-stg.clarovantdigital.com/library/the-emerging-role-of-car-t-cell-therapy-in-relapsed-refractory-hodgkin-lymphoma/2022-08-15T19:31:43+00:00https://lymphoma-stg.clarovantdigital.com/library/the-association-between-patient-characteristics-and-the-efficacy-and-safety-of-selinexor-in-diffuse-large-b-cell-lymphoma-in-the-sadal-study/2022-03-24T23:14:42+00:00https://lymphoma-stg.clarovantdigital.com/library/prolonged-remissions-after-nivolumab-plus-gemcitabine-oxaliplatin-in-relapsed-refractory-t-cell-lymphoma/2023-08-16T12:04:46+00:00https://lymphoma-stg.clarovantdigital.com/library/radiotherapy-as-a-treatment-option-for-local-disease-control-in-primary-cutaneous-diffuse-large-b-cell-lymphoma-leg-type/2023-08-16T12:03:53+00:00https://lymphoma-stg.clarovantdigital.com/library/tislelizumab-for-relapsed-refractory-classical-hodgkin-lymphoma-3-year-follow-up-and-correlative-biomarker-analysis/2025-12-15T22:02:38+00:00https://lymphoma-stg.clarovantdigital.com/library/ocular-involvement-in-patients-with-primary-central-nervous-system-lymphoma-analysis-of-a-multicentre-study-in-spain/2023-11-14T17:03:59+00:00https://lymphoma-stg.clarovantdigital.com/library/translating-the-biology-of-diffuse-large-b-cell-lymphoma-into-treatment/2023-11-14T16:50:43+00:00https://lymphoma-stg.clarovantdigital.com/library/chimeric-antigen-receptor-car-t-cell-treatment-for-mantle-cell-lymphoma-mcl/2023-11-14T16:49:48+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-as-first-line-therapy-in-high-risk-large-b-cell-lymphoma-the-phase-2-zuma-12-trial/2023-11-14T16:48:00+00:00https://lymphoma-stg.clarovantdigital.com/library/single-agent-mosunetuzumab-shows-durable-complete-responses-in-patients-with-relapsed-or-refractory-b-cell-lymphomas-phase-i-dose-escalation-study/2023-11-14T16:46:58+00:00https://lymphoma-stg.clarovantdigital.com/library/guideline-for-the-treatment-of-chronic-lymphocytic-leukaemia/2023-11-14T16:43:36+00:00https://lymphoma-stg.clarovantdigital.com/library/second-line-liso-cel-car-t-cell-therapy-shows-efs-benefit-for-r-r-lbcl/2023-11-14T16:42:30+00:00https://lymphoma-stg.clarovantdigital.com/library/late-mortality-subsequent-malignant-neoplasms-and-hospitalisations-in-long-term-survivors-of-adolescent-and-young-adult-hematological-cancers/2023-11-14T16:40:23+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-testicular-lymphoma-a-case-report-and-review-of-the-literature/2022-03-25T18:48:47+00:00https://lymphoma-stg.clarovantdigital.com/library/checkpoint-cd47-expression-in-classical-hodgkin-lymphoma/2023-11-14T16:37:51+00:00https://lymphoma-stg.clarovantdigital.com/library/determinants-of-sars-cov-2-waning-immunity-in-allogeneic-hematopoietic-stem-cell-transplant-recipients/2023-11-14T16:35:23+00:00https://lymphoma-stg.clarovantdigital.com/library/altered-pathways-and-targeted-therapy-in-double-hit-lymphoma/2023-11-14T16:33:48+00:00https://lymphoma-stg.clarovantdigital.com/library/medication-associated-phthalate-exposure-and-childhood-cancer-incidence/2022-03-25T18:48:48+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-long-term-follow-up-experience-with-yttrium-90-ibritumomab-tiuxetan-in-previously-untreated-patients-with-low-grade-follicular-lymphoma-and-marginal-zone-lymphoma/2023-11-14T17:04:55+00:00https://lymphoma-stg.clarovantdigital.com/library/the-echelon-2-trial-5-year-results-of-a-randomized-phase-iii-study-of-brentuximab-vedotin-with-chemotherapy-for-cd30-positive-peripheral-t-cell-lymphoma/2023-11-14T12:54:12+00:00https://lymphoma-stg.clarovantdigital.com/library/immunotherapeutic-strategies-in-chronic-lymphocytic-leukemia-advances-and-challenges/2023-11-14T12:53:10+00:00https://lymphoma-stg.clarovantdigital.com/library/an-updated-approach-and-understanding-of-breast-implant-associated-anaplastic-large-cell-lymphoma/2023-11-14T12:52:12+00:00https://lymphoma-stg.clarovantdigital.com/library/axi-cel-shows-clinically-meaningful-improvement-in-qol-in-second-line-relapsed-refractory-lbcl/2023-11-14T12:50:13+00:00https://lymphoma-stg.clarovantdigital.com/library/dr-martin-discusses-how-to-approach-mcl/2023-11-13T22:16:09+00:00https://lymphoma-stg.clarovantdigital.com/library/early-intrathecal-therapy-shows-promise-for-managing-neurotoxicity-related-to-car-t/2022-08-09T01:15:48+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-brentuximab-vedotin-and-nivolumab-in-refractory-or-relapsed-hodgkin-lymphoma-a-systematic-review/2023-11-13T22:12:21+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-monotherapy-for-relapsed-or-refractory-non-germinal-center-diffuse-large-b-cell-lymphoma/2025-03-04T15:31:53+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-outcomes-provide-prognostic-information-for-survival-in-patients-with-diffuse-large-b-cell-lymphoma-analysis-of-1239-patients-from-the-goya-study/2022-03-25T18:48:50+00:00https://lymphoma-stg.clarovantdigital.com/library/epigenetic-modifications-in-lymphoma-and-their-role-in-the-classification-of-lymphomas/2025-12-10T20:10:29+00:00https://lymphoma-stg.clarovantdigital.com/library/immunochemotherapy-and-maintenance-with-obinutuzumab-or-rituximab-in-patients-with-previously-untreated-marginal-zone-lymphoma-in-the-randomized-gallium-trial/2023-09-07T19:04:55+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-of-mantle-cell-lymphoma-in-the-era-of-bruton-tyrosine-kinase-inhibitors-a-population-based-analysis/2022-03-28T16:10:46+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-analysis-of-50-cases-of-primary-pulmonary-lymphoma-a-retrospective-study-and-literature-review/2022-03-28T16:19:05+00:00https://lymphoma-stg.clarovantdigital.com/library/the-hodgkin-lymphoma-immune-microenvironment-turning-bad-news-into-good/2024-04-02T17:57:43+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-the-combination-of-tirabrutinib-and-entospletinib-with-or-without-obinutuzumab-in-relapsed-chronic-lymphocytic-leukemia/2023-08-16T11:54:35+00:00https://lymphoma-stg.clarovantdigital.com/library/external-validation-of-the-revised-pretransplant-assessment-of-mortality-score-in-allogeneic-hematopoietic-cell-transplantation-a-cohort-study/2022-03-28T16:49:17+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-children-and-adolescents-with-recurrent-classical-hodgkin-lymphoma-the-italian-experience/2022-03-28T16:53:42+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-diffuse-large-b-cell-lymphoma-of-the-central-nervous-system-molecular-and-biological-features-of-neoplastic-cells/2023-08-16T11:43:41+00:00https://lymphoma-stg.clarovantdigital.com/library/peripheral-t-cell-lymphomas-of-the-t-follicular-helper-type-clinical-pathological-and-genetic-attributes/2025-05-23T19:31:10+00:00https://lymphoma-stg.clarovantdigital.com/library/effects-of-b-cell-lymphoma-on-the-immune-system-and-immune-recovery-after-treatment-the-paradigm-of-targeted-therapy/2023-08-16T11:42:50+00:00https://lymphoma-stg.clarovantdigital.com/library/alk-negative-anaplastic-large-cell-lymphoma-features-and-outcomes-of-235-patients-from-the-international-t-cell-project/2022-03-28T18:20:51+00:00https://lymphoma-stg.clarovantdigital.com/library/shorter-diagnosis-to-treatment-interval-in-diffuse-large-b-cell-lymphoma-is-associated-with-inferior-overall-survival-in-a-large-population-based-registry/2022-03-28T18:28:23+00:00https://lymphoma-stg.clarovantdigital.com/library/anti-cd19-car-t-cells-in-combination-with-ibrutinib-for-the-treatment-of-chronic-lymphocytic-leukemia/2026-01-14T21:46:35+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-stem-cell-transplantation-in-hodgkin-lymphoma-latest-advances-in-the-era-of-novel-therapies/2023-08-28T18:53:33+00:00https://lymphoma-stg.clarovantdigital.com/library/cellular-and-humoral-immune-response-to-sars%e2%80%91cov%e2%80%912-mrna-vaccines-in-patients-treated-with-either-ibrutinib-or-rituximab/2023-08-16T11:35:56+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-decision-making-tdm-a-qualitative-study-exploring-the-perspectives-of-patients-with-chronic-haematological-cancers/2023-08-15T21:26:52+00:00https://lymphoma-stg.clarovantdigital.com/library/prospects-in-the-management-of-patients-with-follicular-lymphoma-beyond-first-line-therapy/2025-05-13T13:41:44+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-atezolizumab-with-obinutuzumab-and-bendamustine-in-previously-untreated-follicular-lymphoma/2023-08-15T21:22:16+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-mediastinal-b-cell-lymphoma-novel-precision-therapies-and-future-directions/2023-08-28T18:52:30+00:00https://lymphoma-stg.clarovantdigital.com/library/determinants-of-drug-resistance-in-b-cell-non-hodgkin-lymphomas-the-case-of-lymphoplasmacytic-lymphoma-waldenstrom-macroglobulinemia/2023-08-15T21:20:57+00:00https://lymphoma-stg.clarovantdigital.com/library/systemic-inflammatory-biomarkers-in-primary-central-nervous-system-lymphoma-versus-high-grade-glioma-exploratory-comparative-and-correlative-analysis/2023-08-15T21:19:30+00:00https://lymphoma-stg.clarovantdigital.com/library/up-to-8-years-follow-up-from-resonate-2-first-line-ibrutinib-treatment-for-patients-with-chronic-lymphocytic-leukemia/2023-08-15T21:18:02+00:00https://lymphoma-stg.clarovantdigital.com/library/cytogenetics-in-chronic-lymphocytic-leukemia-eric-perspectives-and-recommendations/2023-11-13T22:09:14+00:00https://lymphoma-stg.clarovantdigital.com/library/serum-immunoglobulin-g-as-a-discriminator-of-infection-in-follicular-lymphoma-patients-undergoing-chemotherapy-with-bendamustine-in-combination-with-rituximab/2022-04-08T21:04:46+00:00https://lymphoma-stg.clarovantdigital.com/library/ebmt-2022-what-are-the-highlights-for-the-treatment-of-lymphoma/2023-11-13T21:27:26+00:00https://lymphoma-stg.clarovantdigital.com/library/determining-clinical-course-of-diffuse-large-b-cell-lymphoma-using-targeted-transcriptome-and-machine-learning-algorithms/2025-12-10T20:11:36+00:00https://lymphoma-stg.clarovantdigital.com/library/good-car-t-cell-expansion-after-infusion-on-day-10-may-predict-response-in-patients-with-lymphoma/2026-01-15T16:42:44+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-treatment-with-clozapine-and-other-antipsychotic-drugs-and-the-risk-of-haematological-malignancies-in-people-with-schizophrenia-a-nationwide-case-control-and-cohort-study-in-finland/2022-04-08T21:04:46+00:00https://lymphoma-stg.clarovantdigital.com/library/metabolic-characteristics-and-prognostic-differentiation-of-aggressive-lymphoma-using-one-month-post-car-t-fdg-pet-ct/2022-08-09T01:13:07+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-adults-and-children-receiving-car-t-cell-therapy-2021-best-practice-recommendations-of-the-european-society-for-blood-and-marrow-transplantation-ebmt-and-the-joint-accreditation-commi/2023-11-13T21:17:19+00:00https://lymphoma-stg.clarovantdigital.com/library/how-do-you-decide-between-continuous-or-time-limited-therapy-for-cll/2023-11-13T21:14:59+00:00https://lymphoma-stg.clarovantdigital.com/library/the-development-of-a-decision-aid-to-support-hodgkin-lymphoma-survivors-considering-lung-cancer-screening/2022-04-08T21:04:47+00:00https://lymphoma-stg.clarovantdigital.com/library/proposed-new-dynamic-prognostic-index-for-diffuse-large-b-cell-lymphoma-international-metabolic-prognostic-index/2022-04-08T21:04:47+00:00https://lymphoma-stg.clarovantdigital.com/library/irf8-is-a-transcriptional-activator-of-cd37-expression-in-diffuse-large-b-cell-lymphoma/2022-04-08T21:04:47+00:00https://lymphoma-stg.clarovantdigital.com/library/combining-btk-inhibitors-with-bcl2-inhibitors-for-treating-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma/2026-01-14T21:22:51+00:00https://lymphoma-stg.clarovantdigital.com/library/stem-cell-transplant-for-mantle-cell-lymphoma-in-taiwan/2022-04-08T21:04:48+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-mrd-guided-venetoclax-consolidation-following-fixed-duration-combination-treatment-in-previously-untreated-patients-with-chronic-lymphocytic-leukemia-cll-latest-updates-f/2026-01-14T21:22:16+00:00https://lymphoma-stg.clarovantdigital.com/library/t-cells-in-the-skin-lymphoma-and-inflammatory-skin-disease/2022-04-08T21:04:48+00:00https://lymphoma-stg.clarovantdigital.com/library/comorbidities-and-mortality-rate-in-covid-19-patients-with-hematological-malignancies-a-systematic-review-and-meta-analysis/2023-11-13T21:06:17+00:00https://lymphoma-stg.clarovantdigital.com/library/odronextamab-a-human-cd20xcd3-bispecific-antibody-in-patients-with-cd20-positive-b-cell-malignancies-elm-1-results-from-the-relapsed-or-refractory-non-hodgkin-lymphoma-cohort-in-a-single-arm/2023-11-13T21:16:33+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-notch1-mutation-as-a-prognostic-factor-in-chronic-lymphocytic-leukemia-cll-in-iraqi-cll-patients/2023-08-15T21:16:24+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-the-prognostic-significance-of-sf3b1-mutation-in-iraqi-patients-with-chronic-lymphocytic-leukemia-cll/2023-08-15T21:15:23+00:00https://lymphoma-stg.clarovantdigital.com/library/follicular-lymphoma-in-china-systematic-evaluation-of-follicular-lymphoma-prognostic-models-2/2023-11-13T21:04:22+00:00https://lymphoma-stg.clarovantdigital.com/library/t-cell-attributes-of-axi-cel-correlate-with-outcomes-in-large-b-cell-lymphoma/2026-01-15T16:42:09+00:00https://lymphoma-stg.clarovantdigital.com/library/does-up-front-autologous-stem-cell-transplantation-at-first-relapse-improve-outcome-in-transplant-eligible-follicular-lymphoma-patients-whose-disease-relapses-within-24-months/2022-04-14T18:52:51+00:00https://lymphoma-stg.clarovantdigital.com/library/nk-cells-combined-with-bispecific-antibody-induces-promising-efficacy-in-advanced-lymphoma/2024-04-02T17:54:02+00:00https://lymphoma-stg.clarovantdigital.com/library/final-response-analysis-of-alpine-trial-shows-superior-orr-with-zanubrutinib-vs-ibrutinib-in-cll/2023-11-13T20:21:48+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-targeted-therapy-for-diffuse-large-b-cell-lymphoma/2023-11-13T20:20:50+00:00https://lymphoma-stg.clarovantdigital.com/library/tafasitamab-plus-lenalidomide-versus-3-rituximab-based-treatments-for-non-transplant-eligible-relapsed-refractory-diffuse-large-b-cell-lymphoma/2023-11-09T21:16:20+00:00https://lymphoma-stg.clarovantdigital.com/library/the-effect-of-dietary-intervention-with-high-oleocanthal-and-oleacein-olive-oil-in-patients-with-early-stage-chronic-lymphocytic-leukemia-a-pilot-randomized-trial/2023-11-09T21:15:34+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-survival-with-ibrutinib-therapy-in-elderly-patients-with-newly-diagnosed-primary-central-nervous-system-lymphoma/2023-11-09T21:14:47+00:00https://lymphoma-stg.clarovantdigital.com/library/car-nk-cell-therapy-is-quickly-growing-in-immunotherapy/2024-04-02T17:48:12+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-in-relapsed-refractory-mantle-cell-lymphoma-long-term-efficacy-and-safety-results-from-a-phase-2-study/2025-05-05T11:46:31+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-covid-19-in-patients-with-mantle-cell-lymphoma-report-from-the-european-mcl-registry/2023-08-15T21:09:21+00:00https://lymphoma-stg.clarovantdigital.com/library/burden-of-lymphoma-in-china-1990-2019-an-analysis-of-the-global-burden-of-diseases-injuries-and-risk-factors-study-2019/2022-04-20T18:41:25+00:00https://lymphoma-stg.clarovantdigital.com/library/monoclonal-antibodies-in-the-treatment-of-diffuse-large-b-cell-lymphoma-moving-beyond-rituximab/2023-08-15T21:01:37+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-predicts-therapeutic-outcome-in-mantle-cell-lymphoma/2023-08-15T21:00:16+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-with-ibrutinib-treatment-for-patients-with-relapsed-refractory-mantle-cell-lymphoma-a-pooled-analysis-of-3-clinical-trials-with-nearly-10-years-of-follow-up/2023-08-15T20:59:35+00:00https://lymphoma-stg.clarovantdigital.com/library/intravascular-large-b-cell-lymphoma-a-review-with-a-focus-on-the-prognostic-value-of-skin-involvement/2023-08-15T20:53:03+00:00https://lymphoma-stg.clarovantdigital.com/library/monocyte-to-lymphocyte-ratio-in-the-diagnosis-of-lymphoma-in-adult-patients/2023-08-15T21:13:58+00:00https://lymphoma-stg.clarovantdigital.com/library/bendamustine-or-high-dose-cytarabine-based-induction-with-rituximab-in-transplant-eligible-mantle-cell-lymphoma/2023-08-15T20:51:22+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-the-durability-of-the-immune-humoral-response-to-covid-19-vaccines-in-patients-with-cancer-undergoing-treatment-or-who-received-a-stem-cell-transplant/2026-01-15T16:35:10+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-diagnostic-review-of-diffuse-large-b-cell-lymphoma-and-its-tumor-microenvironment/2025-12-10T20:08:59+00:00https://lymphoma-stg.clarovantdigital.com/library/humoral-responses-against-sars-cov-2-and-variants-of-concern-after-mrna-vaccines-in-patients-with-non-hodgkin-lymphoma-and-chronic-lymphocytic-leukemia/2026-01-15T16:41:03+00:00https://lymphoma-stg.clarovantdigital.com/library/current-treatments-in-marginal-zone-lymphoma/2026-01-06T21:11:11+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-tisagenlecleucel-in-primary-cns-lymphoma-a-phase-i-ii-clinical-trial/2023-11-09T21:09:11+00:00https://lymphoma-stg.clarovantdigital.com/library/change-in-neurocognitive-performance-among-patients-with-non-hodgkins-lymphoma-in-the-first-year-after-car-t-cell-therapy/2023-11-09T21:07:41+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-as-monotherapy-versus-combination-therapy-in-chinese-patients-with-relapsed-refractory-mantle-cell-lymphoma-a-multicenter-study/2023-11-09T21:06:47+00:00https://lymphoma-stg.clarovantdigital.com/library/low-burden-tp53-mutations-in-cll-clinical-impact-and-clonal-evolution-within-the-context-of-different-treatment-options/2023-11-09T21:05:37+00:00https://lymphoma-stg.clarovantdigital.com/library/can-nivolumab-alone-cure-patients-with-relapse-or-refractory-hodgkin-lymphoma-a-5-year-analysis-of-the-french-early-access-program-epa/2023-11-09T21:03:59+00:00https://lymphoma-stg.clarovantdigital.com/library/cns-prophylaxis-in-dlbcl-first-do-no-harm/2022-05-01T19:14:05+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-axi-cel-achieves-high-response-rate-in-high-risk-lbcl/2023-11-09T21:02:25+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-achieves-durable-response-in-r-r-large-b-cell-lymphoma/2023-11-09T21:01:18+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-chronic-lymphocytic-leukaemia-on-melanoma-outcomes-a-retrospective-case-control-study/2023-11-09T20:09:42+00:00https://lymphoma-stg.clarovantdigital.com/library/rationale-for-oncedaily-or-twice-daily-dosing-of-zanubrutinib-in-patients-with-mantle-cell-lymphoma/2023-11-09T20:06:10+00:00https://lymphoma-stg.clarovantdigital.com/library/5-year-zuma-1-os-analysis-appears-to-support-efs-findings-with-axi-cel-in-r-r-lbcl/2023-11-09T20:04:38+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-immune-related-adverse-events-in-patients-treated-with-chimeric-antigen-receptor-t-cell-therapy-asco-guideline/2023-11-09T20:03:38+00:00https://lymphoma-stg.clarovantdigital.com/library/axi-cel-demonstrates-durable-responses-in-indolent-non-hodgkin-lymphoma/2023-11-09T20:02:02+00:00https://lymphoma-stg.clarovantdigital.com/library/environmental-pesticide-exposure-and-non-hodgkin-lymphoma-survival-a-population-based-study/2023-11-09T20:01:00+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cells-shown-effective-without-increased-risk-of-crs-or-icans-in-cns-involved-lbcl/2023-11-09T19:58:37+00:00https://lymphoma-stg.clarovantdigital.com/library/similar-efficacy-for-axi-cel-and-tisa-cel-in-follicular-lymphoma-noted-with-match-adjusted-comparison/2023-11-09T19:57:15+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hsct-induces-durable-response-in-b-cell-lymphoma/2023-11-09T19:52:37+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-and-influence-of-chimaeric-antigen-receptor-t-trial-eligibility-criteria-in-second-line-a-population-based-study-of-736-patients/2022-08-09T00:55:20+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-elderly-patients-with-primary-cns-lymphoma-in-different-socioeconomic-settings-a-12-year-population-based-analysis-of-combined-modality-treatment/2023-11-09T17:43:17+00:00https://lymphoma-stg.clarovantdigital.com/library/trail-score-a-simple-model-to-predict-immunochemotherapy-tolerability-in-patients-with-diffuse-large-b-cell-lymphoma/2022-05-01T19:14:08+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-symptoms-and-tolerability-of-loncastuximab-tesirine-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2026-01-15T16:39:39+00:00https://lymphoma-stg.clarovantdigital.com/library/very-low-dose-rt-is-effective-although-not-standard-in-indolent-non-hodgkin-lymphoma/2026-01-15T14:14:07+00:00https://lymphoma-stg.clarovantdigital.com/library/hiv-aids-associated-lymphoma-review/2022-05-01T19:14:09+00:00https://lymphoma-stg.clarovantdigital.com/library/endoscopic-features-of-colorectal-lymphoma-according-to-histological-type-2/2023-11-09T17:38:04+00:00https://lymphoma-stg.clarovantdigital.com/library/arsenic-in-drinking-water-and-incidences-of-leukemia-and-lymphoma-implication-for-its-dural-effects-in-carcinogenicity/2022-05-02T19:58:15+00:00https://lymphoma-stg.clarovantdigital.com/library/assessment-of-cranial-radiotherapy-treatment-in-t-cell-lymphoblastic-lymphoma-retrospective-study-from-tertiary-care-center/2022-05-02T20:14:38+00:00https://lymphoma-stg.clarovantdigital.com/library/micro-rnas-in-response-to-active-forms-of-vitamin-d3-in-human-leukemia-and-lymphoma-cells/2023-08-15T20:47:05+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-medication-instruction-sheets-for-patients-undergoing-r-chop-therapy-in-non-hodgkin-lymphoma/2023-08-15T20:46:11+00:00https://lymphoma-stg.clarovantdigital.com/library/the-eha-research-roadmap-hematopoietic-stem-cells-and-allotransplantation/2023-08-15T20:44:27+00:00https://lymphoma-stg.clarovantdigital.com/library/nodular-lymphocytic-predominant-hodgkin-lymphoma-nlphl-treatment-outcome-study-in-a-tertiary-care-cancer-hospital-in-pakistan/2026-01-20T19:42:58+00:00https://lymphoma-stg.clarovantdigital.com/library/relevant-features-and-treatment-options-of-dlbcl-patients-with-late-relapse-after-a-5-year-remission/2025-12-10T20:09:38+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retrospective-study-on-the-clinicopathological-and-molecular-features-of-22-cases-of-natural-killer-t-cell-lymphoma-in-children-and-adolescents/2026-09-02T16:04:06+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-with-use-of-radiation-therapy-and-risk-of-transformation-in-early-stage-follicular-lymphoma/2022-05-11T19:10:22+00:00https://lymphoma-stg.clarovantdigital.com/library/genome-wide-crispr-screen-identifies-cdk6-as-a-therapeutic-target-in-adult-t-cell-leukemia-lymphoma/2023-11-03T20:55:59+00:00https://lymphoma-stg.clarovantdigital.com/library/allo-hsct-may-be-effective-for-patients-with-hepatosplenic-t-cell-lymphoma/2025-12-15T19:44:38+00:00https://lymphoma-stg.clarovantdigital.com/library/open-label-phase-2-study-of-blinatumomab-after-frontline-r-chemotherapy-in-adults-with-newly-diagnosed-high-risk-dlbcl/2022-05-11T19:10:23+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-of-patients-with-b-cell-non-hodgkin-lymphoma-in-real-world-settings-findings-from-the-hemato-oncology-latin-america-observational-registry-study/2023-10-27T18:33:58+00:00https://lymphoma-stg.clarovantdigital.com/library/pet2-response-associated-with-survival-in-newly-diagnosed-diffuse-large-b-cell-lymphoma-results-of-two-independent-prospective-cohorts/2022-05-11T19:10:23+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-early-outcomes-with-brexu-cel-in-mcl-demonstrate-feasibility-and-positive-efficacy/2023-10-27T18:32:48+00:00https://lymphoma-stg.clarovantdigital.com/library/pre-phase-strategy-to-mitigate-first-cycle-effect-in-diffuse-large-b-cell-lymphoma/2022-05-11T19:10:23+00:00https://lymphoma-stg.clarovantdigital.com/library/demographic-differences-among-patients-treated-with-chimeric-antigen-receptor-t-cell-therapy-in-the-united-states/2022-08-09T00:53:06+00:00https://lymphoma-stg.clarovantdigital.com/library/results-of-a-united-kingdom-real-world-study-of-polatuzumab-vedotin-bendamustine-and-rituximab-for-relapsed-refractory-dlbcl/2023-10-27T18:25:43+00:00https://lymphoma-stg.clarovantdigital.com/library/central-nervous-system-international-prognostic-index-impacts-overall-survival-in-diffuse-large-b-cell-lymphoma-treated-with-r-chop-in-a-third-level-cancer-center-from-mexico/2022-05-16T19:00:35+00:00https://lymphoma-stg.clarovantdigital.com/library/a-new-staging-system-based-on-the-dynamic-prognostic-nomogram-for-elderly-patients-with-primary-gastrointestinal-diffuse-large-b-cell-lymphoma/2023-11-09T14:45:11+00:00https://lymphoma-stg.clarovantdigital.com/library/invasive-fungal-disease-in-patients-with-chronic-lymphocytic-leukemia-in-japan-a-retrospective-database-study/2023-08-15T20:39:47+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-values-of-myeloid-differentiation-factor-88-myd88-and-transducin-%ce%b2-like-receptor-1-tblr1-expression-in-tissues-of-diffuse-large-b-cell-non-hodgkin-lymphoma-patients/2023-08-15T20:38:46+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-prevalence-of-lymphatic-neoplasms-in-poland-2009-2015-determined-on-analysis-of-national-health-fund-data-used-in-the-maps-of-healthcare-needs/2023-08-15T20:37:15+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-following-venetoclax-treatment-failure/2024-03-18T19:57:05+00:00https://lymphoma-stg.clarovantdigital.com/library/leukemic-high-grade-b-cell-lymphoma-is-associated-with-myc-translocation-double-hit-triple-hit-status-transformation-and-cns-disease-risk-the-mayo-clinic-experience/2023-08-15T20:34:01+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-presentation-outcome-and-prognostic-markers-in-patients-with-intravascular-large-b-cell-lymphoma-a-lymphoma-study-association-lysa-retrospective-study/2023-08-15T20:30:38+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-of-early-progressed-follicular-lymphoma-in-korea-a-multicenter-retrospective-analysis/2026-04-24T19:44:59+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-vaccines-elicit-strong-cellular-immunity-and-robust-clinical-protection-in-cll/2023-08-15T20:26:51+00:00https://lymphoma-stg.clarovantdigital.com/library/therapy-related-myeloid-neoplasms-in-patients-with-chronic-lymphocytic-leukemia-who-received-fcr-fc-as-frontline-therapy/2023-09-29T19:59:59+00:00https://lymphoma-stg.clarovantdigital.com/library/a-clinical-practice-comparison-of-patients-with-chronic-lymphocytic-leukemia-with-and-without-deletion-17p-receiving-first-line-treatment-with-ibrutinib/2023-08-15T19:13:47+00:00https://lymphoma-stg.clarovantdigital.com/library/tazemetostat-in-relapsed-refractory-follicular-lymphoma-a-propensity-score-matched-analysis-of-e7438-g000-101-trial-outcomes/2023-08-15T19:12:54+00:00https://lymphoma-stg.clarovantdigital.com/library/all-oral-low-dose-chemotherapy-tepip-is-effective-and-well-tolerated-in-relapsed-refractory-patients-with-aggressive-b-cell-lymphoma/2026-01-15T14:10:34+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-monotherapy-in-relapsed-refractory-indolent-non-hodgkin-lymphoma/2022-05-17T20:46:11+00:00https://lymphoma-stg.clarovantdigital.com/library/marginal-zone-lymphoma-present-status-and-future-perspectives/2023-08-15T19:11:24+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-progression-diagnosis-with-intrinsic-cellular-patterns-via-unsupervised-clustering/2023-08-15T19:09:46+00:00https://lymphoma-stg.clarovantdigital.com/library/whole-genome-exome-sequencing-uncovers-mutations-and-copy-number-variations-in-primary-diffuse-large-b-cell-lymphoma-of-the-central-nervous-system/2023-08-15T19:08:35+00:00https://lymphoma-stg.clarovantdigital.com/library/cellular-therapy-in-high-risk-relapsed-refractory-chronic-lymphocytic-leukemia-and-richter-syndrome/2023-08-15T19:03:31+00:00https://lymphoma-stg.clarovantdigital.com/library/controversies-in-the-interpretation-of-liquid-biopsy-data-in-lymphoma/2026-01-14T20:54:25+00:00https://lymphoma-stg.clarovantdigital.com/library/lymphocytosis-and-chronic-lymphocytic-leukaemia-investigation-and-management/2023-08-15T19:00:08+00:00https://lymphoma-stg.clarovantdigital.com/library/depletion-of-cll-cells-by-venetoclax-treatment-reverses-oxidative-stress-and-impaired-glycolysis-in-cd4-t-cells/2023-08-15T18:59:12+00:00https://lymphoma-stg.clarovantdigital.com/library/cd24-is-a-potential-immunotherapeutic-target-for-mantle-cell-lymphoma/2022-05-19T20:25:33+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-among-the-elderly-a-narrative-review-of-current-knowledge-and-future-perspectives/2023-09-08T21:49:27+00:00https://lymphoma-stg.clarovantdigital.com/library/site-specific-survival-of-extra-nodal-diffuse-large-b-cell-lymphoma-and-comparison-with-gastrointestinal-diffuse-large-b-cell-lymphoma/2022-05-19T20:55:21+00:00https://lymphoma-stg.clarovantdigital.com/library/case-report-primary-mediastinal-large-b-cell-lymphoma-invasion-of-extranodal-thyroid-tissue-mimicking-tuberculosis-and-confounded-by-similar-ultrasonic-appearance/2023-08-14T18:11:42+00:00https://lymphoma-stg.clarovantdigital.com/library/proton-therapy-in-supradiaphragmatic-lymphoma-predicting-treatment-related-mortality-to-help-optimize-patient-selection/2025-05-27T12:18:29+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-mortality-risk-factors-and-trends-for-hodgkin-lymphoma-a-global-data-analysis/2022-06-03T19:55:36+00:00https://lymphoma-stg.clarovantdigital.com/library/an-artificial-intelligence-system-applied-to-recurrent-cytogenetic-aberrations-and-genetic-progression-scores-predicts-myc-rearrangements-in-large-b-cell-lymphoma/2022-06-03T19:55:36+00:00https://lymphoma-stg.clarovantdigital.com/library/treosulfan-plus-fludarabine-versus-team-as-conditioning-treatment-before-autologous-stem-cell-transplantation-for-b-cell-non-hodgkin-lymphoma/2025-12-19T15:18:05+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-and-safety-trends-of-autologous-stem-cell-transplantation-in-non-hodgkin-lymphoma-a-report-from-a-tertiary-care-center-in-india/2023-10-27T18:22:12+00:00https://lymphoma-stg.clarovantdigital.com/library/subcutaneous-panniculitis-like-t-cell-lymphoma-in-a-child-presenting-as-an-abdominal-wall-mass/2022-06-03T19:55:37+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-with-ice-chemotherapy-well-tolerated-in-young-patients-with-burkitt-lymphoma/2023-10-27T18:20:50+00:00https://lymphoma-stg.clarovantdigital.com/library/utomilumab-may-enhance-effectiveness-of-car-t-for-advanced-large-b-cell-lymphoma/2022-08-09T00:51:51+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-responses-against-sars-cov-2-variants-after-two-and-three-doses-of-vaccine-in-b-cell-malignancies-uk-proseco-study/2023-10-27T18:10:55+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-adrenal-lymphoma-as-a-rare-cause-of-primary-adrenal-insufficiency-challenges-in-management-and-a-review-of-the-literature/2022-06-03T19:55:37+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-1-transcend-cll-004-study-of-lisocabtagene-maraleucel-in-patients-with-relapsed-refractory-cll-or-sll-2/2026-01-14T21:57:11+00:00https://lymphoma-stg.clarovantdigital.com/library/nmr-based-metabolomic-profiling-can-differentiate-follicular-lymphoma-from-benign-lymph-node-tissues-and-may-be-predictive-of-outcome/2022-06-03T19:55:38+00:00https://lymphoma-stg.clarovantdigital.com/library/preparing-for-car-t-cell-therapy-patient-selection-bridging-therapies-and-lymphodepletion/2025-12-19T15:17:09+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-and-survival-outcomes-in-patients-with-r-r-follicular-lymphoma-a-multicenter-cohort-study/2022-06-03T19:55:38+00:00https://lymphoma-stg.clarovantdigital.com/library/infiltration-of-bilateral-optic-nerves-in-burkitt-lymphoma-a-case-report/2022-06-03T19:55:38+00:00https://lymphoma-stg.clarovantdigital.com/library/modifiable-risk-factors-for-neurocognitive-and-psychosocial-problems-after-hodgkin-lymphoma/2022-06-03T19:55:38+00:00https://lymphoma-stg.clarovantdigital.com/library/a-multicenter-real-world-analysis-of-primary-central-nervous-system-lymphoma-in-those-with-and-without-human-immunodeficiency-virus/2023-10-27T18:27:17+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-comorbidity-in-older-patients-with-peripheral-t-cell-lymphoma-an-international-retrospective-analysis-of-891-patients/2023-10-27T18:03:17+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-ibrutinib-venetoclax-in-patients-with-chronic-lymphocytic-leukemia-and-comorbidities/2023-10-27T18:01:22+00:00https://lymphoma-stg.clarovantdigital.com/library/watch-and-wait-approach-remains-reasonable-for-some-patients-with-follicular-lymphoma/2022-06-03T19:55:39+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-obesity-on-hodgkins-lymphoma-patients-treated-with-uniform-chemotherapy-protocol-at-princess-noorah-oncology-center-national-guard-health-affairs-jeddah-saudi-arabia-retrosp/2022-06-03T19:58:53+00:00https://lymphoma-stg.clarovantdigital.com/library/seroconversion-to-mrna-sars-cov-2-vaccines-in-hematologic-patients/2026-01-15T16:34:39+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-patterns-and-outcomes-of-mantle-cell-lymphoma/2023-08-15T18:53:27+00:00https://lymphoma-stg.clarovantdigital.com/library/hodgkin-lymphoma-biology-and-differential-diagnostic-problem/2023-08-15T18:46:39+00:00https://lymphoma-stg.clarovantdigital.com/library/a-case-report-and-literature-review-of-cutaneous-intravascular-large-b-cell-lymphoma-presenting-clinically-as-panniculitis/2023-08-15T18:45:50+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-the-bnt162b-mrna-covid-19-vaccine-in-patients-with-chronic-lymphocytic-leukemia/2026-08-30T22:59:34+00:00https://lymphoma-stg.clarovantdigital.com/library/targetable-alterations-in-primary-extranodal-diffuse-large-b-cell-lymphoma/2023-08-15T18:37:10+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-therapy-in-mantle-cell-lymphoma-a-review-of-the-current-literature/2026-01-14T21:45:19+00:00https://lymphoma-stg.clarovantdigital.com/library/enduring-undetectable-mrd-and-updated-outcomes-in-relapsed-refractory-cll-after-fixed-duration-venetoclax-rituximab/2026-01-14T20:53:42+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-treatment-in-relapsed-or-refractory-dlbcl-after-car-t-cell-therapy/2023-08-15T18:34:15+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-adapted-chemoimmunotherapy-using-brentuximab-vedotin-and-rituximab-in-children-adolescents-and-young-adults-with-newly-diagnosed-hodgkins-lymphoma-a-phase-ii-non-randomized-controlle/2023-08-28T18:51:44+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-tirabrutinib-and-idelalisib-with-or-without-obinutuzumab-in-relapsed-chronic-lymphocytic-leukemia/2023-08-15T18:32:41+00:00https://lymphoma-stg.clarovantdigital.com/library/the-eha-research-roadmap-malignant-lymphoid-diseases/2023-08-15T18:31:02+00:00https://lymphoma-stg.clarovantdigital.com/library/associations-between-smoking-and-alcohol-and-follicular-lymphoma-incidence-and-survival-a-family-based-case-control-study-in-australia/2022-06-22T21:02:54+00:00https://lymphoma-stg.clarovantdigital.com/library/parental-age-and-childhood-lymphoma-and-solid-tumor-risk-a-literature-review-and-meta-analysis/2022-06-22T21:11:09+00:00https://lymphoma-stg.clarovantdigital.com/library/high-grade-b-cell-lymphoma-with-myc-and-bcl2-and-or-bcl6-rearrangements-biopsy-analysis-of-70-cases-from-the-slovak-lymphoma-registry/2023-08-15T18:29:49+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-in-lymphoproliferative-disorders-a-comprehensive-review/2023-08-15T18:28:38+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-autologous-stem-cell-transplantation-for-mantle-cell-lymphoma-a-systematic-analysis-and-treatment-recommendation/2023-08-15T18:27:37+00:00https://lymphoma-stg.clarovantdigital.com/library/follicular-lymphoma-grade-3-a-comprehensive-review/2023-08-15T18:26:24+00:00https://lymphoma-stg.clarovantdigital.com/library/how-we-treat-nk-t-cell-lymphomas/2026-09-02T16:03:29+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-and-association-with-event-free-survival-efs-in-children-with-newly-diagnosed-high-risk-hodgkin-lymphoma-hl/2023-10-27T17:51:45+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-combo-new-standard-for-transplant-ineligible-mantle-cell-lymphoma-in-older-patients/2023-10-27T17:50:29+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-guided-intermittent-dosing-in-patients-with-cancer-successful-treatment-of-chemoresistant-anaplastic-large-cell-lymphoma-using-intermittent-lorlatinib-dosing/2023-10-27T17:48:43+00:00https://lymphoma-stg.clarovantdigital.com/library/three-year-follow-up-of-kte-x19-in-patients-with-relapsed-refractory-mantle-cell-lymphoma-including-high-risk-subgroups-in-the-zuma-2-study/2023-10-27T17:44:51+00:00https://lymphoma-stg.clarovantdigital.com/library/new-directions-for-mantle-cell-lymphoma-in-2022/2026-01-14T21:20:53+00:00https://lymphoma-stg.clarovantdigital.com/library/revising-the-treatment-pathways-in-lymphoma-new-standards-of-care/2023-10-27T14:46:41+00:00https://lymphoma-stg.clarovantdigital.com/library/btk-inhibitors-impair-humoral-and-cellular-responses-to-recombinant-zoster-vaccine-in-cll/2023-10-27T14:45:13+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-obinutuzumab-doubles-pfs-in-follicular-lymphoma/2023-10-27T14:26:06+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-guided-stop-and-start-of-venetoclax-plus-ibrutinib-for-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukaemia-hovon141-vision-primary-analysis-of-an-open-label/2023-10-27T14:23:59+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-plus-obinutuzumab-may-improve-pfs-not-os-in-chronic-lymphocytic-leukemia/2023-10-27T11:45:04+00:00https://lymphoma-stg.clarovantdigital.com/library/time-limited-venetoclax-obinutuzumab-ibrutinib-is-superior-to-chemoimmunotherapy-in-frontline-chronic-lymphocytic-leukemia/2023-10-27T11:43:24+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-bendamustine-and-rituximab-in-untreated-mantle-cell-lymphoma/2022-06-23T13:58:35+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-multicenter-single-arm-study-of-parsaclisib-a-pi3k-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-in-china-updated-data-from-the-study/2026-01-15T13:50:43+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-in-patients-with-relapsed-refractory-r-r-marginal-zone-lymphoma-mzl-results-of-a-phase-2-multicenter-open-label-trial/2023-10-26T21:27:14+00:00https://lymphoma-stg.clarovantdigital.com/library/gemstone-201-preplanned-primary-analysis-of-a-multicenter-single-arm-phase-2-study-of-sugemalimab-suge-in-patients-pts-with-relapsed-or-refractory-extranodal-natural-killer-t-cell-lymphoma/2023-10-26T21:26:28+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-venetoclax-produces-high-mrd-negativity-rate-in-previously-untreated-cll/2026-01-14T21:20:07+00:00https://lymphoma-stg.clarovantdigital.com/library/tipping-the-balance-toward-rational-combination-therapies-to-overcome-venetoclax-resistance-in-mantle-cell-lymphoma/2023-10-26T21:14:26+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evidence-of-brexucabtagene-autoleucel-for-the-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma-3/2023-10-26T20:56:45+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-with-obinutuzumab-leads-to-worse-outcomes-in-haematological-patients-diagnosed-with-omicron-variant-covid-19/2023-10-26T20:52:33+00:00https://lymphoma-stg.clarovantdigital.com/library/up-to-8-year-follow-up-from-resonate-2-first-line-ibrutinib-treatment-for-patients-with-chronic-lymphocytic-leukemia/2023-10-26T20:50:24+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-monotherapy-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-2/2022-06-23T13:58:37+00:00https://lymphoma-stg.clarovantdigital.com/library/direct-acting-antivirals-as-primary-treatment-for-hepatitis-c-virus-associated-indolent-non-hodgkin-lymphomas-the-bart-study-of-the-fondazione-italiana-linfomi/2022-06-23T13:58:37+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-versus-standard-of-care-with-salvage-chemotherapy-followed-by-autologous-stem-cell-transplantation-as-second-line-treatment-in-patients-with-relapsed-or-refractory-large-b-cel/2023-10-26T20:44:22+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-overall-survival-with-first-line-brentuximab-vedotin-plus-chemotherapy-in-patients-with-stage-iii-iv-classical-hodgkin-lymphoma-6-year-analysis-of-echelon-1/2023-10-26T20:38:13+00:00https://lymphoma-stg.clarovantdigital.com/library/pharmacokinetics-and-exposure-response-analysis-of-venetoclaxobinutuzumab-in-chronic-lymphocytic-leukemia-phase-1b-study-and-phase-3-cll14-trial/2023-10-26T20:14:53+00:00https://lymphoma-stg.clarovantdigital.com/library/relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2023-10-26T20:12:53+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-effectiveness-of-rituximab-maintenance-among-older-patients-with-mantle-cell-lymphoma/2023-11-27T19:15:01+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-in-patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-and-2-prior-therapies-pivotal-phase-ii-expansion-results/2023-10-26T18:39:49+00:00https://lymphoma-stg.clarovantdigital.com/library/the-combination-of-ibrutinib-plus-venetoclax-results-in-a-high-rate-of-mrd-negativity-in-previously-untreated-cll-the-results-of-the-planned-interim-analysis-of-the-phase-iii-ncri-flair-trial/2026-01-14T21:19:24+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-in-treating-waldenstrom-macroglobulinemia-the-last-shall-be-the-first/2023-10-26T18:38:06+00:00https://lymphoma-stg.clarovantdigital.com/library/high-surface-igm-levels-associate-with-shorter-response-to-ibrutinib-and-btk-bypass-in-cll-patients/2023-08-15T18:25:12+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-responses-toxicity-and-survival-in-patients-with-classical-hodgkin-lymphoma-aged-50-years-a-single-center-experience-over-twodecades/2022-06-23T18:29:50+00:00https://lymphoma-stg.clarovantdigital.com/library/immunotherapy-in-indolent-non-hodgkins-lymphoma/2023-10-02T21:19:19+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-risk-of-infusion-reactions-and-effectiveness-of-front%e2%80%91line-obinutuzumab-plus-chlorambucil-compared-with-other-frontline-treatments-for-chronic-lymphocytic-leukemia/2023-08-15T17:44:01+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-efficacy-of-tafasitamab-plus-lenalidomide-versus-systemic-therapies-for-relapsed-refractory-dlbcl-re-mind2-an-observational-retrospective-matched-cohort-study/2023-08-15T17:40:15+00:00https://lymphoma-stg.clarovantdigital.com/library/igh-translocations-in-chinese-patients-with-chronic-lymphocytic-leukemia-clinicopathologic-characteristics-and-genetic-profile/2023-08-15T17:38:04+00:00https://lymphoma-stg.clarovantdigital.com/library/kif23-is-a-potential-biomarker-of-diffuse-large-b-cell-lymphoma/2022-06-23T20:02:16+00:00https://lymphoma-stg.clarovantdigital.com/library/systemic-relapse-in-a-young-adult-patient-with-primary-cns-diffuse-large-b-cell-lymphoma/2022-06-23T20:10:26+00:00https://lymphoma-stg.clarovantdigital.com/library/cancer-therapy-approval-timings-reviewspeed-and-publication-of-pivotal-registration-trials-in-the-us-and-europe-2010-2019/2022-06-24T00:55:36+00:00https://lymphoma-stg.clarovantdigital.com/library/predictive-value-of-baseline-metabolic-tumor-volume-in-early%e2%80%91stage-favorable-hodgkin-lymphoma/2023-08-15T17:35:01+00:00https://lymphoma-stg.clarovantdigital.com/library/rate-of-major-bleeding-with-ibrutinib-versus-bendamustine-rituximab-in-chronic-lymphocytic-leukemia-a-population-based-cohort-study/2023-08-15T17:32:12+00:00https://lymphoma-stg.clarovantdigital.com/library/modified-stage-grouping-of-diffuse-large-b-cell-lymphoma-involving-the-same-side-of-the-diaphragm-in-the-rituximab-era/2023-08-15T16:41:22+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-immune-based-treatments-for-diffuse-large-b-cell-lymphoma-the-post-car-t-cell-era/2022-08-15T19:19:16+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-plus-r-gdp-r2-gdp-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-final-results-f-the-r2-gdp-gotel-trial-and-immune-biomarker-subanalysis/2022-06-24T12:01:02+00:00https://lymphoma-stg.clarovantdigital.com/library/immunoglobulin-gene-sequence-as-an-inherited-and-acquired-risk-factor-for-chronic-lymphocytic-leukemia/2023-08-15T16:39:55+00:00https://lymphoma-stg.clarovantdigital.com/library/tisagenlecleucel-in-adult-relapsed-or-refractory-follicular-lymphoma-the-phase-2-elara-trial/2022-08-15T19:12:38+00:00https://lymphoma-stg.clarovantdigital.com/library/systems-drug-discovery-for-diffuse-large-b-cell-lymphoma-based-on-pathogenic-molecular-mechanism-via-big-data-mining-and-deep-learning-method/2025-12-10T19:56:54+00:00https://lymphoma-stg.clarovantdigital.com/library/frailty-in-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma-receiving-curative-intent-therapy-a-population-based-study/2022-06-24T12:25:14+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapies-in-italy-patient-access-barriers-and-recommendations-for-health-system-solutions/2022-08-15T18:29:33+00:00https://lymphoma-stg.clarovantdigital.com/library/febrile-neutropenia-risk-factors-in-actively-treated-diffuse-large-b%e2%80%91cell-lymphoma-patients/2022-06-24T12:47:20+00:00https://lymphoma-stg.clarovantdigital.com/library/pattern-of-extranodal-involvement-and-its-impact-on-survival-in-diffuse-large-b%e2%80%91cell-lymphoma-from-a-tertiary-cancer-center-in-rural-india/2022-06-24T12:51:32+00:00https://lymphoma-stg.clarovantdigital.com/library/cd73-promotes-chronic-lymphocytic-leukemia/2023-08-15T16:36:57+00:00https://lymphoma-stg.clarovantdigital.com/library/punctual-and-kinetic-mrd-analysis-from-the-fondazione-italiana-linfomi-mcl0208-phase-iii-trial-in-mantle-cell-lymphoma/2026-01-14T20:52:58+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-elderly-diffuse-large-b-cell-lymphoma-patients-treated-with-r-chop-10-year-follow-up-of-the-lnh03-6b-trial/2023-08-15T16:33:52+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-in-patients-with-chronic-lymphocytic-leukemia-clinical-outcome-and-b-and-t-cell-immunity-during-13-months-in-consecutive-patients/2023-08-15T16:30:04+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-of-ifcg-regimen-for-firstline-treatment-of-patients-with-cll-with-mutated-ighv-and-without-del17p-tp53-mutation/2023-08-15T16:28:27+00:00https://lymphoma-stg.clarovantdigital.com/library/how-to-treat-older-patients-with-mantle-cell-lymphoma-in-the-era-of-targeted-drugs/2022-07-05T13:28:46+00:00https://lymphoma-stg.clarovantdigital.com/library/cell-free-dna-for-genomic-analysis-in-primary-mediastinal-large-b-cell-lymphoma/2025-12-17T19:05:55+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-thyroid-lymphoma-ptl-a-rare-case-report-and-review-of-the-literature/2022-07-06T14:29:33+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-safety-for-patients-with-tisagenlecleucel-treated-relapsed-refractory-diffuse-large-b-cell-lymphoma/2022-08-15T18:27:50+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-approaches-in-molecular-characterization-of-classical-hodgkin-lymphoma/2023-08-15T16:13:55+00:00https://lymphoma-stg.clarovantdigital.com/library/tumor-microenvironment-and-immunotherapy-based-approaches-in-mantle-cell-lymphoma/2023-08-15T16:02:56+00:00https://lymphoma-stg.clarovantdigital.com/library/a-bibliometric-analysis-for-relapsed-refractory-non-hodgkin-lymphoma/2022-07-07T15:19:36+00:00https://lymphoma-stg.clarovantdigital.com/library/intrathoracic-infections-in-hodgkin-lymphoma-hl-patients-may-cooperate-with-hl-to-trigger-hemophagocytic-lymphohistiocytosis/2025-12-15T19:47:53+00:00https://lymphoma-stg.clarovantdigital.com/library/extranodal-primary-cd20-negative-diffuse-large-b-cell-lymphoma-with-cytoplasmic-p16-expression/2022-07-07T15:30:44+00:00https://lymphoma-stg.clarovantdigital.com/library/double-expressor-appendiceal-burkitts-lymphoma-a-case-report-and-literature-review/2023-08-15T16:00:47+00:00https://lymphoma-stg.clarovantdigital.com/library/pd-1-pd-l1-pathway-a-therapeutic-target-in-cd30-large-cell-lymphomas/2023-08-15T15:59:27+00:00https://lymphoma-stg.clarovantdigital.com/library/very-late-relapses-in-hodgkin-lymphoma-treated-with-chemotherapy-with-or-without-radiotherapy-linear-pattern-and-distinct-prognostic-factors/2022-07-07T19:39:56+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-diffuse-large-b-cell-lymphoma-of-ovary-report-of-cases-and-literature-review/2022-07-07T20:45:12+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retrospective-cohort-study-of-treatment-outcomes-of-adult-patients-with-relapsed-or-refractory-follicular-lymphoma-record-fl/2022-07-07T21:11:38+00:00https://lymphoma-stg.clarovantdigital.com/library/budget-impact-analysis-of-car-t-cell-therapy-for-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-in-germany/2022-08-15T18:23:26+00:00https://lymphoma-stg.clarovantdigital.com/library/dutch-physicians-perspectives-on-diagnosis-and-treatment-of-waldenstroms-macroglobulinemia-before-and-after-the-implementation-of-a-national-guideline/2023-08-15T15:57:43+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-extranodal-diffuse-large-b-cell-lymphoma-in-the-rituximab-era-a-single-center-retrospective-analysis/2023-10-26T18:17:23+00:00https://lymphoma-stg.clarovantdigital.com/library/sequential-treatment-with-bendamustine-obinutuzumab-ga101-and-ibrutinib-in-chronic-lymphocytic-leukemia-cll-final-results-of-the-cll2-big-trial/2026-01-14T21:18:53+00:00https://lymphoma-stg.clarovantdigital.com/library/abcs-of-adcs-in-management-of-relapsed-refractory-diffuse-large-b-cell-lymphoma/2022-07-12T20:24:52+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-vs-continuous-therapy-in-cll/2023-10-26T18:12:31+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-biomarkers-to-predict-sars-cov-2-vaccine-effectiveness-in-patients-with-hematological-malignancies/2026-01-15T16:39:16+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-protein-energy-malnutrition-on-outcomes-among-patients-with-diffuse-large-b-cell-lymphoma-admitted-for-inpatient-chemotherapy/2023-10-26T18:09:59+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-in-children-and-young-adults-with-newly-diagnosed-classical-hodgkin-lymphoma-with-slow-early-response-to-frontline-chemotherapy-the-phase-2-open-label-keynote-667-study/2023-10-26T18:07:54+00:00https://lymphoma-stg.clarovantdigital.com/library/absence-of-btk-bcl2-and-plcg2-mutations-in-relapsing-chronic-lymphocytic-leukemia-cll-after-first-line-treatment-with-fixed-duration-ibrutinib-i-plus-venetoclax-v/2025-12-15T22:25:12+00:00https://lymphoma-stg.clarovantdigital.com/library/low-lymphocyte-to-monocyte-ratio-predicts-poor-outcome-in-high-risk-aggressive-large-b-cell-lymphoma/2023-10-26T17:57:35+00:00https://lymphoma-stg.clarovantdigital.com/library/response-adapted-anti-pd-1-based-salvage-therapy-for-hodgkin-lymphoma-with-nivolumab-alone-or-in-combination-with-ice/2026-01-15T14:13:34+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-liso-cel-as-second-line-2l-therapy-for-r-r-large-b-cell-lymphoma-lbcl-in-patients-pt-not-intended-for-hematopoietic-stem-cell-transplantation-hsct-primary-analysis/2023-10-26T17:29:35+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-management-of-cll-in-2021/2026-01-14T21:18:07+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-plus-chemotherapy-demonstrates-long-term-benefit-over-rituximab-plus-chemotherapy-in-patients-with-previously-untreated-follicular-lymphoma-final-analysis-of-the-gallium-study/2023-10-26T16:36:42+00:00https://lymphoma-stg.clarovantdigital.com/library/a-longitudinal-analysis-of-early-lung-function-trajectory-in-survivors-of-childhood-hodgkin-lymphoma/2022-07-12T20:24:54+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-outcomes-and-roles-of-transplantation-and-maintenance-rituximab-in-patients-with-previously-untreated-mantle-cell-lymphoma-results-from-large-real-world-cohorts/2023-11-27T19:16:09+00:00https://lymphoma-stg.clarovantdigital.com/library/the-molecular-rationale-for-the-combination-of-polatuzumab-vedotin-plus-rituximab-in-diffuse-large-b-cell-lymphoma/2023-10-26T16:32:51+00:00https://lymphoma-stg.clarovantdigital.com/library/orelabrutinib-sintilimab-combo-induces-rapid-responses-in-peripheral-cns-lymphoma/2023-10-26T16:31:50+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-tisagenlecleucel-in-pediatric-and-young-adult-patients-pts-with-relapsed-or-refractory-r-r-mature-b-cell-non-hodgkin-lymphoma-nhl-the-phase-ii-bianca-study/2023-10-26T16:30:07+00:00https://lymphoma-stg.clarovantdigital.com/library/mucosa-associated-lymphoid-tissue-lymphoma-masked-as-gastric-varices-with-acute-upper-gastrointestinal-bleeding-a-case-report/2023-10-26T16:25:18+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-bendamustine-and-rituximab-in-untreated-mantle-cell-lymphoma-2/2023-10-26T22:18:21+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-zandelisib-administered-by-intermittent-dosing-id-in-patients-with-relapsed-or-refractory-r-r-follicular-lymphoma-primary-analysis-of-the-global-phase-2-study-tidal/2022-07-12T20:24:55+00:00https://lymphoma-stg.clarovantdigital.com/library/retrospective-analysis-of-the-efficacy-and-tolerability-of-gemcitabine-based-chemotherapy-in-relapsed-refractory-lymphoma-patients-not-eligible-for-stem-cell-transplant/2022-07-12T20:24:56+00:00https://lymphoma-stg.clarovantdigital.com/library/r-chop-vs-da-epoch-r-for-double-expressor-lymphoma-a-university-of-california-hematologic-malignancies-consortium-retrospective-analysis/2022-07-12T20:24:56+00:00https://lymphoma-stg.clarovantdigital.com/library/central-venous-catheter-associated-complications-in-pediatric-patients-diagnosed-with-hodgkin-lymphoma-implications-for-catheter-choice/2023-10-26T15:53:21+00:00https://lymphoma-stg.clarovantdigital.com/library/predicting-time-to-treatment-in-follicular-lymphoma-on-watchful-waiting-using-baseline-metabolic-tumour-burden/2022-07-12T20:24:56+00:00https://lymphoma-stg.clarovantdigital.com/library/radiotherapy-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-what-is-the-right-regimen-for-palliation/2022-07-12T20:24:56+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-ibrutinib-plus-venetoclax-for-first-line-treatment-of-cll-primary-analysis-of-the-captivate-fd-cohort/2023-10-26T14:58:56+00:00https://lymphoma-stg.clarovantdigital.com/library/the-diagnostic-and-treatment-challenges-of-concomitant-mantle-cell-lymphoma-and-igm-myeloma/2023-10-26T14:57:36+00:00https://lymphoma-stg.clarovantdigital.com/library/relevance-of-bone-marrow-biopsies-for-response-assessment-in-us-national-cancer-institute-national-clinical-trials-network-follicular-lymphoma-clinical-trials/2022-07-12T20:24:57+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-mosunetuzumab-a-bispecific-antibody-in-patients-with-relapsed-or-refractory-follicular-lymphoma-a-single-arm-multicentre-phase-2-study/2022-07-12T20:24:57+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-recipients-require-fair-amount-of-health-care-resources-after-treatment/2022-08-09T00:37:14+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-strategies-for-advanced-classical-hodgkin-lymphoma-in-the-times-of-dacarbazine-shortage/2022-07-12T20:24:57+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-i-ii-study-of-10-min-dosing-of-bendamustine-hydrochloride-rapid-infusion-formulation-in-patients-with-previously-untreated-indolent-b-cell-non-hodgkin-lymphoma-mantle-cell-lymphoma-or-rela/2022-07-12T20:24:58+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-versus-bendamustine-and-rituximab-in-untreated-chronic-lymphocytic-leukaemia-and-small-lymphocytic-lymphoma-sequoia-a-randomised-controlled-phase-3-trial/2025-03-03T21:00:47+00:00https://lymphoma-stg.clarovantdigital.com/library/antibiotic-use-certain-gut-bacteria-affect-car-t-efficacy-toxicity/2025-12-15T19:42:55+00:00https://lymphoma-stg.clarovantdigital.com/library/camidanlumab-tesirine-elicits-encouraging-responses-in-relapsed-refractory-classical-hodgkin-lymphoma/2023-10-26T14:49:59+00:00https://lymphoma-stg.clarovantdigital.com/library/improving-health-related-quality-of-life-in-women-with-breast-blood-and-gynaecological-cancer-with-an-ehealth-enabled-12-week-lifestyle-intervention-the-womens-wellness-after-cancer-program-randomi/2022-07-12T20:24:58+00:00https://lymphoma-stg.clarovantdigital.com/library/genomic-features-of-car-t-treatment-failure-in-patients-with-lymphoma/2022-08-09T00:34:42+00:00https://lymphoma-stg.clarovantdigital.com/library/liposomal-doxorubicin-supercharge-containing-front-line-treatment-in-patients-with-advanced-stage-diffuse-large-b-cell-lymphoma-or-classical-hodgkin-lymphoma-preliminary-results-of-a-single-centre-ph/2023-10-03T15:27:31+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-persistence-and-time-to-next-treatment-with-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-including-patients-at-high-risk-for-atrial-fibrillation-or-str/2025-03-03T20:59:56+00:00https://lymphoma-stg.clarovantdigital.com/library/bispecific-antibodies-for-patients-with-r-r-b-cell-lymphoma-latest-updates-from-phase-ii-trials/2026-01-14T19:44:51+00:00https://lymphoma-stg.clarovantdigital.com/library/overall-survival-with-brentuximab-vedotin-in-stage-iii-or-iv-hodgkins-lymphoma/2023-10-26T14:41:45+00:00https://lymphoma-stg.clarovantdigital.com/library/clonally-unrelated-richter-syndrome-are-truly-de-novo-diffuse-large-b-cell-lymphomas-with-a-mutational-profile-reminiscent-of-clonally-related-richter-syndrome/2023-10-03T15:24:27+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-biosimilars-prove-effective-in-large-b-cell-lymphoma/2023-10-26T14:37:49+00:00https://lymphoma-stg.clarovantdigital.com/library/sporadic-burkitt-lymphoma-of-the-thoracic-and-lumbar-spinal-canal-in-an-adult-oncogenicity-and-a-literature-review/2023-10-03T15:23:27+00:00https://lymphoma-stg.clarovantdigital.com/library/mismatched-donor-transplantation-with-post-transplantation-cyclophosphamide-for-advanced-cutaneous-t-cell-lymphoma-a-single-center-experience/2023-10-26T14:36:09+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-erythropoiesis-stimulating-agents-in-chemotherapy-induced-anemia/2022-07-29T14:07:36+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-and-epidemiological-profile-of-elderly-hodgkin-lymphoma-in-india/2022-07-29T14:07:36+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-subgroups-of-diffuse-large-b-cell-lymphoma-biology-and-implications-for-clinical-practice/2025-12-10T20:12:32+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-as-second-line-therapy-in-adults-with-relapsed-or-refractory-large-b-cell-lymphoma-who-were-not-intended-for-haematopoietic-stem-cell-transplantation-pilot-an-open-label-p/2022-07-29T14:07:37+00:00https://lymphoma-stg.clarovantdigital.com/library/a-review-of-the-incidence-of-tumor-lysis-syndrome-in-patients-with-chronic-lymphocytic-leukemia-treated-with-venetoclax-and-debulking-strategies/2023-10-03T12:00:32+00:00https://lymphoma-stg.clarovantdigital.com/library/cytomorphologic-features-of-pediatric-type-follicular-lymphoma-on-fine-needle-aspiration-biopsy-case-series-and-a-review-of-the-literature/2023-10-03T11:57:58+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evidence-on-shared-decision-making-is-critical-for-improving-patient-satisfaction-in-dlbcl/2023-10-03T11:55:16+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-represents-viable-treatment-option-for-acalabrutinib-intolerant-b-cell-malignancies/2023-10-03T11:53:50+00:00https://lymphoma-stg.clarovantdigital.com/library/study-examines-quality-of-life-outcomes-among-patients-participating-in-phase-iii-randomized-trials-of-cancer-drugs/2022-07-29T14:07:38+00:00https://lymphoma-stg.clarovantdigital.com/library/practical-management-of-chronic-lymphocytic-leukemia-with-acalabrutinib/2023-10-03T11:52:14+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-elicits-50-response-rate-in-btk-pretreated-mcl/2023-10-03T11:50:44+00:00https://lymphoma-stg.clarovantdigital.com/library/mantle-cell-lymphoma-treatment-options-for-elderly-unfit-patients-a-systematic-review/2022-07-29T14:07:38+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-richter-syndrome-in-patients-with-chronic-lymphocytic-leukemia-cll-treated-with-platinum-or-anthracycline-based-chemotherapy-with-or-without-a-btk-inhibitor-btki/2023-10-03T15:30:04+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-plus-avd-for-first-line-treatment-of-early-stage-unfavorable-hodgkin-lymphoma-breach-a-multicenter-open-label-randomized-phase-ii-trial/2022-07-29T14:07:39+00:00https://lymphoma-stg.clarovantdigital.com/library/complete-responses-to-odronextamab-in-two-patients-with-diffuse-large-b-cell-lymphoma-refractory-to-chimeric-antigen-receptor-t-cell-therapy/2022-07-29T14:07:39+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-topical-hypericin-photodynamic-therapy-for-early-stage-cutaneous-t-cell-lymphoma-mycosis-fungoides/2023-10-03T11:48:36+00:00https://lymphoma-stg.clarovantdigital.com/library/exploring-the-role-of-gut-microbiome-in-cancer-therapy/2023-10-03T11:26:44+00:00https://lymphoma-stg.clarovantdigital.com/library/second-primary-malignancies-in-diffuse-large-b-cell-lymphoma-survivors-with-40-years-of-follow-up-influence-of-chemotherapy-and-radiotherapy/2023-10-03T11:24:41+00:00https://lymphoma-stg.clarovantdigital.com/library/therapy-related-myeloid-neoplasms-following-chimeric-antigen-receptor-t-cell-therapy-for-non-hodgkin-lymphoma/2022-07-29T14:07:40+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-risk-of-cardiovascular-disease-mortality-among-classic-hodgkin-lymphoma-survivors/2022-07-29T14:07:40+00:00https://lymphoma-stg.clarovantdigital.com/library/liso-cel-as-a-second-line-treatment-for-patients-with-r-r-lbcl-not-intended-for-hsct/2023-09-29T19:36:39+00:00https://lymphoma-stg.clarovantdigital.com/library/study-reports-time-limited-venetoclax-based-regimens-of-benefit-in-front-line-treatment-of-cll/2025-12-15T20:08:57+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-a-pegasparaginase-based-chemotherapy-regimen-vs-an-l-asparaginase-based-chemotherapy-regimen-for-newly-diagnosed-advanced-extranodal-natural-killer-t-cell-lymphoma/2023-09-29T19:34:08+00:00https://lymphoma-stg.clarovantdigital.com/library/use-of-btk-inhibitors-in-chronic-lymphocytic-leukemia_small-lymphocytic-lymphoma-cll_sll-a-practical-guidance/2025-03-03T20:56:43+00:00https://lymphoma-stg.clarovantdigital.com/library/targeted-radiotherapy-remains-important-in-pediatric-hodgkin-lymphoma-with-slow-early-response-to-chemotherapy/2022-07-29T14:07:41+00:00https://lymphoma-stg.clarovantdigital.com/library/polarix-how-does-myc-and-bcl2-expression-impact-outcomes-post-frontline-treatment-with-pv-in-dlbcl/2023-09-29T19:22:58+00:00https://lymphoma-stg.clarovantdigital.com/library/durvalumab-as-monotherapy-and-in-combination-therapy-in-patients-with-lymphoma-or-chronic-lymphocytic-leukemia-the-fusion-nhl-001-trial/2023-09-29T19:04:40+00:00https://lymphoma-stg.clarovantdigital.com/library/a-real-world-study-of-combined-modality-therapy-for-early-stage-hodgkin-lymphoma-too-little-treatment-impacts-outcome/2023-08-15T15:56:46+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluating-the-impact-of-eligibility-criteria-in-first-line-clinical-trials-for-follicular-lymphoma-a-mer-leo-cohort-analysis/2023-09-08T21:49:57+00:00https://lymphoma-stg.clarovantdigital.com/library/genomic-and-microenvironmental-landscape-of-stage-i-follicular-lymphoma-compared-to-stage-iii-iv/2022-07-29T14:31:14+00:00https://lymphoma-stg.clarovantdigital.com/library/optical-genome-mapping-a-promising-new-tool-to-assess-genomic-complexity-in-chronic-lymphocytic-leukemia-cll/2023-08-15T15:55:47+00:00https://lymphoma-stg.clarovantdigital.com/library/deregulation-and-epigenetic-modification-of-bcl2-family-genes-cause-resistance-to-venetoclax-in-hematologic-malignancies/2023-08-15T15:54:50+00:00https://lymphoma-stg.clarovantdigital.com/library/influence-of-hyperglycemia-on-the-prognosis-of-patients-with-diffuse-large-b-cell-lymphoma/2022-08-03T18:27:56+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-with-adrenal-involvement-presenting-as-other-iatrogenic-immunodeficiency-associated-lymphoproliferative-disorders-sustained-remission-with-methotrexate-termination-alone/2023-08-15T15:53:37+00:00https://lymphoma-stg.clarovantdigital.com/library/trends-in-use-of-and-medicare-spending-on-short-course-radiotherapy-for-lymphomas-from-2015-to-2019/2022-08-03T19:11:50+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-mantle-cell-lymphoma-in-the-frontline-setting-are-we-ready-for-a-risk-adapted-approach/2026-01-14T20:51:17+00:00https://lymphoma-stg.clarovantdigital.com/library/burkitt-lymphoma-incidence-in-five-continents/2023-08-15T15:52:04+00:00https://lymphoma-stg.clarovantdigital.com/library/classifying-germinal-center-derived-lymphomas-navigate-a-complex-transcriptional-landscape/2022-08-03T19:39:10+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-preferences-for-treatment-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-a-discrete-choice-experiment/2022-08-03T20:03:44+00:00https://lymphoma-stg.clarovantdigital.com/library/a-multicenter-study-of-239-patients-aged-over-70-years-with-diffuse-large-b-cell-lymphoma-in-china/2022-08-03T20:47:56+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-of-polatuzumab-vedotin-combined-with-chemoimmunotherapy-in-untreated-diffuse-large-b-cell-lymphoma/2025-12-19T18:16:26+00:00https://lymphoma-stg.clarovantdigital.com/library/evolution-in-the-definition-of-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma-a-model-for-the-future-of-personalized-medicine/2022-08-03T21:19:13+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-salvage-therapy-options-for-initial-treatment-of-relapsed-refractory-classical-hodgkins-lymphoma-so-many-options-how-to-choose/2026-01-15T14:10:04+00:00https://lymphoma-stg.clarovantdigital.com/library/occurrence-of-myd88l265p-and-cd79b-mutations-in-diffuse-large-b-cell-lymphoma-with-bone-marrow-infiltration-a-case-report/2023-08-15T15:47:43+00:00https://lymphoma-stg.clarovantdigital.com/library/patients-with-chronic-lymphocytic-leukemia-have-a-very-high-risk-of-ineffective-response-to-the-bnt162b2-vaccine/2026-01-15T16:34:08+00:00https://lymphoma-stg.clarovantdigital.com/library/pneumocystis-jirovecii-pneumonia-in-non-hodgkin-lymphoma-after-rituximab-based-chemotherapy-a-case-series/2023-08-15T15:44:49+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-diffuse-large-b-cell-and-high-grade-b-cell-lymphomas-with-synchronous-cns-and-systemic-involvement-at-diagnosis-treated-with-high-dose-methotrexate-and-r-chop-a-single-cente/2022-08-04T00:41:37+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-testing-at-diagnosis-has-prognostic-value-in-patients-with-chronic-lymphocytic-leukemia-including-at-early-stages/2023-08-15T15:43:18+00:00https://lymphoma-stg.clarovantdigital.com/library/abo-blood-group-type-and-risk-of-venous-thromboembolism-in-patients-with-cancer/2022-08-04T00:55:19+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-for-mantle-cell-lymphoma-with-central-nervous-system-relapse/2023-08-15T15:41:52+00:00https://lymphoma-stg.clarovantdigital.com/library/humoral-responses-to-repetitive-doses-of-covid-19-mrna-vaccines-in-patients-with-car-t-cell-therapy/2026-01-15T16:33:38+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-of-anaplastic-large-cell-lymphoma-of-the-breast-in-the-us-2000-to-2018/2022-08-04T16:53:48+00:00https://lymphoma-stg.clarovantdigital.com/library/pi3k-inhibitors-in-chronic-lymphocytic-leukemia-where-do-we-go-from-here/2023-08-15T15:38:31+00:00https://lymphoma-stg.clarovantdigital.com/library/regulatory-t-cells-tregs-in-lymphoid-malignancies-and-the-impact-of-novel-therapies/2023-08-15T15:37:14+00:00https://lymphoma-stg.clarovantdigital.com/library/influence-of-statins-on-the-survival-outcomes-of-patients-with-diffuse-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis/2023-08-15T15:36:23+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-the-types-and-relative-quantities-of-ighv-gene-mutations-in-predicting-prognosis-of-patients-with-chronic-lymphocytic-leukemia/2023-08-15T15:35:29+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathologic-study-of-mantle-cell-lymphoma-with-epstein-barr-virus-infection-a-case-series-and-literature-review/2023-08-15T15:34:32+00:00https://lymphoma-stg.clarovantdigital.com/library/seroconversion-and-outcomes-after-initial-and-booster-covid-19-vaccination-in-adults-with-hematologic-malignancies/2026-01-15T16:33:07+00:00https://lymphoma-stg.clarovantdigital.com/library/relative-hypercoagulation-induced-by-suppressed-fibrinolysis-after-tisagenlecleucel-infusion-in-malignant-lymphoma/2026-01-14T21:45:45+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-venetoclax-obinutuzumab-provides-robust-pfs-benefit-in-untreated-cll/2023-09-29T19:02:59+00:00https://lymphoma-stg.clarovantdigital.com/library/radiotherapy-or-autologous-stem-cell-transplantation-for-primary-cns-lymphoma-in-patients-age-60-years-and-younger-long-term-results-of-the-randomized-phase-ii-precis-study/2025-05-27T12:19:07+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-risk-factors-for-acute-kidney-injury-after-chimeric-antigen-receptor-t-cell-therapy/2023-09-29T19:00:02+00:00https://lymphoma-stg.clarovantdigital.com/library/zandelisib-with-continuous-or-intermittent-dosing-as-monotherapy-or-in-combination-with-rituximab-in-patients-with-relapsed-or-refractory-b-cell-malignancy-a-multicentre-first-in-patient-dose-escal/2023-09-29T18:53:43+00:00https://lymphoma-stg.clarovantdigital.com/library/multidisciplinary-team-approach-is-ideal-for-irae-management-in-follicular-lymphoma-2/2022-08-18T19:59:50+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-micrornas-in-cerebrospinal-fluid-and-plasma-a-new-diagnostic-modality-in-lymphoma-treatment/2023-09-29T18:49:34+00:00https://lymphoma-stg.clarovantdigital.com/library/the-future-role-of-bispecific-antibodies-in-lymphoma/2026-01-14T19:44:28+00:00https://lymphoma-stg.clarovantdigital.com/library/latest-advances-in-the-treatment-of-mantle-cell-lymphoma/2026-01-14T21:16:20+00:00https://lymphoma-stg.clarovantdigital.com/library/expression-of-pd1-and-pdl1-as-immune-checkpoint-inhibitors-in-mantle-cell-lymphoma/2023-09-29T17:49:55+00:00https://lymphoma-stg.clarovantdigital.com/library/patterns-of-therapy-utilization-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2022-08-18T19:59:51+00:00https://lymphoma-stg.clarovantdigital.com/library/patients-with-cll-have-a-lower-risk-of-death-from-covid-19-in-the-omicron-era/2023-08-15T18:41:40+00:00https://lymphoma-stg.clarovantdigital.com/library/mental-health-disorders-are-more-common-in-patients-with-hodgkin-lymphoma-and-may-negatively-impact-overall-survival/2022-08-18T19:59:52+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-and-survival-outcomes-of-waldenstrom-macroglobulinemia-in-latin-american-patients-a-multinational-retrospective-cohort-study/2023-09-08T21:58:13+00:00https://lymphoma-stg.clarovantdigital.com/library/predictors-of-secondary-lung-cancer-among-hodgkin-lymphoma-survivors-a-nationwide-analysis/2022-08-18T19:59:52+00:00https://lymphoma-stg.clarovantdigital.com/library/epstein-barr-virus-positive-cd30-positive-diffuse-large-b-cell-lymphoma-in-a-patient-with-angioimmunoblastic-t-cell-lymphoma/2023-09-08T21:57:31+00:00https://lymphoma-stg.clarovantdigital.com/library/smart-start-rituximab-lenalidomide-and-ibrutinib-in-patients-with-newly-diagnosed-large-b-cell-lymphoma/2023-09-08T21:56:46+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-polypharmacy-and-potentially-inappropriate-medications-with-frailty-among-older-adults-with-blood-cancers/2022-08-18T19:59:53+00:00https://lymphoma-stg.clarovantdigital.com/library/rapid-progression-of-large-b-cell-lymphoma-in-behcets-disease-on-immunosuppressive-therapy-a-case-report-with-literature-review/2022-08-18T19:59:53+00:00https://lymphoma-stg.clarovantdigital.com/library/detection-of-early-seeding-of-richter-transformation-in-chronic-lymphocytic-leukemia/2022-08-18T19:59:53+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-trial-to-evaluate-the-combination-of-pixantrone-and-obinutuzumab-for-patients-with-relapsed-aggressive-lymphoma-final-results-of-the-prospective-multicentre-goal-trial/2023-09-08T20:47:48+00:00https://lymphoma-stg.clarovantdigital.com/library/the-cost-effectiveness-of-axicabtagene-ciloleucel-as-second-line-therapy-in-patients-with-large-b-cell-lymphoma-in-the-united-states-an-economic-evaluation-of-the-zuma-7-trial/2025-12-19T18:40:57+00:00https://lymphoma-stg.clarovantdigital.com/library/six-year-results-from-relevance-lenalidomide-plus-rituximab-r2-versus-rituximab-chemotherapy-followed-by-rituximab-maintenance-in-untreated-advanced-follicular-lymphoma/2026-01-06T21:10:27+00:00https://lymphoma-stg.clarovantdigital.com/library/occupational-exposure-to-pesticides-in-mothers-and-fathers-and-risk-of-cancer-in-the-offspring-a-register-based-case-control-study-from-sweden-1960-2015/2022-08-18T19:59:55+00:00https://lymphoma-stg.clarovantdigital.com/library/pfs-not-associated-with-1-year-depth-of-response-to-ibrutinib-in-chronic-lymphocytic-leukemia/2023-09-08T20:45:54+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-i-data-of-golidocitinib-for-r-r-peripheral-t-cell-lymphoma-jackpot8-trial/2023-09-08T20:36:28+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-central-nervous-system-cns-prophylaxis-in-preventing-dlbcl-patients-from-cns-relapse-a-network-meta-analysis/2023-09-08T20:34:00+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-retreatment-of-patients-with-chronic-lymphocytic-leukemia-after-a-previous-venetoclax-based-regimen-2/2023-08-15T16:31:37+00:00https://lymphoma-stg.clarovantdigital.com/library/bendamustine-in-combination-with-ofatumumab-as-first-line-treatment-for-elderly-patients-with-mantle-cell-lymphoma-a-phase-ii-risk-adapted-design/2022-08-18T19:59:56+00:00https://lymphoma-stg.clarovantdigital.com/library/anbalcabtagene-autoleucel-shows-promise-in-relapsed-refractory-lbcl/2026-01-14T22:33:36+00:00https://lymphoma-stg.clarovantdigital.com/library/differential-diagnosis-of-waldenstroms-macroglobulinemia-and-early-management-perspectives-from-clinical-practice/2023-09-08T20:31:34+00:00https://lymphoma-stg.clarovantdigital.com/library/epstein-barr-positive-diffuse-large-cell-non-hodgkin-lymphoma-nos-a-distinct-morphological-entity-that-can-easily-be-confused-with-other-types-of-lymphoma/2022-08-19T13:17:53+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-in-patients-over-80-with-chronic-lymphocytic-leukemia-a-multicenter-italian-cohort/2025-04-14T21:03:49+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-nutrition-in-primary-and-secondary-prevention-of-cardiovascular-damage-in-childhood-cancer-survivors/2022-08-19T14:20:12+00:00https://lymphoma-stg.clarovantdigital.com/library/the-era-of-genomic-research-for-lymphoma-looking-back-and-forward/2023-08-15T15:30:22+00:00https://lymphoma-stg.clarovantdigital.com/library/tp53-abnormalities-are-underlying-the-poor-outcome-associated-with-chromothripsis-in-chronic-lymphocytic-leukemia-patients-with-complex-karyotype/2023-08-15T15:29:27+00:00https://lymphoma-stg.clarovantdigital.com/library/selecting-the-optimal-btk-inhibitor-therapy-in-cll-rationale-and-practical-considerations/2023-08-15T15:28:18+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-non-hodgkin-lymphoma-among-patients-with-hepatitis-b-virus-and-hepatitis-c-virus-in-taiwan-a-nationwide-cohort-study/2023-08-15T15:27:14+00:00https://lymphoma-stg.clarovantdigital.com/library/the-clinical-impact-of-precisely-defining-mantle-cell-lymphoma-contributions-of-elaine-jaffe/2022-08-19T15:18:50+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-comparison-of-tisagenlecleucel-vs-usual-care-in-patients-with-relapsed-or-refractory-follicular-lymphoma/2026-06-08T15:13:47+00:00https://lymphoma-stg.clarovantdigital.com/library/a-gene-expression-signature-based-on-microenvironment-signaling-to-predict-progression-in-chronic-lymphocytic-leukemia/2023-08-15T15:25:42+00:00https://lymphoma-stg.clarovantdigital.com/library/consolidative-mediastinal-radiotherapy-for-advanced-stage-classical-hodgkin-lymphoma-with-bulky-disease-in-patients-who-achieve-complete-response-after-chemotherapy-in-pet-ct-era/2023-08-15T15:24:28+00:00https://lymphoma-stg.clarovantdigital.com/library/a-promising-future-for-precision-epigenetic-therapy-for-follicular-and-diffuse-large-b-cell-lymphoma/2023-08-15T15:20:50+00:00https://lymphoma-stg.clarovantdigital.com/library/interventions-to-reduce-infections-in-patients-with-hematological-malignancies-a-systematic-review-and-meta-analysis/2022-08-19T15:46:16+00:00https://lymphoma-stg.clarovantdigital.com/library/hodgkin-lymphoma-and-hairy-cell-leukemia-arising-from-chronic-lymphocytic-leukemia-case-reports-and-literature-review/2023-08-15T15:18:44+00:00https://lymphoma-stg.clarovantdigital.com/library/immunohistochemical-expression-of-programmed-death-ligand-1-in-oral-extranodal-diffuse-large-b-cell-lymphoma/2022-08-24T13:05:07+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-landscapes-and-curative-effect-of-car-t-cell-immunotherapy-in-relapse-and-refractory-dlbcl-patients/2023-08-23T14:44:44+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-and-biological-prognostic-factors-in-follicular-lymphoma-patients/2022-08-24T13:45:36+00:00https://lymphoma-stg.clarovantdigital.com/library/post-chemotherapy-pneumonia-in-chinese-patients-with-diffuse-large-b-cell-lymphoma-outcomes-and-predictive-model/2022-08-24T13:55:39+00:00https://lymphoma-stg.clarovantdigital.com/library/decitabine-primed-tandem-cd19-cd22-car-t-therapy-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-patients/2025-12-19T15:15:47+00:00https://lymphoma-stg.clarovantdigital.com/library/antibody-response-in-immunocompromised-patients-with-hematologic-cancers-who-received-a-3-dose-mrna-1273-vaccination-schedule-for-covid-19/2026-01-15T16:32:31+00:00https://lymphoma-stg.clarovantdigital.com/library/late-effects-in-mantle-cell-lymphoma-patients-treated-with-or-without-autologous-stem-cell-transplantation/2023-08-15T15:07:50+00:00https://lymphoma-stg.clarovantdigital.com/library/angioimmunoblastic-t-cell-lymphoma-with-exuberant-cd30-positive-follicular-dendritic-cell-proliferation-in-a-sars-cov-2-patient-the-role-of-mutational-analysis-to-exclude-an-associated-follicular-den/2023-08-15T15:06:58+00:00https://lymphoma-stg.clarovantdigital.com/library/effect-of-infection-with-hepatitis-b-virus-on-the-survival-outcome-of-diffuse-large-b-cell-lymphoma-in-the-prophylactic-antiviral-era/2025-12-15T20:01:53+00:00https://lymphoma-stg.clarovantdigital.com/library/pegfilgrastim-in-supportive-care-of-hodgkin-lymphoma/2022-08-24T18:50:33+00:00https://lymphoma-stg.clarovantdigital.com/library/fdg-pet-ct-guided-rebiopsy-may-find-clinically-unsuspicious-transformation-of-follicular-lymphoma/2022-08-24T19:04:18+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-%c2%b1-obinutuzumab-versus-obinutuzumab-chlorambucil-in-treatment-naive-chronic-lymphocytic-leukemia-five-year-follow-up-of-elevate-tn/2023-09-08T20:21:26+00:00https://lymphoma-stg.clarovantdigital.com/library/tumour-cell-characteristics-and-microenvironment-composition-correspond-to-clinical-presentation-in-newly-diagnosed-nodular-lymphocyte-predominant-hodgkin-lymphoma/2026-02-27T11:35:25+00:00https://lymphoma-stg.clarovantdigital.com/library/revealing-the-evolution-of-the-tumor-immune-microenvironment-in-follicular-lymphoma-patients-progressing-within-24-months-using-single-cell-imaging-mass-cytometry/2022-08-26T17:21:08+00:00https://lymphoma-stg.clarovantdigital.com/library/two-year-follow-up-result-of-reliance-study-a-multicenter-phase-2-trial-of-relmacabtagene-autoleucel-in-chinese-patients-with-relapsed-refractory-large-b-cell-lymphoma/2026-01-14T22:32:45+00:00https://lymphoma-stg.clarovantdigital.com/library/the-antibody-drug-conjugate-loncastuximab-tesirine-for-the-treatment-of-diffuse-large-b-cell-lymphoma/2022-08-26T17:21:09+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiotoxicity-associated-with-chimeric-antigen-receptor-car-t-cell-therapy-for-hematologic-malignancies-a-systematic-review/2026-01-14T22:31:36+00:00https://lymphoma-stg.clarovantdigital.com/library/utility-of-measurable-residual-disease-for-predicting-treatment-outcomes-with-bcr-and-bcl2-targeted-therapies-in-patients-with-cll/2026-01-14T21:15:52+00:00https://lymphoma-stg.clarovantdigital.com/library/secondary-malignancies-in-non-hodgkin-lymphoma-survivors-40years-of-follow-up-assessed-by-treatment-modality/2022-08-26T17:21:09+00:00https://lymphoma-stg.clarovantdigital.com/library/myocardial-infarction-as-the-initial-presentation-of-rituximab-induced-interstitial-lung-disease-a-case-report/2023-09-08T19:42:51+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-for-recurrent-mantle-cell-lymphoma-post-ibrutinib-therapy-a-retrospective-cohort-study-from-a-japanese-administrative-database/2023-09-08T17:47:56+00:00https://lymphoma-stg.clarovantdigital.com/library/an-epidemiological-model-to-estimate-the-prevalence-of-diffuse-large-b-cell-lymphoma-in-the-united-states/2025-12-19T18:40:33+00:00https://lymphoma-stg.clarovantdigital.com/library/next-generation-sequencing-highlights-of-diffuse-large-b-cell-lymphoma-in-a-tertiary-care-hospital-in-north-india/2023-09-08T17:34:27+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-trajectories-after-diagnosis-of-diffuse-large-b-cell-lymphoma-a-multistate-modelling-approach-to-estimate-the-chance-of-lasting-remission/2022-08-26T17:21:10+00:00https://lymphoma-stg.clarovantdigital.com/library/analysis-of-the-diagnosis-of-burkitt-like-lymphoma-in-a-patient-with-atypical-cytogenetics-and-molecular-markers/2022-08-26T17:21:10+00:00https://lymphoma-stg.clarovantdigital.com/library/the-incidence-of-respiratory-infections-and-risk-factors-among-cancer-patients-undergoing-chemotherapy-at-a-tertiary-care-hospital-in-western-saudi-arabia/2023-09-08T14:49:27+00:00https://lymphoma-stg.clarovantdigital.com/library/subcutaneous-epcoritamab-plus-r-dhax-c-shows-promising-preliminary-activity-in-asct-eligible-r-r-dlbcl/2026-01-14T22:31:05+00:00https://lymphoma-stg.clarovantdigital.com/library/flow-cytometry-assessment-of-reactive-t-cells-distinguishes-classic-hodgkin-lymphoma-from-benign-lymphadenopathy-in-children/2022-08-26T17:21:11+00:00https://lymphoma-stg.clarovantdigital.com/library/mir-155-regulated-mtor-and-toll-like-receptor-5-in-gastric-diffuse-large-b-cell-lymphoma/2023-09-07T21:17:10+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-stage-i-ii-hodgkin-lymphoma-who-had-uniform-pre-treatment-staging-with-pet-ct-and-treatment-with-limited-field-radiation-therapy-after-chemotherapy/2022-08-26T17:21:11+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-ceac-beam-and-ieac-conditioning-regimens-followed-by-autologous-stem-cell-transplantation-in-peripheral-t-cell-lymphoma-patients/2025-12-19T15:14:49+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-outcomes-in-chronic-lymphocytic-leukemia-and-small-lymphocytic-leukemia/2025-03-03T20:55:52+00:00https://lymphoma-stg.clarovantdigital.com/library/current-treatment-of-burkitt-lymphoma-and-high-grade-b-cell-lymphomas/2023-09-07T20:31:58+00:00https://lymphoma-stg.clarovantdigital.com/library/cytopenias-after-axicabtagene-ciloleucel-therapy-for-large-b-cell-lymphoma/2023-09-07T20:30:15+00:00https://lymphoma-stg.clarovantdigital.com/library/contrast-enhanced-ultrasound-parameters-and-d-dimer-new-prognostic-parameters-for-diffuse-large-b-cell-lymphoma/2022-08-26T17:21:12+00:00https://lymphoma-stg.clarovantdigital.com/library/the-outcome-of-hodgkin-lymphoma-with-reference-to-prognostic-markers/2022-08-26T17:21:13+00:00https://lymphoma-stg.clarovantdigital.com/library/adherence-to-guidelines-recommended-diagnostic-testing-was-associated-with-overall-survival-in-patients-with-diffuse-large-b-cell-lymphoma-after-rituximab-based-treatment-an-observational-cohort-stud/2023-09-07T20:24:50+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-arising-in-patients-with-preexisting-hodgkin-lymphoma/2022-08-26T17:58:25+00:00https://lymphoma-stg.clarovantdigital.com/library/high-risk-stage-iib-hodgkin-lymphoma-treated-in-the-h10-and-ahl2011-trials-tmtv-is-a-useful-risk-factor-to-stratify-patients-at-baseline/2022-08-26T18:04:05+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-and-pathological-characteristics-and-outcomes-among-patients-with-subcutaneous-panniculitis-like-t-cell-lymphoma-and-related-adipotropic-lymphoproliferative-disorders/2022-08-26T18:12:14+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-prognostic-factors-in-primary-breast-diffuse-large-b-cell-lymphoma/2022-09-02T15:55:40+00:00https://lymphoma-stg.clarovantdigital.com/library/subcutaneous-rituximab-in-patients-with-diffuse-large-b-cell-lymphoma-and-follicular-lymphoma-final-results-of-the-non-interventional-study-mabscale/2026-01-14T18:11:14+00:00https://lymphoma-stg.clarovantdigital.com/library/link-between-disease-status-at-24months-and-mortality-in-follicular-lymphoma/2022-10-11T15:02:00+00:00https://lymphoma-stg.clarovantdigital.com/library/thrombotic-and-bleeding-complications-in-patients-with-chronic-lymphocytic-leukemia-and-severe-covid-19-a-study-of-eric-the-european-research-initiative-on-cll/2023-09-07T18:54:48+00:00https://lymphoma-stg.clarovantdigital.com/library/mrd-guided-venetoclax-plus-ibrutinib-for-r-r-cll-results-from-the-phase-ii-hovon141-vision-trial/2026-01-14T21:14:56+00:00https://lymphoma-stg.clarovantdigital.com/library/tumor-immune-contexture-is-a-determinant-of-anti-cd19-car-t-cell-efficacy-in-large-b-cell-lymphoma/2022-10-11T15:02:00+00:00https://lymphoma-stg.clarovantdigital.com/library/an-extremely-rare-presentation-of-non-hodgkin-lymphoma-in-the-head-and-neck-a-case-report/2022-10-11T15:02:01+00:00https://lymphoma-stg.clarovantdigital.com/library/humoral-and-cellular-immune-response-in-patients-with-hematological-disorders-after-two-doses-of-bnt162b2-mrna-covid-19-vaccine-a-single-center-prospective-observational-study-nct05074706/2026-01-15T16:38:52+00:00https://lymphoma-stg.clarovantdigital.com/library/exploration-of-residual-disease-in-stem-cell-products-from-mantle-cell-lymphoma-using-next-generation-sequencing/2026-01-14T21:14:18+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-and-rituximab-plus-cyclophosphamide-doxorubicin-vincristine-and-prednisone-in-patients-with-previously-untreated-non-germinal-centre-b-cell-like-diffuse-large-b-cell-lymphoma-a-chinese-su/2023-09-07T18:48:59+00:00https://lymphoma-stg.clarovantdigital.com/library/chimeric-antigen-receptor-t-cell-therapy-for-cancer-clinical-applications-and-practical-considerations/2026-01-14T22:30:07+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-effectiveness-of-zuma-5-axi-cel-vs-scholar-5-external-control-in-relapsed-refractory-follicular-lymphoma-2/2022-10-11T15:02:01+00:00https://lymphoma-stg.clarovantdigital.com/library/factors-affecting-the-clinical-course-of-follicular-lymphoma-a-multistate-survival-analysis-using-individual-patient-data-from-eight-multicenter-randomized-clinical-trials/2022-10-11T15:02:01+00:00https://lymphoma-stg.clarovantdigital.com/library/r-ceop-as-first-line-treatment-for-anthracycline-ineligible-patients-with-diffuse-large-b-cell-lymphoma/2023-09-07T18:46:59+00:00https://lymphoma-stg.clarovantdigital.com/library/a-case-report-on-the-rare-presentation-of-the-primary-spinal-epidural-non-hodgkins-lymphoma/2022-10-11T15:02:02+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristic-features-of-primary-testicular-lymphoma-and-survival-trends-a-multicenter-clinical-study/2023-09-07T20:25:14+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-front-line-chronic-lymphocytic-leukemia/2026-01-22T21:55:51+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-relapsed-refractory-chronic-lymphocytic-leukemia/2023-09-07T18:41:59+00:00https://lymphoma-stg.clarovantdigital.com/library/targeting-cd19-in-diffuse-large-b-cell-lymphoma-an-expert-opinion-paper/2023-09-07T18:34:56+00:00https://lymphoma-stg.clarovantdigital.com/library/comparing-clinical-trial-population-representativeness-to-real-world-populations-an-external-validity-analysis-encompassing-43895-trials-and-5685738-individuals-across-989-unique-drugs-and-286-con/2022-10-11T15:02:03+00:00https://lymphoma-stg.clarovantdigital.com/library/biomarkers-of-response-to-ibrutinib-plus-nivolumab-in-relapsed-diffuse-large-b-cell-lymphoma-follicular-lymphoma-or-richters-transformation/2023-09-07T18:37:25+00:00https://lymphoma-stg.clarovantdigital.com/library/plm60-plus-pegaspargase-shows-promise-in-extranodal-natural-killer-and-t-cell-lymphoma/2023-09-07T18:30:21+00:00https://lymphoma-stg.clarovantdigital.com/library/abcl-200-primary-and-secondary-extranodal-diffuse-large-b-cell-lymphoma-a-single-center-survey-from-india/2023-09-07T18:28:34+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-as-consolidation-after-chemo-immunotherapy-results-of-the-uk-national-cancer-research-institute-phase-ii-iii-galactic-trial/2024-04-04T18:40:09+00:00https://lymphoma-stg.clarovantdigital.com/library/brexu-cel-elicits-sustained-3-year-responses-in-relapsed-refractory-mcl/2023-09-07T18:25:51+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-appears-superior-to-ibrutinib-in-patients-with-relapsed-refractory-cll-sll/2025-03-03T20:54:48+00:00https://lymphoma-stg.clarovantdigital.com/library/bendamustine-is-safe-and-effective-for-lymphodepletion-before-tisagenlecleucel-in-patients-with-refractory-or-relapsed-large-b-cell-lymphomas/2024-04-04T18:55:00+00:00https://lymphoma-stg.clarovantdigital.com/library/ixazomib-with-or-without-rituximab-following-maintenance-autologous-stem-cell-transplant-in-mantle-cell-lymphoma-a-single-center-phase-i-trial/2023-09-07T20:19:02+00:00https://lymphoma-stg.clarovantdigital.com/library/camidanlumab-tesirine-appears-safe-effective-in-relapsed-refractory-classical-hodgkin-lymphoma/2023-09-07T17:08:02+00:00https://lymphoma-stg.clarovantdigital.com/library/the-prognostic-significance-of-cd79b-mutation-in-diffuse-large-b-cell-lymphoma-a-meta-analysis-and-systematic-literature-review/2022-10-11T15:02:04+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-of-axicabtagene-ciloleucel-in-r-r-dlbcl/2025-12-19T18:40:08+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-management-of-patients-with-p53-aberrations/2026-01-14T21:13:51+00:00https://lymphoma-stg.clarovantdigital.com/library/initial-safety-run-in-results-of-the-phase-3-lotis-5-trial-novel-combination-of-loncastuximab-tesirine-with-rituximab-lonca-r-versus-immunochemotherapy-in-patients-with-r-r-dlbcl/2023-09-07T17:05:02+00:00https://lymphoma-stg.clarovantdigital.com/library/clinically-relevant-germline-variants-in-allogeneic-hematopoietic-stem-cell-transplant-recipients/2023-09-07T17:03:38+00:00https://lymphoma-stg.clarovantdigital.com/library/tafasitamab-lenalidomide-shows-efficacy-for-2-years-in-r-r-dlbcl/2023-09-07T17:02:31+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-preferences-regarding-treatment-options-for-waldenstroms-macroglobulinemia-a-discrete-choice-experiment/2023-09-07T16:50:47+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-maintenance-following-first-line-br-r-chop-offers-significant-real-world-benefits-in-mcl/2023-09-07T20:17:56+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-assessment-with-low-pass-whole-genome-sequencing-of-cell-free-dna-before-cd19-car-t-cell-therapy-for-large-b-cell-lymphoma/2022-10-11T15:02:06+00:00https://lymphoma-stg.clarovantdigital.com/library/differentiating-central-nervous-system-infection-from-disease-infiltration-in-hematological-malignancy/2022-10-11T15:02:06+00:00https://lymphoma-stg.clarovantdigital.com/library/punctual-and-kinetic-mrd-analysis-from-the-fondazione-italiana-linfomi-mcl0208-phase-3-trial-in-mantle-cell-lymphoma/2026-01-14T21:13:21+00:00https://lymphoma-stg.clarovantdigital.com/library/bruton-tyrosine-kinase-inhibitors-in-b-cell-lymphoma-beyond-the-antitumour-effect/2023-09-07T16:02:45+00:00https://lymphoma-stg.clarovantdigital.com/library/orelabrutinib-plus-rchop-effective-for-extranodal-non-gcb-diffuse-large-b-cell-lymphoma/2022-10-11T15:02:06+00:00https://lymphoma-stg.clarovantdigital.com/library/do-we-have-to-exclude-all-relapsed-diffuse-large-b-cell-lymphoma-patients-not-in-complete-remission-from-autologous-stem-cell-transplant/2022-10-11T15:02:06+00:00https://lymphoma-stg.clarovantdigital.com/library/generation-of-a-crispr-activation-mouse-that-enables-modelling-of-aggressive-lymphoma-and-interrogation-of-venetoclax-resistance/2023-09-07T16:01:36+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-rituximab-and-lenalidomide-in-unfit-or-frail-patients-aged-75-years-or-older-with-de-novo-diffuse-large-b-cell-lymphoma-a-phase-2-single-arm-study/2023-09-08T21:51:48+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-acalabrutinib-and-venetoclax-after-an-optional-debulking-with-bendamustine-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia-cll2-baag-a-multicentre-open-label-phase-2-trial/2026-01-14T21:12:28+00:00https://lymphoma-stg.clarovantdigital.com/library/high-percentages-of-peripheral-blood-t-cell-activation-in-childhood-hodgkins-lymphoma-are-associated-with-inferior-outcome/2022-10-12T15:47:27+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-hbv-reactivation-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-patients-receiving-bruton-tyrosine-kinase-inhibitors-therapy/2022-10-12T15:49:47+00:00https://lymphoma-stg.clarovantdigital.com/library/assessment-of-pretreatment-and-posttreatment-evolution-of-neurofilament-light-chain-levels-in-patients-who-develop-immune-effector-cell-associated-neurotoxicity-syndrome/2022-10-12T15:52:40+00:00https://lymphoma-stg.clarovantdigital.com/library/effective-tumor-debulking-with-ibrutinib-before-initiation-of-venetoclax-results-from-the-captivate-minimal-residual-disease-and-fixed-duration-cohorts/2026-01-14T20:50:45+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-in-patients-with-chronic-lymphocytic-leukemia-with-disease-progression-on-ibrutinib/2023-08-15T14:41:49+00:00https://lymphoma-stg.clarovantdigital.com/library/experiences-with-glofitamab-administration-following-car-t-therapy-in-patients-with-relapsed-mantle-cell-lymphoma/2023-08-15T14:40:16+00:00https://lymphoma-stg.clarovantdigital.com/library/next%e2%80%91generation-sequencing-for-mrd-monitoring-in-b%e2%80%91lineage-malignancies-from-bench-to-bedside/2026-01-14T20:49:22+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-cytogenetic-profiling-reveals-similarities-and-differences-between-localized-nodal-and-systemic-follicular-lymphomas/2023-08-15T14:38:36+00:00https://lymphoma-stg.clarovantdigital.com/library/what-are-the-attributes-prioritized-in-the-choice-of-therapy-in-chronic-lymphocytic-leukemia-a-patient-physician-cross-matching-analysis-of-a-discrete-choice-experiment/2026-01-14T20:48:27+00:00https://lymphoma-stg.clarovantdigital.com/library/hysteroscopic-resection-followed-by-adjuvant-radiotherapy-report-of-a-new-therapeutic-approach-to-primary-cervical-diffuse-large-b-cell-lymphoma/2023-08-15T14:35:33+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-associated-cardiotoxicity-from-the-pharmaceutical-to-the-clinical/2023-08-15T14:34:05+00:00https://lymphoma-stg.clarovantdigital.com/library/expression-and-significance-of-cyclin-dependent-protein-kinase-6-in-diffuse-large-b-cell-lymphoma/2022-10-12T16:16:45+00:00https://lymphoma-stg.clarovantdigital.com/library/ezh2-mutations-at-diagnosis-in-follicular-lymphoma-a-promising-biomarker-to-guide-frontline-treatment/2023-08-15T14:31:35+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-infection-in-patients-with-chronic-lymphocytic-leukemia-receiving-acalabrutinib-in-the-phase-3b-assure-study/2023-08-15T14:30:24+00:00https://lymphoma-stg.clarovantdigital.com/library/ctdna-is-useful-to-detect-mutations-at-codon-641-of-exon-16-of-ezh2-a-biomarker-for-relapse-in-patients-with-diffuse-large-b-cell-lymphoma/2023-08-15T14:29:20+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retro-prospective-observational-study-to-determine-the-proportion-of-double-expressors-in-diffuse-large-b-cell-lymphomas-not-otherwise-specified-dlbcl-nos-in-a-tertiary-care-setting/2023-08-15T14:28:50+00:00https://lymphoma-stg.clarovantdigital.com/library/genetics-of-transformed-follicular-lymphoma/2023-08-15T14:25:21+00:00https://lymphoma-stg.clarovantdigital.com/library/challenges-in-the-diagnosis-of-marginal-zone-lymphoma-with-symptoms-of-small-intestinal-disease-a-case-report-and-scoping-review-of-the-literature/2023-08-15T14:21:32+00:00https://lymphoma-stg.clarovantdigital.com/library/the-clinical-importance-of-prognostic-markers-in-cll/2023-08-15T14:19:53+00:00https://lymphoma-stg.clarovantdigital.com/library/integrative-prognostic-models-predict-long-term-survival-after-immunochemotherapy-in-chronic-lymphocytic-leukemia-patients/2023-08-15T14:18:30+00:00https://lymphoma-stg.clarovantdigital.com/library/a-rare-case-of-bcl2-positive-multiple-myeloma-complicated-with-follicular-lymphoma/2023-08-15T14:16:13+00:00https://lymphoma-stg.clarovantdigital.com/library/metabolic-imaging-in-b-cell-lymphomas-during-car-t-cell-therapy/2022-10-13T02:44:22+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-tisagenlecleucel-plus-pembrolizumab-in-patients-with-r-r-dlbcl-results-from-the-phase-ib-portia-study/2026-01-14T21:44:52+00:00https://lymphoma-stg.clarovantdigital.com/library/effects-of-the-btn162b2-mrna-covid%e2%80%9019-vaccine-in-humoral-and-cellular-immunity-in-patients-with-chronic-lymphocytic-leukemia/2023-08-15T14:11:02+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-outcomes-of-patients-with-follicular-lymphoma-after-relapse-or-progression-a-single-center-real-world-data-analysis/2023-08-15T14:09:07+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-pathogenesis-of-follicular-lymphoma-from-genetics-to-clinical-practice/2023-08-15T14:08:11+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-and-bendamustine-br-compared-with-rituximab-bendamustine-and-cytarabine-r-bac-in-previously-untreated-elderly-patients-with-mantle-cell-lymphoma/2023-08-15T14:06:48+00:00https://lymphoma-stg.clarovantdigital.com/library/richter-syndrome-from-molecular-pathogenesis-to-druggable-targets/2023-08-15T14:05:23+00:00https://lymphoma-stg.clarovantdigital.com/library/immunopeptidome-diversity-in-chronic-lymphocytic-leukemia-identifies-patients-with-favorable-disease-outcome/2023-08-15T13:51:33+00:00https://lymphoma-stg.clarovantdigital.com/library/a-tumor-volume-and-performance-status-model-to-predict-outcome-prior-to-treatment-in-diffuse-large-b-cell-lymphoma/2023-08-15T13:51:03+00:00https://lymphoma-stg.clarovantdigital.com/library/viral-agents-as-potential-drivers-of-diffuse-large-b-cell-lymphoma-tumorigenesis/2023-08-15T13:49:26+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-outcomes-in-zuma-7-a-phase-3-study-of-axicabtagene-ciloleucel-in-second-line-large-b-cell-lymphoma/2022-10-14T20:08:49+00:00https://lymphoma-stg.clarovantdigital.com/library/anti-spike-t-cell-and-antibody-responses-to-sars-cov-2-mrna-vaccines-in-patients-with-hematologic-malignancies/2026-01-15T16:32:02+00:00https://lymphoma-stg.clarovantdigital.com/library/t-cell-lymphoblastic-lymphoma-with-cutaneous-involvement-in-a-child-a-rare-case-report/2022-10-14T20:12:59+00:00https://lymphoma-stg.clarovantdigital.com/library/hodgkin-lymphoma-and-female-fertility-a-multicenter-study-in-women-treated-with-abvd/2025-12-28T14:21:48+00:00https://lymphoma-stg.clarovantdigital.com/library/associations-of-clinical-and-circulating-metabolic-biomarkers-with-low-physical-fitness-and-function-in-adults-with-chronic-lymphocytic-leukemia/2023-08-15T13:45:18+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-trends-of-primary-cutaneous-t-cell-lymphoma-in-the-us-from-2000-to-2018-a-seer-population-data-analysis/2022-10-14T20:18:09+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-diffuse-large-b-cell-lymphoma-of-orbit-a-population-based-analysis/2022-10-14T20:20:05+00:00https://lymphoma-stg.clarovantdigital.com/library/cd5-diffuse-large-b-cell-lymphoma-has-heterogeneous-clinical-features-and-poor-prognosis-a-single-center-retrospective-study-in-china/2022-10-14T20:21:29+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-blk-expression-in-r-chop-treated-diffuse-large-b-cell-lymphoma/2022-10-14T20:23:07+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-and-clinical-outcomes-among-patients-with-relapsed-refractory-classical-hodgkins-lymphoma/2022-10-14T20:24:44+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-and-outcomes-of-patients-with-follicular-lymphoma-a-real-world-study-of-926-patients-in-china/2023-08-15T13:43:57+00:00https://lymphoma-stg.clarovantdigital.com/library/effects-of-ibrutinib-on-t-cell-immunity-in-patients-with-chronic-lymphocytic-leukemia-2/2023-08-15T13:42:34+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathological-features-and-individualized-treatment-of-kidney-involvement-in-b-cell-lymphoproliferative-disorder/2023-08-15T13:41:31+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-landscape-of-relapsed-refractory-mantle-cell-lymphoma-an-updated-review/2022-10-14T20:39:26+00:00https://lymphoma-stg.clarovantdigital.com/library/analysis-of-data-on-fludarabine-cyclophosphamide-and-rituximab-chemoimmunotherapy-for-chronic-lymphocytic-leukemia/2023-09-07T15:53:40+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnosis-and-management-of-classical-hodgkin-lymphomaduring-the-covid-19-pandemic/2023-09-07T15:50:05+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-fdg-pet-analysis-to-identify-patients-with-aggressive-non-hodgkin-lymphoma-who-benefit-from-treatment-intensification-a-post-hoc-analysis-of-the-petal-trial/2023-09-07T15:49:11+00:00https://lymphoma-stg.clarovantdigital.com/library/universal-chimeric-antigen-receptor-t-cell-therapy-the-future-of-cell-therapy-a-review-providing-clinical-evidence/2023-09-07T14:53:55+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-shows-promising-activity-as-first-line-use-in-classical-hodgkin-lymphoma/2023-09-07T14:52:14+00:00https://lymphoma-stg.clarovantdigital.com/library/mantle-cell-lymphoma-in-human-immunodeficiency-virus-infected-patients/2022-10-28T18:44:35+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-and-radiographic-predictors-of-progression-and-survival-in-relapsed-refractory-lymphoma-patients-receiving-anti-cd19-car-t-cell-therapy/2022-10-28T18:44:35+00:00https://lymphoma-stg.clarovantdigital.com/library/alk-positive-anaplastic-large-cell-lymphoma-in-a-patient-with-chronic-lymphocytic-leukemia-a-case-report-and-literature-review/2023-09-07T14:49:38+00:00https://lymphoma-stg.clarovantdigital.com/library/sex-differences-in-lymphoma-incidence-and-mortality-by-subtype-a-population-based-study/2022-10-28T18:44:36+00:00https://lymphoma-stg.clarovantdigital.com/library/secondary-malignancies-and-survival-of-fcr-treated-patients-with-chronic-lymphocytic-leukemia-in-central-europe/2023-09-07T14:48:24+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-treatment-in-the-elderly-patient-with-chronic-lymphocytic-leukemia/2026-01-14T21:11:56+00:00https://lymphoma-stg.clarovantdigital.com/library/current-understanding-of-breast-implant-associated-anaplastic-large-cell-lymphoma/2022-10-28T18:44:36+00:00https://lymphoma-stg.clarovantdigital.com/library/high-surface-igm-levels-associate-with-shorter-response-to-ibrutinib-and-btk-bypass-in-patients-with-cll/2023-09-07T14:47:03+00:00https://lymphoma-stg.clarovantdigital.com/library/proteogenomics-refines-the-molecular-classification-of-chronic-lymphocytic-leukemia/2023-09-07T14:45:53+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-diffuse-large-b-cell-lymphoma-of-the-uterine-cervix-with-severe-lower-urinary-tract-symptoms-a-rare-case-report-and-review-of-the-literature/2022-10-28T18:44:37+00:00https://lymphoma-stg.clarovantdigital.com/library/latest-advances-in-the-treatment-for-patients-with-hodgkin-lymphoma/2023-09-07T18:40:05+00:00https://lymphoma-stg.clarovantdigital.com/library/about-time-why-central-nervous-system-prophylaxis-timing-in-diffuse-large-b-cell-lymphoma-matters-and-does-the-protocol-need-updating/2023-09-07T14:42:16+00:00https://lymphoma-stg.clarovantdigital.com/library/jak-inhibition-with-ruxolitinib-in-relapsed-or-refractory-classical-hodgkin-lymphoma-final-results-of-a-phase-ii-open-label-multicentre-clinical-trial-jericho/2023-09-07T14:40:20+00:00https://lymphoma-stg.clarovantdigital.com/library/immunogenicity-of-a-third-dose-of-the-bnt162b2-covid%e2%80%9119-vaccine-in-patients-with-cll-effects-on-treatment-selection/2026-01-15T16:30:38+00:00https://lymphoma-stg.clarovantdigital.com/library/btk-inhibitors-in-the-treatment-of-hematological-malignancies-and-inflammatory-diseases-mechanisms-and-clinical-studies/2023-08-15T13:14:42+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-prognostic-testing-and-treatment-patterns-in-cll-sll-results-from-1462-patients-in-the-informcll-registry/2025-03-03T19:47:15+00:00https://lymphoma-stg.clarovantdigital.com/library/transformation-of-fl-into-dlbcl-with-a-pmbl-gene-expression-signature/2023-08-14T18:09:16+00:00https://lymphoma-stg.clarovantdigital.com/library/the-prognostic-nutritional-index-an-independent-predictor-of-overall-survival-for-newly-diagnosed-follicular-lymphoma-in-china/2022-10-28T22:42:01+00:00https://lymphoma-stg.clarovantdigital.com/library/coexisting-conditions-and-concomitant-medications-do-not-affect-venetoclax-management-and-survival-in-chronic-lymphocytic-leukemia/2023-08-23T20:41:32+00:00https://lymphoma-stg.clarovantdigital.com/library/b-cell-malignancies-treated-with-targeted-drugs-and-sars-cov-2-infection/2023-08-15T12:38:11+00:00https://lymphoma-stg.clarovantdigital.com/library/whole%e2%80%91exome-sequencing-analysis-identifies-distinct-mutational-profile-and-novel-prognostic-biomarkers-in-primary-gastrointestinal-diffuse-large-b%e2%80%91cell-lymphoma/2023-11-09T14:46:01+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-treatment-of-chronic-lymphocytic-leukemia-with-ibrutinib-plus-obinutuzumab-versus-chlorambucil-plus-obinutuzumab-final-analysis-of-the-randomized-phase-iii-illuminate-trial/2023-08-15T12:36:31+00:00https://lymphoma-stg.clarovantdigital.com/library/effectiveness-and-safety-of-ibrutinib-for-chronic-lymphocytic-leukemia-in-routine-clinical-practice-3%e2%80%91year-follow%e2%80%91up-of-the-belgian-ibrutinib-real%e2%80%91world-data-bird-study/2023-08-15T12:34:50+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-high%e2%80%91dose-methotrexate-for-cns-prophylaxis-in-diffuse-large-b%e2%80%91cell-lymphoma-with-an-intermediate-or-high-cns%e2%80%91international-prognostic-index-a-single%e2%80%91center/2022-10-28T22:55:31+00:00https://lymphoma-stg.clarovantdigital.com/library/is-there-still-a-role-for-transplant-for-patients-with-mantle-cell-lymphoma-mcl-in-the-era-of-car-t-cell-therapy/2023-08-15T12:30:44+00:00https://lymphoma-stg.clarovantdigital.com/library/clonal-evolution-in-chronic-lymphocytic-leukemia-is-scant-in-relapsed-but-accelerated-in-refractory-cases-after-chemoimmune-therapy/2023-08-15T12:29:41+00:00https://lymphoma-stg.clarovantdigital.com/library/transformed-waldenstrom-macroglobulinemia-update-on-diagnosis-prognosis-and-treatment/2022-11-02T22:56:57+00:00https://lymphoma-stg.clarovantdigital.com/library/increasing-tissue-requirements-in-lymphoma-trials-may-exclude-patients-with-high-risk-disease-or-worse-prognosis/2025-12-15T21:59:08+00:00https://lymphoma-stg.clarovantdigital.com/library/hypophosphatemia-due-to-increased-effector-cell-metabolic-activity-is-associated-with-neurotoxicity-symptoms-in-cd19-targeted-car-t-cell-therapy/2023-08-15T12:27:37+00:00https://lymphoma-stg.clarovantdigital.com/library/targeted-sequencing-reveals-the-relationship-between-mutations-and-patients-clinical-indicators-blood-cell-counts-and-early-progression-in-diffuse-large-b-cell-lymphoma/2022-11-02T23:04:52+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-four-prognostic-indices-in-follicular-lymphoma-treated-in-first-line-with-immunochemotherapy/2022-11-02T23:36:02+00:00https://lymphoma-stg.clarovantdigital.com/library/lymphomas-associated-with-epstein-barr-virus-infection-in-2020-results-from-a-large-unselected-case-series-in-france/2023-08-15T12:23:20+00:00https://lymphoma-stg.clarovantdigital.com/library/herbicide-use-in-farming-and-other-jobs-in-relation-to-non-hodgkins-lymphoma-nhl-risk/2023-08-15T12:21:28+00:00https://lymphoma-stg.clarovantdigital.com/library/prolonged-covid-19-in-an-immunocompromised-patient-treated-with-obinutuzumab-and-bendamustine-for-follicular-lymphoma/2023-08-15T11:50:31+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-related-cytokine-release-syndrome-and-therapeutic-response-is-modulated-by-the-gut-microbiome-in-hematologic-malignancies/2026-01-14T21:44:16+00:00https://lymphoma-stg.clarovantdigital.com/library/targeted-therapies-in-cll-sll-and-the-cumulative-incidence-of-infection-a-systematic-review-and-meta-analysis/2025-03-03T19:45:39+00:00https://lymphoma-stg.clarovantdigital.com/library/induction-of-neutralizing-antibodies-in-cll-patients-after-sars%e2%80%91cov%e2%80%912-mrna-vaccination-a-monocentric-experience/2023-08-14T23:45:57+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-implications-of-circulating-tumor-dna-in-predicting-the-outcome-of-diffuse-large-b-cell-lymphoma-patients-receiving-first%e2%80%91line-therapy/2026-01-14T20:47:38+00:00https://lymphoma-stg.clarovantdigital.com/library/monitoring-of-circulating-tumor-dna-predicts-response-to-treatment-and-early-progression-in-follicular-lymphoma-results-of-a-prospective-pilot-study/2023-08-14T23:42:44+00:00https://lymphoma-stg.clarovantdigital.com/library/changing-incidence-and-survival-of-primary-central-nervous-system-lymphoma-in-australia-a-33-year-national-population-based-study/2023-08-14T23:39:39+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-of-follicular-lymphoma-in-the-united-states-a-claims-analysis/2025-12-19T18:17:05+00:00https://lymphoma-stg.clarovantdigital.com/library/an-integrated-prognosticmodel-for-diffuse-large-b-cell-lymphoma-treatedwith-immunochemotherapy/2023-10-27T20:53:24+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-and-outcome-of-acute-myeloid-leukaemia-among-survivors-of-primary-diffuse-large-b-cell-lymphoma-a-retrospective-observational-study-based-on-seer-database/2026-01-06T20:53:41+00:00https://lymphoma-stg.clarovantdigital.com/library/differential-diagnosis-of-hematologic-and-solid-tumors-using-targeted-transcriptome-and-q1-artificial-intelligence/2022-11-03T16:08:17+00:00https://lymphoma-stg.clarovantdigital.com/library/improving-outcomes-for-high-risk-dlbcl-a-pilot-study-looking-at-the-role-of-fractionated-cyclophosphamide-with-rchop-chemoimmunotherapy-scuba-1-trial/2022-11-03T16:10:10+00:00https://lymphoma-stg.clarovantdigital.com/library/contribution-of-patient-registries-to-regulatory-decision-making-on-rare-diseases-medicinal-products-in-europe/2022-11-03T16:12:01+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-with-lisocabtagene-maraleucel-vs-standard-of-care-in-relapsed-or-refractory-lbcl/2023-08-14T23:37:35+00:00https://lymphoma-stg.clarovantdigital.com/library/oral-hdac-inhibitor-tucidinostat-in-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma-phase-iib-results/2022-11-03T16:15:22+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-phenotypic-markers-and-outcomes-of-diffuse-large-b-cell-lymphoma-between-hiv-infected-and-hiv-uninfected-chinese-patients/2022-11-03T16:16:58+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-lenalidomide-in-diffuse-large-b%e2%80%91cell-lymphoma-a-meta%e2%80%91analysis-of-randomized-controlled-trials/2022-11-03T17:29:37+00:00https://lymphoma-stg.clarovantdigital.com/library/two-distinct-clinical-patterns-of-ibrutinib-to-venetoclax-transition-in-relapsed-chronic-lymphocytic-leukemia-patients/2023-08-14T23:34:09+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-associated-with-rituximab-platinum-salt-based-immunochemotherapy-in-b-cell-lymphomas-results-of-a-phase-1b-ii-study-of-the-lysa-group/2023-08-14T23:37:01+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-atezolizumab-with-rituximab-and-chop-in-previously-untreated-diffuse-large-b-cell-lymphoma/2025-12-10T19:40:54+00:00https://lymphoma-stg.clarovantdigital.com/library/synchronous-mantle-cell-lymphoma-bone-marrow-involvement-complicated-with-extensive%e2%80%91stage-small-cell-lung-cancer-a-case-report-and-literature-review/2022-11-03T18:49:02+00:00https://lymphoma-stg.clarovantdigital.com/library/bispecific-antibodies-for-the-treatment-of-b-cell-lymphoma-promises-unknowns-and-opportunities/2026-01-14T21:43:53+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retrospective-cohort-study-of-polatuzumab-vedotin-combined-with-immunochemotherapy-in-chinese-patients-with-relapse-refractory-diffuse-large-b-cell-lymphoma/2023-09-26T20:58:17+00:00https://lymphoma-stg.clarovantdigital.com/library/btk-inhibitors-and-car-t%e2%80%91cell-therapy-in-treating-mantle-cell-lymphoma-finding-a-dancing-partner/2022-11-09T21:09:44+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-trends-in-hematological-malignancies-in-the-nordic-countries-through-50-years/2022-11-09T21:12:01+00:00https://lymphoma-stg.clarovantdigital.com/library/t%e2%80%91cell-counts-in-peripheral-blood-at-leukapheresis-predict-responses-to-subsequent-car%e2%80%91t-cell-therapy/2026-01-15T16:30:15+00:00https://lymphoma-stg.clarovantdigital.com/library/case-report-development-of-diffuse-large-b-cell-lymphoma-a-long-time-after-hairy-cell-leukemia/2022-11-09T21:16:43+00:00https://lymphoma-stg.clarovantdigital.com/library/a-probabilistic-cost%e2%80%91effectiveness-analysis-of-venetoclax-and-obinutuzumab-as-a-first%e2%80%91line-therapy-in-chronic-lymphocytic-leukemia-in-canada/2023-08-14T21:26:31+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-for-patients-with-chronic-lymphocytic-leukemia-cll-previously-treated-with-both-a-covalent-btk-and-bcl2-inhibitor-in-the-united-states-a-real-world-database-study/2023-08-14T21:25:48+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-of-nivolumab-combined-with-ibrutinib-in-patients-with-diffuse-large-b-cell-richter-transformation-of-cll/2023-08-14T21:00:00+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-rituximab-biosimilars-or-reference-product-as-first-line-treatment-in-patients-with-low-tumour-burden-follicular-lymphoma-a-systematic-review-and-meta-analysis/2023-08-14T20:55:25+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-experience-among-patients-with-relapsed-refractory-mantle-cell-lymphoma-after-bruton-tyrosine-kinase-inhibitor-failure-in-europe-the-scholar-2-retrospective-chart-review-study/2023-08-14T20:52:59+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-of-chimeric-antigen-receptor-t-cell-therapy-in-adults-with-relapsed-or-refractory-follicular-lymphoma/2025-12-19T18:15:10+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-clinical-effectiveness-and-safety-of-ct-p10-in-patients-with-diffuse-large-b-cell-lymphoma-an-observational-study-in-europe/2023-08-14T20:32:08+00:00https://lymphoma-stg.clarovantdigital.com/library/pre-transplant-platelet-to-lymphocyte-ratio-predicts-outcome-after-allogeneic-hematopoietic-stem-cell-transplantation/2023-08-14T20:30:19+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-biomarkers-in-the-peripheral-blood-and-tumor-microenvironment-of-classical-hodgkin-lymphoma-patients-in-relation-to-tumor-burden-and-response-to-treatment/2022-11-09T21:45:10+00:00https://lymphoma-stg.clarovantdigital.com/library/genomic-profling-reveals-differences-in-primary-central-nervous-system-lymphoma-and-large-b-cell-lymphoma-with-subtyping-suggesting-sensitivity-to-btk-inhibition/2023-08-14T20:29:05+00:00https://lymphoma-stg.clarovantdigital.com/library/the-value-of-thymus-and-activation-related-chemokine-immunohistochemistry-in-classic-hodgkin-lymphoma-diagnostics/2022-11-09T21:51:34+00:00https://lymphoma-stg.clarovantdigital.com/library/coming-of-age-for-btk-inhibitor-therapy-a-review-of-zanubrutinib-in-waldenstrom-macroglobulinemia/2023-08-14T20:27:45+00:00https://lymphoma-stg.clarovantdigital.com/library/genomic-pathways-and-treatment-strategies-for-patients-with-waldenstroms-macroglobulinemia/2023-09-07T14:37:12+00:00https://lymphoma-stg.clarovantdigital.com/library/what-are-the-latest-advances-in-the-treatment-of-nk-t-cell-lymphoma/2023-09-07T14:34:29+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-with-chemotherapy-in-pediatric-high-risk-hodgkins-lymphoma/2023-09-07T14:30:31+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-advances-in-lymphoma-implications-for-managed-care/2023-09-07T14:19:44+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-after-allogeneic-hematopoietic-stem-cell-transplantation-for-adults-with-primary-mediastinal-b-cell-lymphoma-a-sfgm-tc-and-lysa-study/2023-09-07T14:17:58+00:00https://lymphoma-stg.clarovantdigital.com/library/triple-expressor-lymphoma-presentation-with-acute-paraparesis-due-to-spinal-cord-compression/2023-09-07T14:15:55+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-vaccine-related-beliefs-and-behaviors-among-patients-with-and-survivors-of-hematologic-malignancies/2023-09-07T14:14:28+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-in-chile-the-impact-of-combined-chop-plus-rituximab-in-the-public-health-system/2023-09-07T14:11:38+00:00https://lymphoma-stg.clarovantdigital.com/library/umrd-as-a-surrogate-endpoint-for-clinical-trials-regulatory-approvals-and-therapy-decisions-in-cll/2026-01-14T21:11:01+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-versus-ibrutinib-in-relapsed-refractory-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-interim-analysis-of-a-randomized-phase-iii-trial/2025-12-15T22:30:27+00:00https://lymphoma-stg.clarovantdigital.com/library/the-outcome-of-older-adults-with-classic-hodgkin-lymphoma-in-british-columbia-2/2023-09-07T14:07:49+00:00https://lymphoma-stg.clarovantdigital.com/library/high-dose-cytarabine-and-autologous-stem-cell-transplantation-in-mantle-cell-lymphoma-long-term-follow-up-of-the-randomized-mantle-cell-lymphoma-younger-trial-of-the-european-mantle-cell-lymphoma-net/2023-09-07T14:03:23+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-and-doxorubicin-vinblastine-and-dacarbazine-in-early-stage-unfavorable-hodgkin-lymphoma-final-analysis-of-the-randomized-german-hodgkin-study-group-phase-ii-nivahl-trial/2023-09-07T18:39:18+00:00https://lymphoma-stg.clarovantdigital.com/library/the-advanced-stage-hodgkin-lymphoma-international-prognostic-index-development-and-validation-of-a-clinical-prediction-model-from-the-holistic-consortium/2023-01-20T19:53:23+00:00https://lymphoma-stg.clarovantdigital.com/library/chimeric-antigen-receptor-t-cell-therapies-barriers-and-solutions-to-access/2023-01-20T19:53:23+00:00https://lymphoma-stg.clarovantdigital.com/library/cd47-overexpression-is-common-in-intestinal-non-gcb-type-diffuse-large-b-cell-lymphoma-and-associated-with-18q21-gain/2023-09-06T01:11:59+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-assessment-of-second-primary-malignancies-in-a-treated-and-untreated-chronic-lymphocytic-leukemia-population-in-the-united-states/2025-12-19T18:39:31+00:00https://lymphoma-stg.clarovantdigital.com/library/non-restrictive-diet-does-not-increase-infections-in-patients-with-neutropenia-after-stem-cell-transplantation-final-analysis-of-the-neutrodiet-multicenter-randomized-trial/2023-09-06T00:51:01+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-trial-of-acalabrutinib-lenalidomide-rituximab-alr-with-real-time-monitoring-of-mrd-in-patients-with-treatment-naive-mantle-cell-lymphoma/2025-06-23T15:18:13+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-plus-r-chop-induces-high-response-rates-and-a-favorable-safety-profile-in-patients-with-previously-untreated-diffuse-large-b-cell-lymphoma-dlbcl-results-from-a-phase-ib-study/2026-01-14T22:29:40+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-real-world-data/2026-01-14T22:28:55+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-monotherapy-provides-deep-and-durable-responses-including-minimal-residual-disease-mrd-negativity-novel-subgroup-analyses-in-patients-with-relapsed-refractory-r-r-large-b-cell-lymphom/2026-01-14T19:43:59+00:00https://lymphoma-stg.clarovantdigital.com/library/indirect-comparisons-of-the-efficacy-of-subcutaneous-epcoritamab-vs-chemoimmunotherapy-in-patients-with-relapsed-or-refractory-large-b-cell-lymphoma/2026-01-14T18:10:26+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-trial-to-evaluate-safety-of-subcutaneous-epcoritamab-monotherapy-in-the-outpatient-setting-among-patients-with-relapsed-or-refractory-diffuse-grade-1-3a-large-b-cell-and-follicular-lymphoma-e/2026-01-14T22:27:01+00:00https://lymphoma-stg.clarovantdigital.com/library/subcutaneous-epcoritamab-in-combination-with-rituximab-lenalidomide-r2-for-first-line-treatment-of-follicular-lymphoma-initial-results-from-phase-1-2-trial/2026-01-14T22:26:13+00:00https://lymphoma-stg.clarovantdigital.com/library/improvements-in-lymphoma-symptoms-and-health-related-quality-of-life-in-patients-with-relapsed-or-refractory-large-b-cell-lymphoma-treated-with-subcutaneous-epcoritamab-epcore-nhl-1/2026-01-14T18:07:39+00:00https://lymphoma-stg.clarovantdigital.com/library/subcutaneous-epcoritamab-with-rituximab-lenalidomide-in-patients-with-relapsed-or-refractory-follicular-lymphomaphase-1-2-trial-update/2026-01-14T22:25:35+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-rituximab-or-lenalidomide-rituximab-bendamustine-in-patients-with-relapsed-refractory-follicular-lymphoma-priimary-analysis-of-the-randomized-phase-ii-hovon110-rebel-trial/2024-01-05T15:04:07+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-in-relapsed-refractory-dlbcl-patients-who-received-polatuzumab-vedotin-plus-bendamustine-and-rituximab-or-tafasitamab-plus-lenalidomide-by-line-of-therapy/2023-09-06T00:27:36+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ib-ii-study-of-polatuzumab-vedotin-plus-obinutuzumab-and-lenalidomide-in-patients-with-relapsed-refractory-follicular-lymphoma-final-analysis-and-progression-free-survival-update/2023-09-06T00:20:48+00:00https://lymphoma-stg.clarovantdigital.com/library/assessment-of-durable-responses-after-brexucabtagene-autoleucel-kte-x19-in-the-zuma-2-study-in-relapsed-refractory-mantle-cell-lymphoma-r-r-mcl/2023-09-06T00:19:06+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-monotherapy-induces-high-complete-response-rates-in-patients-with-heavily-pretreated-relapsed-or-refractory-mantle-cell-lymphoma/2026-01-14T22:24:55+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-canadian-patients-pts-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-r-r-dlbcl-in-the-real-world/2026-01-15T14:12:55+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-older-patients-with-diffuse-large-b-cell-lymphoma-treated-with-r-chop-10-year-follow-up-of-the-lnh03-6b-trial/2023-09-06T00:02:31+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-ibrutinib-combined-with-standard-first-line-treatment-or-as-substitute-for-autologous-stem-cell-transplantation-in-younger-patients-with-mantle-cell-lymphoma-results-from-the-r/2023-09-06T00:01:14+00:00https://lymphoma-stg.clarovantdigital.com/library/metabolic-tumor-volume-predicts-outcomes-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-treated-with-loncastuximab-tesirine-in-the-lotis-2-trial/2023-09-06T00:04:00+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-clinical-outcomes-and-correlative-efficacy-analyses-in-patients-pts-with-relapsed-refractory-follicular-lymphoma-r-r-fl-treated-with-tisagenlecleucel-in-the-elara-trial/2023-09-05T23:58:29+00:00https://lymphoma-stg.clarovantdigital.com/library/odronextamab-in-patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-results-from-a-prespecified-analysis-of-the-pivotal-phase-ii-study-elm-2/2026-01-14T22:24:22+00:00https://lymphoma-stg.clarovantdigital.com/library/odronextamab-in-patients-with-relapsed-refractory-r-r-follicular-lymphoma-fl-grade-1-3a-results-from-a-prespecified-analysis-of-the-pivotal-phase-ii-study-elm-2/2026-01-14T22:23:56+00:00https://lymphoma-stg.clarovantdigital.com/library/odronextamab-regn1979-a-human-cd20-x-cd3-bispecific-antibody-induces-durable-complete-responses-in-patients-with-highly-refractory-b-cell-non-hodgkin-lymphoma-including-patients-refractory-to-ca-2/2026-01-16T14:48:58+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-for-patients-with-relapsed-or-refractory-r-r-aggressive-b-cell-non-hodgkins-lymphoma-abnhl-treated-with-commercial-tisagenlecleucel-subgroup-analyses-from-the-center-for-inter/2023-08-28T21:52:56+00:00https://lymphoma-stg.clarovantdigital.com/library/time-limited-ibrutinib-and-tisagenlecleucel-is-highly-effective-in-the-treatment-of-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-including-those-with-tp53-mutated-and-btki-refractory-dis/2023-08-28T21:49:57+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-in-bilateral-basal-ganglia-a-rare-case-report/2023-08-28T21:48:34+00:00https://lymphoma-stg.clarovantdigital.com/library/tafasitamab-and-lenalidomide-in-relapsed-refractory-large-b-cell-lymphoma-r-r-lbcl-real-world-outcomes-in-a-multicenter-retrospective-study/2023-08-28T21:46:58+00:00https://lymphoma-stg.clarovantdigital.com/library/l-mind-a-safety-and-efficacy-analysis-of-tafasitamab-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-r-r-dlbcl-receiving-treatment-for-at-least-2-years/2023-08-28T21:47:39+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-dlbcl-a-structured-literature-review-of-the-epidemiology-treatment-guidelines-and-real-world-treatment-patterns/2023-08-28T21:44:17+00:00https://lymphoma-stg.clarovantdigital.com/library/the-evolving-role-of-radiation-therapy-in-dlbcl-from-early-stage-to-refractory-disease/2023-08-28T21:43:23+00:00https://lymphoma-stg.clarovantdigital.com/library/addition-of-high-dose-cytarabine-to-immunochemotherapy-before-autologous-stem-cell-transplantation-in-patients-aged-65-years-or-younger-with-mantle-cell-lymphoma-mcl-younger-a-long-term-follow-up-o/2023-08-28T21:42:06+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-dlbcl-patients-achieving-complete-remission-after-r-ice-chemoimmunotherapy/2023-08-28T21:41:19+00:00https://lymphoma-stg.clarovantdigital.com/library/what-factors-explain-inferior-survival-for-eu-vs-us-patients-with-dlbcl-after-car-t-cell-therapy/2025-12-19T18:38:51+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-combined-with-r-ice-polar-ice-as-second-line-therapy-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2023-08-28T21:39:57+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-in-frontline-therapy-of-hodgkin-lymphoma-in-patients-with-significant-comorbidities-ineligible-for-standard-chemotherapy-sgn35-015-part-e/2023-08-28T19:15:26+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-brentuximab-vedotin-maintenance-after-autologous-stem-cell-transplant-in-relapsed-refractory-classical-hodgkin-lymphoma-an-time-variable-analysis-of-the-effect-of-dose-on-progr/2023-09-07T20:16:45+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-a-novel-subcutaneous-cd3xcd20-bispecific-t-cell-engaging-antibody-in-relapsed-or-refractory-large-b-cell-lymphoma-dose-expansion-in-a-phase-i-ii-trial/2026-01-14T22:23:27+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-comparison-of-time-to-next-treatment-for-patients-with-cll-initiated-on-first-line-treatment-with-ibrutinib-versus-acalabrutinib/2023-08-28T21:38:50+00:00https://lymphoma-stg.clarovantdigital.com/library/recent-bendamustine-treatment-before-apheresis-has-a-negative-impact-on-outcomes-in-patients-with-large-b-cell-lymphoma-receiving-chimeric-antigen-receptor-t-cell-therapy/2023-08-28T21:38:12+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-plus-venetoclax-and-rituximab-in-patients-with-treatment-naive-tn-mantle-cell-lymphoma-mcl-2-year-safety-and-efficacy-analysis/2023-08-28T21:37:15+00:00https://lymphoma-stg.clarovantdigital.com/library/assessing-the-burden-of-adverse-events-in-a-head-to-head-trial-of-acalabrutinib-versus-ibrutinib-in-previously-treated-chronic-lymphocytic-leukemia-cll/2023-08-28T21:36:16+00:00https://lymphoma-stg.clarovantdigital.com/library/contribution-of-obinutuzumab-to-acalabrutinib-therapy-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia-analysis-of-survival-outcomes-by-genomic-features/2023-08-28T21:35:37+00:00https://lymphoma-stg.clarovantdigital.com/library/comparing-acalabrutinib-and-ibrutinib-in-the-real-world-a-study-of-2509-patients-with-chronic-lymphocytic-leukemia/2023-08-28T21:35:03+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-results-from-a-multicenter-phase-2-study-of-acalabrutinib-venetoclax-obinutuzumab-avo-in-a-population-of-previously-untreated-patients-with-cll-enriched-for-high-risk-disease/2023-08-28T21:29:29+00:00https://lymphoma-stg.clarovantdigital.com/library/combined-ibrutinib-and-venetoclax-for-first-line-treatment-of-patients-with-chronic-lymphocytic-leukemia-cll-4-year-follow-up-data/2026-01-14T21:10:16+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-etoposide-and-asct-on-survival-among-patients-aged/2023-08-28T17:49:11+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-with-polatuzumab-vedotin-is-effective-and-has-a-manageable-safety-profile-in-patients-aged-65-years-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-r-r-dlbcl-and-1-prior-therap/2026-01-14T22:22:48+00:00https://lymphoma-stg.clarovantdigital.com/library/cancer-related-distress-and-risk-for-anxiety-and-depression-among-lymphoma-survivors/2023-08-28T21:26:27+00:00https://lymphoma-stg.clarovantdigital.com/library/anxiety-and-depression-among-patients-newly-diagnosed-with-lymphoma-and-myeloma/2023-08-28T21:26:01+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-phase-2-trial-of-first-line-bendamustine-rituximab-br-based-induction-followed-by-rituximab-r-%c2%b1-lenalidomide-l-consolidation-for-mantle-cell-lymphoma-ecog-acrin-e1411/2023-08-28T21:27:58+00:00https://lymphoma-stg.clarovantdigital.com/library/total-metabolic-tumor-volume-is-confirmed-as-independent-prognostic-factor-in-treatment-naive-follicular-lymphoma-patients-and-can-be-combined-with-flipi2-to-improve-prognostic-accuracy-a-foll12-subs/2023-09-05T23:59:15+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hematopoietic-stem-cell-transplantation-in-transformed-follicular-lymphoma-tfl-results-of-a-retrospective-multicenter-study-from-geltamo-geth-tc-spanish-groups/2023-09-07T14:54:28+00:00https://lymphoma-stg.clarovantdigital.com/library/distinct-immunogenetic-profiles-of-chronic-lymphocytic-leukemia-in-asia-a-taiwan-cooperative-oncology-group-registry-study/2023-08-14T20:25:30+00:00https://lymphoma-stg.clarovantdigital.com/library/chemotherapy-delivery-time-affects-treatment-outcomes-of-female-patients-with-diffuse-large-b-cell-lymphoma/2023-01-27T20:27:42+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-anaplastic-large-cell-lymphoma-following-postmastectomy-implant-reconstruction-inwomen-with-breast-cancer-and-ductal-carcinoma-in-situ/2023-02-10T20:21:13+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-dlbcl-early-patient-management-and-emerging-treatment-options/2023-08-14T19:24:06+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukaemia-small-lymphocytic-lymphoma-and-mantle-cell-lymphoma-from-early-lesions-to-transformation/2025-03-03T19:44:51+00:00https://lymphoma-stg.clarovantdigital.com/library/chimeric-antigen-receptor-t-cell-therapy-in-hematologic-malignancies-and-patient-reported-outcomes-a-scoping-review/2023-02-10T20:29:30+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-treated-with-polatuzumab-vedotin-based-therapy/2023-08-14T20:19:12+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-versus-investigators-choice-in-relapsed-refractory-chronic-lymphocytic-leukemia-final-ascend-trial-results/2023-08-14T20:17:21+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-obinutuzumabchemotherapy-combinations-in-front-line-treatment-of-follicular-non-hodgkin-lymphoma-during-the-covid-19-pandemic-a-study-of-krohem-the-croatian-cooperative-group/2023-08-14T20:16:04+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-treatment-with-bendamustine-and-rituximab-for-old-and-frail-patients-with-aggressive-lymphoma-results-of-the-b-r-enda-trial/2023-09-08T21:50:28+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-diagnosis-to-treatment-interval-in-patients-with-newly-diagnosed-mantle-cell-lymphoma/2023-02-10T23:33:38+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiovascular-adverse-events-associated-with-cyclophosphamide-pegylated-liposomal-doxorubicin-vincristine-and-prednisone-with-or-without-rituximab-r-cdop-in-non-hodgkins-lymphoma-a-s/2023-02-10T23:32:02+00:00https://lymphoma-stg.clarovantdigital.com/library/hiv-associated-burkitt-lymphoma-in-the-combination-antiretroviral-therapy-era-real-world-outcomes-and-prognostication/2023-08-14T20:12:50+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-nivolumab-doxorubicin-and-dacarbazine-anad-for-advanced-stage-classic-hodgkin-lymphoma-updated-efficacy-and-safety-results-from-the-single-arm-phase-2-study-sgn35-027-part-2/2023-08-28T19:12:56+00:00https://lymphoma-stg.clarovantdigital.com/library/consolidative-hdc-asct-versus-non-myeloablative-immunochemotherapy-for-patients-with-primary-cns-lymphoma/2023-08-28T21:24:55+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-treatment-with-zanubrutinib-plus-rituximab-zr-followed-by-short-course-r-dhaox-shows-potent-efficacy-in-patients-with-mantle-cell-lymphoma-mcl-preliminary-results-of-phase-ii-chess-clin/2026-01-14T21:09:46+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-utility-and-value-of-information-analysis-of-tisagenlecleucel-for-relapsed-refractory-diffuse-large-b-cell-lymphoma-in-the-irish-healthcare-setting/2023-02-10T23:55:24+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-second-primary-malignancies-in-patients-with-chronic-lymphocytic-leukemia-a-population-based-study-in-the-netherlands-1989-2019/2023-08-28T17:38:45+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-profiling-for-detection-risk-stratification-and-classification-of-brain-lymphomas/2023-08-28T17:37:42+00:00https://lymphoma-stg.clarovantdigital.com/library/global-burden-risk-factors-and-trends-of-non-hodgkin-lymphoma-in-2020-and-projections-to-2040-a-population-based-study/2023-08-28T21:22:52+00:00https://lymphoma-stg.clarovantdigital.com/library/effectiveness-of-therapeutic-exercise-models-on-cancer-related-fatigue-in-patients-with-cancer-undergoing-chemotherapy-a-systematic-review-and-network-meta-analysis/2023-02-10T23:55:25+00:00https://lymphoma-stg.clarovantdigital.com/library/a-24-month-updated-analysis-of-the-comparative-effectiveness-of-zuma-5-axi-cel-vs-scholar-5-external-control-in-relapsed-refractory-follicular-lymphoma/2023-02-10T23:55:25+00:00https://lymphoma-stg.clarovantdigital.com/library/bispecific-antibodies-for-follicular-lymphoma-frontline-treatment-and-beyond/2026-01-14T19:42:41+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-ribosome-related-genes-signature-in-diffuse-large-b-cell-lymphoma/2023-02-10T23:55:25+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-combinations-for-the-frontline-treatment-of-patients-with-dlbcl/2026-01-15T17:08:10+00:00https://lymphoma-stg.clarovantdigital.com/library/an-extranodal-site-of-diffuse-large-b-cell-lymphoma-presenting-as-ovarian-cancer/2023-08-28T17:28:22+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-of-definitive-chemoradiotherapy-for-early-stage-extranodal-natural-killer-t-cell-lymphoma-nasal-type-a-retrospective-analysis-from-a-single-center/2023-08-28T17:27:40+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-of-pembrolizumab-mk-3475-after-autologous-stem-cell-transplantation-in-patients-with-t-cell-non-hodgkin-lymphoma-2/2023-08-28T21:20:17+00:00https://lymphoma-stg.clarovantdigital.com/library/using-ctdna-analysis-in-risk-profiling-of-frontline-dlbcl-results-from-the-polarix-study/2023-08-28T21:19:32+00:00https://lymphoma-stg.clarovantdigital.com/library/brexucabtagene-autoleucel-for-relapsed-or-refractory-mantle-cell-lymphoma-in-standard-of-care-practice-results-from-the-us-lymphoma-car-t-consortium/2026-01-14T22:21:37+00:00https://lymphoma-stg.clarovantdigital.com/library/a-remote-whole-food-dietary-intervention-to-reduce-fatigue-and-improve-diet-quality-in-lymphoma-survivors-results-of-a-feasibility-pilot-study/2023-02-10T23:55:26+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-versus-ibrutinib-in-r-r-cll-sll-final-alpine-results/2025-12-15T22:29:42+00:00https://lymphoma-stg.clarovantdigital.com/library/stereotactic-radiosurgery-for-primary-central-nervous-system-lymphoma/2023-08-24T20:28:40+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-of-axicabtagene-ciloleucel-and-tisagenlecleucel-as-second-line-or-later-therapy-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2023-02-24T21:44:09+00:00https://lymphoma-stg.clarovantdigital.com/library/systematic-literature-review-of-real%e2%80%91world-effectiveness-results-data-for-first%e2%80%91line-ibrutinib-in-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/2025-03-03T19:44:02+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-safety-and-molecular-response-predictors-of-oral-ixazomib-and-short-course-rituximab-in-untreated-inhl/2023-09-07T17:11:52+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-and-analysis-of-prognostic-factors-for-primary-diffuse-large-b-cell-lymphoma-of-the-brain/2023-02-24T21:55:52+00:00https://lymphoma-stg.clarovantdigital.com/library/identification-of-myc-bcl2-double-expressers-lymphomas-in-diffuse-large-b-cell-lymphoma-patients-and-association-with-their-prognostic-parameters-and-survival-rates-a-single-centre-experience/2023-08-14T20:10:22+00:00https://lymphoma-stg.clarovantdigital.com/library/barriers-to-enrollment-in-clinical-trials-of-patients-with-aggressive-b-cell-nhl-that-progressed-after-car-t-cell-therapy/2023-02-24T22:22:21+00:00https://lymphoma-stg.clarovantdigital.com/library/influence-of-sociodemographic-determinants-on-the-hodgkin-lymphoma-baseline-characteristics-in-long-survivors-patients-enrolled-in-the-prospective-phase-3-trial-ahl2011/2023-02-24T23:09:08+00:00https://lymphoma-stg.clarovantdigital.com/library/btk-inhibitor-combined-with-anti%e2%80%91pd%e2%80%911-monoclonal-antibody-for-the-treatment-of-cd20%e2%80%91negative-primary-central-nervous-system-lymphoma-a-case-report/2023-08-14T19:34:24+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-with-high%e2%80%91dose-methotrexate-is-effective-and-cost%e2%80%91effective-in-newly-diagnosed-primary-central-nervous-system-lymphoma/2023-08-14T19:33:19+00:00https://lymphoma-stg.clarovantdigital.com/library/combined-epigenetic-and-immunotherapy-for-blastic-and-classical-mantle-cell-lymphoma/2023-02-24T23:26:06+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-plus-salvage-chemotherapy-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2023-08-14T19:29:56+00:00https://lymphoma-stg.clarovantdigital.com/library/rac1-a-potential-diagnostic-and-prognostic-marker-for-diffuse-large-b-cell-lymphoma/2023-02-24T23:30:03+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-of-patients-with-mantle-cell-lymphoma-in-the-rituximab-era-retrospective-binational-analysis-between-2000-and-2020/2023-08-14T19:28:54+00:00https://lymphoma-stg.clarovantdigital.com/library/minimizing-acute-toxicity-and-late-effects-in-the-treatment-of-hodgkin-lymphoma-in-patients-with-sickle-cell-disease/2023-02-24T23:50:45+00:00https://lymphoma-stg.clarovantdigital.com/library/how-to-prioritize-treatment-in-dual-malignancy-a-case-report-of-patient-with-non-hodgkin-lymphoma-and-breast-cancer/2023-02-24T23:59:42+00:00https://lymphoma-stg.clarovantdigital.com/library/sequence-analyses-of-relapsed-or-refractory-diffuse-large-b-cell-lymphomas-unravel-three-genetic-subgroups-of-patients-and-the-gna13-mutant-as-poor-prognostic-biomarker-results-of-lnh-ep1-study/2023-02-27T19:37:50+00:00https://lymphoma-stg.clarovantdigital.com/library/cd5-negative-primary-mantle-cell-lymphoma-presenting-with-a-bilateral-conjunctival-mass-a-potential-diagnostic-pitfall/2023-02-27T18:18:01+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-a-dose-dense-short-term-therapy-in-patients-with-myc-translocated-aggressive-lymphoma/2023-02-27T18:55:49+00:00https://lymphoma-stg.clarovantdigital.com/library/the-new-german-evidence-based-guideline-on-diffuse-large-b-cell-lymphoma-key-aspects-for-radiation-oncologists/2023-02-27T19:07:56+00:00https://lymphoma-stg.clarovantdigital.com/library/burkitt-lymphoma-risk-shows-geographic-and-temporal-associations-with-plasmodium-falciparum-infections-in-uganda-tanzania-and-kenya/2023-02-27T19:22:58+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-profiling-of-ebv-associated-diffuse-large-b-cell-lymphoma/2023-08-14T19:20:21+00:00https://lymphoma-stg.clarovantdigital.com/library/the-frequency-of-differentiated-cd3cd27-cd28-t-cells-predicts-response-to-cart-cell-therapy-in-diffuse-large-b-cell-lymphoma/2025-03-04T16:05:27+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-vaccination-response-and-its-practical-application-in-patients-with-chronic-lymphocytic-leukemia/2023-08-14T19:13:12+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-prediction-in-patients-with-large-b-cell-lymphoma-undergoing-chimeric-antigen-receptor-t-cell-therapy/2023-08-14T19:12:00+00:00https://lymphoma-stg.clarovantdigital.com/library/the-novel-prognostic-index-model-of-combining-circulating-tumor-dna-and-pink-e-predicts-the-clinical-outcomes-for-newly-diagnosed-extranodal-nk-t-cell-lymphoma/2023-08-14T19:09:37+00:00https://lymphoma-stg.clarovantdigital.com/library/non-hodgkin-lymphoma-developed-shortly-after-mrna-covid-19-vaccination-report-of-a-case-and-review-of-the-literature/2023-08-14T19:06:59+00:00https://lymphoma-stg.clarovantdigital.com/library/high-rate-of-durable-responses-with-undetectable-minimal-residual-disease-with-frontline-venetoclax-and-rituximab-in-young-and-fit-patients-with-chronic-lymphocytic-leukemia-and-an-adverse-biologic-pr/2023-08-14T19:05:29+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathological-characteristics-of-primary-pulmonary-hodgkin-lymphoma-pphl-two-institutional-experiences-with-comprehensive-literature-review-of-115-pphl-cases/2023-02-28T15:22:01+00:00https://lymphoma-stg.clarovantdigital.com/library/functional-testing-coronary-artery-calcifications-and-outcomes-in-hodgkin-lymphoma-survivors-treated-with-chest-radiation/2023-02-28T15:34:29+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-and-high-frequency-low-dose-subcutaneous-rituximab-for-initial-therapy-of-chronic-lymphocytic-leukemia/2023-08-14T19:03:24+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-in-patients-relapsed-refractory-after-%e2%89%a52-prior-lines-of-therapy-for-follicular-lymphoma-a-systematic-literature-review-and-meta%e2%80%91analysis/2023-08-14T18:59:24+00:00https://lymphoma-stg.clarovantdigital.com/library/a-study-on-the-prevention-of-hemorrhage-and-perforation-in-patients-with-primary-gastric-diffuse-large-b-cell-lymphoma-during-treatment-with-immunochemotherapy/2023-08-14T18:56:52+00:00https://lymphoma-stg.clarovantdigital.com/library/the-ir2-regimen-ibrutinib-plus-lenalidomide-and-rituximab-for-relapsed-refractory-dlbcl-a-multicentre-non-randomised-open-label-phase-2-study/2023-08-14T18:55:35+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-treatment-guidelines-for-tafasitamab-plus-lenalidomide-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2023-08-14T18:52:57+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-fatigue-in-long-term-survivors-of-hodgkins-lymphoma-after-contemporary-risk-adapted-treatment/2023-02-28T18:43:00+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-positron-emission-tomography-during-frontline-chemoimmunotherapy-for-follicular-lymphoma/2023-02-28T18:58:29+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-radiation-and-procarbazine-dose-with-risk-of-colorectal-cancer-among-survivors-of-hodgkin-lymphoma/2023-02-28T19:18:56+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-allogeneic-hematopoietic-cell-transplantation-for-chronic-lymphocytic-leukemia-a-review/2023-08-14T18:47:21+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-chimeric-antigen-receptor-t-cell-therapy-and-autologous-stem-cell-transplant-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-a-systematic-review/2023-02-28T19:55:09+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-survival-of-patients-with-mantle-cell-lymphoma-after-total-body-irradiation-high-dose-chemotherapy-and-stem-cell-transplantation-a-monocenter-study/2023-02-28T20:02:04+00:00https://lymphoma-stg.clarovantdigital.com/library/low-t3-syndrome-as-a-predictor-of-poor-outcomes-in-patients-with-follicular-lymphoma/2023-02-28T20:07:24+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-in-previously-untreated-dlbcl-an-asia-subpopulation-analysis-from-the-phase-3-polarix-trial/2023-08-14T18:44:42+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-classification-and-therapeutics-in-diffuse-large-b-cell-lymphoma/2025-12-10T19:52:15+00:00https://lymphoma-stg.clarovantdigital.com/library/the-oral-pi3k%ce%b4-inhibitor-linperlisib-for-the-treatment-of-relapsed-and-or-refractory-follicular-lymphoma-a-phase-2-single-arm-open-label-clinical-trial/2023-08-14T18:40:54+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-complete-remission-of-a-patient-with-double-hit-diffuse-large-b-cell-lymphoma-treated-by-chemoimmunotherapy-and-chinese-herbal-medicine/2023-02-28T21:20:57+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-impact-of-ibrutinib-plus-r-chop-in-untreated-dlbcl-co-expressing-bcl2-and-myc-in-the-phase-3-phoenix-trial/2025-12-10T19:54:43+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-predictive-of-vision-loss-in-patients-with-vitreoretinal-lymphoma-a-single-tertiary-center-experience/2023-03-20T17:30:01+00:00https://lymphoma-stg.clarovantdigital.com/library/the-diagnostic-accuracy-of-bone-marrow-biopsy-versus-pet-ct-scan-in-identifying-bone-marrow-involvement-in-diffuse-large-b-cell-lymphoma-patients-at-a-cancer-hospital/2023-03-24T18:33:31+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluating-risk-factors-and-treatment-for-tumor-lysis-syndrome/2023-08-24T20:27:09+00:00https://lymphoma-stg.clarovantdigital.com/library/bortezomib-dexamethasone-rituximab-and-cyclophosphamide-as-first-line-treatment-for-waldenstrom-macroglobulinemia-a-prospectively-randomized-trial-of-the-european-consortium-for-waldenstrom-macrogl/2023-03-24T18:33:31+00:00https://lymphoma-stg.clarovantdigital.com/library/treating-richter-transformation-in-cll/2026-01-14T19:41:49+00:00https://lymphoma-stg.clarovantdigital.com/library/bispecific-lv20-19-car-t-cells-induce-92-percent-cr-rate-in-relapsed-refractory-mantle-cell-lymphoma/2026-01-14T22:21:09+00:00https://lymphoma-stg.clarovantdigital.com/library/bridging-radiation-rapidly-and-effectively-cytoreduces-high-risk-relapsed-refractory-aggressive-b-cell-lymphomas-prior-to-chimeric-antigen-receptor-t-cell-therapy/2026-01-14T22:38:19+00:00https://lymphoma-stg.clarovantdigital.com/library/multidisciplinary-antenatal-management-of-a-late-pregnancy-complicated-with-advanced-stage-breast-burkitt-lymphoma-case-report-and-a-review-of-the-literature/2023-03-24T18:33:32+00:00https://lymphoma-stg.clarovantdigital.com/library/zamtocabtagene-autoleucel-produces-high-orr-in-relapsed-refractory-dlbcl/2026-01-14T22:19:39+00:00https://lymphoma-stg.clarovantdigital.com/library/spontaneous-regression-in-chronic-lymphocytic-leukaemia-clinical-features-of-50-cases-from-the-eric-registry-and-review-of-the-literature/2023-08-24T20:20:58+00:00https://lymphoma-stg.clarovantdigital.com/library/how-robust-is-pod24-as-a-predictor-of-survival-in-indolent-lymphomas/2023-03-24T18:33:33+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-cutaneous-gamma-delta-t-cell-lymphoma-a-case-report-and-review-of-literature/2023-03-24T18:33:33+00:00https://lymphoma-stg.clarovantdigital.com/library/virtual-care-during-the-covid-19-pandemic-for-patients-with-hematologic-malignancies-a-single-institution-experience/2023-08-24T20:19:38+00:00https://lymphoma-stg.clarovantdigital.com/library/spontaneous-tumor-lysis-syndrome-in-a-patient-with-a-known-history-of-chronic-lymphocytic-leukemia-prior-to-cytotoxic-chemotherapy/2023-08-24T20:18:55+00:00https://lymphoma-stg.clarovantdigital.com/library/late-effects-in-patients-with-mantle-cell-lymphoma-treated-with-or-without-autologous-stem-cell-transplantation/2023-03-24T18:33:34+00:00https://lymphoma-stg.clarovantdigital.com/library/leukemic-phase-follicular-lymphoma-in-a-young-adult/2025-04-14T21:15:32+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-landscape-for-r-r-waldenstroms-macroglobulinemia/2023-03-24T18:33:34+00:00https://lymphoma-stg.clarovantdigital.com/library/descar-t-analysis-outcomes-following-anti-cd19-car-t-cell-failure/2023-03-24T18:33:34+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-aggressive-b-cell-lymphoma-after-failure-of-anti-cd19-car-t-cell-therapy-a-descar-t-analysis/2023-03-24T18:33:34+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-risk-factors-of-infections-among-diffuse-large-b-cell-lymphoma-and-classical-hodgkins-lymphoma-patients-in-a-tertiary-care-center-in-saudi-arabia-a-retrospective-cohort-study/2023-03-24T18:33:35+00:00https://lymphoma-stg.clarovantdigital.com/library/response-adapted-omission-of-radiotherapy-in-children-and-adolescents-with-early-stage-classical-hodgkin-lymphoma-and-an-adequate-response-to-vincristine-etoposide-prednisone-and-doxorubicin-euron/2023-03-24T18:33:35+00:00https://lymphoma-stg.clarovantdigital.com/library/health-benefits-and-cost-effectiveness-of-childrens-oncology-group-breast-cancer-screening-guidelines-for-chest-irradiated-hodgkin-lymphoma-survivors/2023-03-24T18:33:35+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-excess-mortality-and-net-survival-among-elderly-diffuse-large-b-cell-lymphoma-patients-after-front-line-r-chop-treatment/2023-03-24T18:33:35+00:00https://lymphoma-stg.clarovantdigital.com/library/cutaneous-t-cell-lymphoma-current-and-emerging-therapies/2025-08-19T18:03:19+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathological-spectrum-of-b-cell-non-hodgkin-lymphoma-in-pakistan-population-a-single-center-study/2026-03-13T19:37:05+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-recipients-receive-more-psychological-support-fear-cancer-progression-less/2023-08-28T21:15:08+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-analysis-evaluates-inpatient-vs-outpatient-car-t-cell-therapy-administration-in-mcl-and-fl/2023-03-24T18:33:36+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiotoxicities-of-novel-therapies-in-hematologic-malignancies-chimeric-antigen-receptor-t-cell-therapy-and-bispecific-t-cell-engager-therapy/2026-01-14T22:18:37+00:00https://lymphoma-stg.clarovantdigital.com/library/the-diagnostic-dilemma-of-splenic-non-hodgkins-lymphoma-and-splenic-abscess-a-narrative-review/2023-03-24T18:33:37+00:00https://lymphoma-stg.clarovantdigital.com/library/treatments-for-relapsed-refractory-diffuse-large-b-cell-lymphoma-a-preliminary-evaluation-of-the-place-in-therapy-of-glofitamab-a-bispecific-monoclonal-antibody/2023-08-24T19:56:03+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-pirtobrutinib-a-highly-selective-non-covalent-reversible-btk-inhibitor-in-relapsed-refractory-waldenstrom-macroglobulinemia-results-from-the-phase-1-2-bruin-study/2023-08-28T21:14:14+00:00https://lymphoma-stg.clarovantdigital.com/library/lisaftoclax-apg-2575-safety-and-activity-as-monotherapy-or-combined-with-acalabrutinib-or-rituximab-in-patients-pts-with-treatment-naive-relapsed-or-refractory-chronic-lymphocytic-leukemia-small/2025-03-03T20:51:31+00:00https://lymphoma-stg.clarovantdigital.com/library/epigenetic-age-acceleration-and-neurocognitive-function-among-long-term-survivors-of-pediatric-hodgkin-lymphoma/2025-12-15T21:28:53+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-survival-results-from-the-remodl-b-trial-isrctn-51837425-show-improved-outcomes-in-diffuse-large-b-cell-lymphoma-molecular-subgroups-from-the-addition-of-bortezomib-to-r-chop-chemoimmunoth/2023-08-28T21:12:29+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-liso-cel-versus-standard-of-care-soc-with-salvage-chemotherapy-followed-by-autologous-stem-cell-transplantation-asct-as-second-line-2l-treatment-in-patients-with-relap/2023-08-28T21:11:37+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-monotherapy-demonstrates-durable-efficacy-with-a-manageable-safety-profile-in-patients-with-relapsed-refractory-follicular-lymphoma-who-received-2-prior-therapies-updated-results-from/2026-01-14T22:18:04+00:00https://lymphoma-stg.clarovantdigital.com/library/residual-disease-kinetics-among-patients-with-high-risk-factors-treated-with-first-line-fixed-duration-ibrutinib-plus-venetoclax-ibrven-versus-chlorambucil-plus-obinutuzumab-clbo-the-glow-study/2026-01-14T21:07:28+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-results-and-overall-survival-update-from-the-phase-3-randomized-study-augment-lenalidomide-plus-rituximab-r2-vs-rituximab-plus-placebo-in-patients-with-relapsed-refractory-indolent-non-ho/2023-08-28T21:09:19+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-efficacy-and-safety-of-zanubrutinib-in-patients-with-relapsed-refractory-r-r-marginal-zone-lymphoma-mzl-final-analysis-of-the-magnolia-bgb-3111-214-trial/2023-08-28T21:08:43+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-and-venetoclax-in-previously-untreated-waldenstrom-macroglobulinemia/2023-08-28T21:08:13+00:00https://lymphoma-stg.clarovantdigital.com/library/ytb323-rapcabtagene-autoleucel-demonstrates-durable-efficacy-and-a-manageable-safety-profile-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-phase-i-study-update/2026-01-16T15:00:25+00:00https://lymphoma-stg.clarovantdigital.com/library/classification-of-b-cell-lymphomas-and-immunodeficiency-related-lymphoproliferations-whats-new/2023-08-14T18:08:31+00:00https://lymphoma-stg.clarovantdigital.com/library/improvement-of-diagnosis-in-children-with-burkitt-lymphoma-in-kenya-feasibility-study-for-the-implementation-of-fluorescence-in-situ-hybridisation-testing-for-myc-and-the-myc-igh-translocation/2023-08-14T19:18:33+00:00https://lymphoma-stg.clarovantdigital.com/library/reclassification-of-diffuse-large-b-cell-lymphoma-to-large-b-cell-lymphoma-with-irf4-rearrangement-in-an-adult-population/2023-03-27T18:07:13+00:00https://lymphoma-stg.clarovantdigital.com/library/reproductive-ability-in-survivors-of-childhood-adolescent-and-young-adult-hodgkin-lymphoma-a-review/2023-03-27T18:15:51+00:00https://lymphoma-stg.clarovantdigital.com/library/radiation-exposure-in-acute-myeloid-leukaemia-diffuse-large-b-cell-lymphoma-and-multiple-myeloma-patients-in-the-first-year-following-diagnosis/2023-03-27T18:35:16+00:00https://lymphoma-stg.clarovantdigital.com/library/estimating-the-prevalence-of-epstein-barr-virus-in-primary-gastric-lymphoma-a-systematic-review-and-meta-analysis/2023-08-14T18:32:17+00:00https://lymphoma-stg.clarovantdigital.com/library/overexpression-of-bcl2-bcl6-vegfr1-and-twist1-in-circulating-tumor-cells-derived-from-patients-with-dlbcl-decreases-event-free-survival/2023-03-27T19:10:50+00:00https://lymphoma-stg.clarovantdigital.com/library/understanding-the-impact-of-covid-19-on-chronic-lymphocytic-leukemia-cll-caregiving-and-related-resource-needs/2023-08-14T18:17:05+00:00https://lymphoma-stg.clarovantdigital.com/library/a-multicenter-analysis-of-the-outcomes-with-venetoclax-in-patients-with-relapsed-mantle-cell-lymphoma/2023-08-23T20:42:20+00:00https://lymphoma-stg.clarovantdigital.com/library/the-gut-microbiota-correlate-with-the-disease-characteristics-and-immune-status-of-patients-with-untreated-diffuse-large-b-cell-lymphoma/2023-10-03T11:27:26+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-primary-mediastinal-large-b-cell-lymphoma-treated-with-rchop/2023-08-14T18:05:27+00:00https://lymphoma-stg.clarovantdigital.com/library/relapsed-refractory-diffuse-large-b-cell-lymphoma-with-cardiac-involvement-a-case-report-and-literature-review/2023-08-14T17:57:12+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-profiling-in-diffuse-large-b-cell-lymphoma-the-promise-and-the-challenge/2025-12-10T19:55:43+00:00https://lymphoma-stg.clarovantdigital.com/library/dietary-intake-of-animal-based-products-and-likelihood-of-follicular-lymphoma-and-survival-a-population-based-family-case-control-study/2023-03-28T18:29:23+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-outcomes-between-hodgkins-lymphoma-patients-treated-in-and-outside-clinical-trials-a-study-based-on-the-eortc-dutch-late-effects-cohort-linked-data/2023-03-28T19:01:26+00:00https://lymphoma-stg.clarovantdigital.com/library/drug-resistance-mechanism-and-new-targeted-drugs-and-treatments-of-relapse-and-refractory-dlbcl/2025-12-10T19:53:23+00:00https://lymphoma-stg.clarovantdigital.com/library/5-year-follow-up-supports-curative-potential-of-axicabtagene-ciloleucel-in-refractory-large-b-cell-lymphoma-zuma-1/2023-03-28T20:32:02+00:00https://lymphoma-stg.clarovantdigital.com/library/dual-targeting-of-cd19-and-cd22-with-bicistronic-car-t-cells-in-patients-with-relapsed-refractory-large-b-cell-lymphoma/2026-01-14T21:43:15+00:00https://lymphoma-stg.clarovantdigital.com/library/a-multicenter-phase-ii-study-of-full-dose-thp-cop-therapy-for-elderly-patients-with-newly-diagnosed-advanced-stage-aggressive-non-hodgkin-lymphoma/2023-03-28T21:20:21+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-pd-1-and-pd-l1-inhibitors-in-relapsed-and-refractory-hodgkins-lymphoma-a-systematic-review-and-meta-analysis-of-20-prospective-studies/2023-08-14T17:31:09+00:00https://lymphoma-stg.clarovantdigital.com/library/cellular-and-humoral-immunotherapy-in-children-adolescents-and-young-adults-with-non-hodgkin-lymphoma/2023-03-29T14:10:23+00:00https://lymphoma-stg.clarovantdigital.com/library/cellular-therapies-in-chronic-lymphocytic-leukemia-and-richters-transformation-recent-developments-in-chimeric-antigen-receptor-t-cells-natural-killer-cells-and-allogeneic-stem-cell-transp/2023-08-14T17:18:47+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-richter-transformation-of-chronic-lymphocytic-leukemia-in-the-modern-era/2023-08-14T17:16:56+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-in-grade-3b-follicular-lymphoma-an-international-study-led-by-the-australasian-lymphoma-alliance/2023-03-29T17:08:25+00:00https://lymphoma-stg.clarovantdigital.com/library/biopathology-of-childhood-adolescent-and-young-adult-non-hodgkin-lymphoma/2023-03-29T17:34:38+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-upon-second-line-treatment-in-patients-with-chronic-lymphocytic-leukaemia/2023-08-14T17:14:45+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-following-autologous-transplantation-in-pediatric-patients-with-relapsed-refractory-hodgkin-lymphoma/2023-08-28T18:49:26+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-rice-or-rvici-for-relapsed-refractory-mature-b-cell-non-hodgkin-lymphoma-in-children-and-young-adults-sparkle-trial/2023-03-29T18:16:28+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-salvage-treatments-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-including-chimeric-antigen-receptor-t-cell-therapy-a-systematic-review-and-meta%e2%80%90analysis/2023-03-29T18:25:29+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-mediastinal-b-cell-lymphoma-in-children-and-young-adults/2025-12-15T19:28:54+00:00https://lymphoma-stg.clarovantdigital.com/library/factors-associated-with-changes-in-healthy-lifestyle-behaviors-among-hematological-cancer-patients-during-the-covid-19-pandemic/2023-08-14T17:12:33+00:00https://lymphoma-stg.clarovantdigital.com/library/post-treatment-neutrophil-and-lymphocyte-counts-predict-progression-free-survival-following-first-line-chemotherapy-in-hodgkins-lymphoma/2023-03-29T21:11:11+00:00https://lymphoma-stg.clarovantdigital.com/library/high-risk-of-infection-in-real-world-patients-receiving-ibrutinib-idelalisib-or-venetoclax-for-mature-b-cell-leukaemia-lymphoma/2023-08-14T17:11:31+00:00https://lymphoma-stg.clarovantdigital.com/library/the-geriatric-prognostic-index-a-clinical-prediction-model-for-survival-of-older-diffuse-large-b-cell-lymphoma-patients-treated-with-standard-immunochemotherapy/2023-03-30T14:13:08+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-advances-in-epigenetic-therapies-for-lymphoma/2023-03-30T15:05:28+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-bone-lymphoma-a-review-of-the-literature-with-emphasis-on-histopathology-and-histogenesis/2023-03-30T15:22:42+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-the-treatment-of-hodgkin-lymphoma-current-and-future-approaches/2023-08-28T18:47:30+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-trials-portfolio-and-regulatory-history-of-idelalisib-in-indolent-non-hodgkin-lymphoma-a-systematic-review-and-meta-analysis/2023-08-14T16:58:15+00:00https://lymphoma-stg.clarovantdigital.com/library/small-volume-biopsy-diagnostic-yield-at-initial-diagnosis-versus-recurrence-transformation-of-follicular-lymphoma-a-retrospective-cyto%e2%80%90heme-interinstitutional-collaborative-study/2023-03-30T18:23:37+00:00https://lymphoma-stg.clarovantdigital.com/library/the-inherited-genetic-contribution-and-polygenic-risk-score-for-risk-of-cll-and-mbl-a-narrative-review/2023-08-14T16:56:40+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-brentuximab-vedotin-bendamustine-for-r-r-hodgkin-lymphoma-in-children-adolescents-and-young-adults/2023-08-28T18:46:14+00:00https://lymphoma-stg.clarovantdigital.com/library/different-prognostic-impact-of-recurrent-gene-mutations-in-chronic-lymphocytic-leukemia-depending-on-ighv-gene-somatic-hypermutation-status-a-study-by-eric-in-harmony/2023-08-14T16:53:32+00:00https://lymphoma-stg.clarovantdigital.com/library/the-place-of-allogeneic-stem-cell-transplantation-in-aggressive-b-cell-non-hodgkin-lymphoma-in-the-era-of-car-t-cell-therapy/2023-08-14T16:52:27+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-in-octogenarians-aged-85-and-older-can-benefit-from-treatment-with-curative-intent-a-report-on-129-patients-prospectively-registered-in-the-elderly-project-of-the-fondaz/2023-03-31T14:35:25+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hematopoietic-stem-cell-transplantation-in-hodgkin-lymphoma-in-switzerland-20-years-of-experience-2001-2020/2023-08-14T16:50:37+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-i-ii-study-of-lenalidomide-and-obinutuzumab-with-chop-for-newly-diagnosed-diffuse-large-b-cell-lymphoma/2023-08-14T16:49:39+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiac-involvement-in-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/2025-03-03T19:43:19+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-plus-chlorambucil-versus-ibrutinib-in-previously-untreated-chronic-lymphocytic-leukemia-patients-without-tp53-disruptions-a-real-life-cll-campus-study/2023-08-14T16:47:14+00:00https://lymphoma-stg.clarovantdigital.com/library/a-systematic-review-evaluating-the-efficacy-of-autologous-hematopoietic-transplantation-for-diffuse-large-b-cell-lymphomatype-richter-syndrome/2023-08-14T16:46:00+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-mutation-profile-is-associated-with-the-prognosis-and-treatment-response-of-chinese-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma/2023-08-14T16:45:08+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-prognostic-risk-analysis-and-progression-factor-exploration-of-primary-breast-lymphoma-2/2023-08-28T17:55:42+00:00https://lymphoma-stg.clarovantdigital.com/library/the-european-landscape-on-allogeneic-haematopoeietic-cell-transplantation-in-chronic-lymphocytic-leukaemia-between-2009-and-2019-a-perspective-from-the-chronic-malignancies-working-party-of-the-ebmt/2023-08-14T16:42:24+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-a-second-cancer-and-infection-in-patients-with-indolent-b%e2%80%90cell-lymphoma-exposed-to-first%e2%80%90line-bendamustine-plus-rituximab-a-retrospective-analysis-of-an-administrative-claims/2023-08-14T16:40:44+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-among-patients-with-chronic-lymphocytic-leukemia-cll-small-lymphocytic-lymphoma-sll-who-received-treatment-with-a-covalent-btk-and-bcl2-inhibitor-in-the-united-states-a-real-wor/2025-12-15T22:34:15+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-data-for-lenalidomide-maintenance-in-responding-patients-of-diffuse-large-b-cell-lymphoma/2023-09-07T19:03:47+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathological-analysis-of-primary-thyroid-non-hodgkin-lymphoma-a-single-center-study/2023-03-31T23:05:04+00:00https://lymphoma-stg.clarovantdigital.com/library/the-evolving-use-of-measurable-residual-disease-in-chronic-lymphocytic-leukemia-clinical-trials/2026-01-14T20:46:37+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-axicabtagene-ciloleucel-versus-standard-of-care-in-patients-65-years-of-age-or-older-with-relapsed-refractory-large-b-cell-lymphoma/2023-04-03T15:12:41+00:00https://lymphoma-stg.clarovantdigital.com/library/anti-spike-antibody-response-to-the-covid-vaccine-in-lymphoma-patients/2023-08-14T16:23:52+00:00https://lymphoma-stg.clarovantdigital.com/library/systematic-review-of-outcomes-and-patient-heterogeneity-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2023-04-03T23:07:54+00:00https://lymphoma-stg.clarovantdigital.com/library/a-comprehensive-assessment-of-lymphocyte-subsets-their-prognostic-significance-and-changes-after-first-line-therapy-administration-in-patients-with-chronic-lymphocytic-leukemia/2023-08-14T16:22:42+00:00https://lymphoma-stg.clarovantdigital.com/library/steroid-prescribing-in-primary-care-increases-prior-to-hodgkin-lymphoma-diagnosis-a-uk-nationwide-case-control-study/2023-04-03T23:20:45+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-and-clinical-diversity-in-primary-central-nervous-system-lymphoma/2023-08-14T20:09:10+00:00https://lymphoma-stg.clarovantdigital.com/library/plasticity-in-classical-hodgkin-composite-lymphomas-a-systematic-review/2023-04-04T00:07:19+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-rituximab-and-bendamustine-combination-in-relapsed-or-refractory-diffuse-large-b%e2%80%91cell-lymphoma-a-real%e2%80%91world-data-from-turkey/2023-08-14T16:21:36+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-in-mantle-cell-lymphoma-a-real%e2%80%91world-retrospective-multi%e2%80%91center-analysis-of-77-patients-treated-in-the-czech-republic/2023-04-06T17:34:10+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-tisagenlecleucel-in-adult-japanese-patients-with-relapsed-or-refractory-follicular-lymphoma-results-from-the-phase-2-elara-trial/2023-04-06T17:43:22+00:00https://lymphoma-stg.clarovantdigital.com/library/identification-of-six-diagnostic-biomarkers-for-chronic-lymphocytic-leukemia-based-on-machine-learning-algorithms/2023-08-14T16:20:15+00:00https://lymphoma-stg.clarovantdigital.com/library/natural-killer-cells-in-chronic-lymphocytic-leukemia-functional-impairment-and-therapeutic-potential/2024-04-02T17:59:07+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-markers-in-patients-with-chronic-lymphocytic-leukaemia-on-targeted-therapy-chemoimmunotherapy-with-anti%e2%80%91cd20-monoclonal-antibody-a-systematic-review-and-meta%e2%80%91analysis-of-p/2023-08-14T16:13:52+00:00https://lymphoma-stg.clarovantdigital.com/library/maternal-and-perinatal-outcomes-following-a-diagnosis-of-hodgkin-lymphoma-during-or-prior-to-pregnancy-a-systematic-review/2023-04-06T18:26:16+00:00https://lymphoma-stg.clarovantdigital.com/library/anti-pd1-consolidation-in-patients-with-hodgkin-lymphoma-at-high-risk-of-relapse-after-autologous-stem-cell-transplantation-a-multicenter-real-life-study/2023-08-14T16:12:09+00:00https://lymphoma-stg.clarovantdigital.com/library/a-deep-learning-aided-automated-method-for-calculating-metabolic-tumor-volume-in-diffuse-large-b-cell-lymphoma/2023-08-14T16:11:06+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-stem-cell-transplant-in-cd30-ptcl-following-frontline-brentuximab-vedotin-plus-chp-or-chop-in-echelon-2/2023-08-28T18:45:26+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hematopoietic-stem-cell-transplantation-in-non-hodgkin-lymphoma-in-switzerland-30-years-of-experience-sooner-is-better/2023-04-06T18:52:15+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-bone-marrow-lymphoma-de-novo-and-transformed-subtypes/2023-04-06T19:02:44+00:00https://lymphoma-stg.clarovantdigital.com/library/low-toxicity-and-excellent-outcomes-in-patients-with-dlbcl-without-residual-lymphoma-at-the-time-of-cd19-car-t-cell-therapy/2026-01-14T21:41:47+00:00https://lymphoma-stg.clarovantdigital.com/library/unusual-complications-in-the-management-of-chronic-lymphocytic-leukemia/2023-08-14T16:06:03+00:00https://lymphoma-stg.clarovantdigital.com/library/histologic-transformation-of-follicular-lymphoma-pathologists-viewpoint/2023-04-06T20:12:34+00:00https://lymphoma-stg.clarovantdigital.com/library/adding-venetoclax-to-lenalidomide-and-rituximab-is-safe-and-effective-in-patients-with-untreated-mantle-cell-lymphoma/2023-08-14T16:05:07+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-patient-reported-outcomes-among-recipients-of-axicabtagene-ciloleucel-for-relapsed-refractory-large-b-cell-lymphoma/2026-01-16T14:59:29+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-1-2-study-of-zilovertamab-and-ibrutinib-in-mantle-cell-lymphoma-mcl-chronic-lymphocytic-leukemia-cll-or-marginal-zone-lymphoma-mzl/2026-01-20T19:14:22+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-discontinuation-patterns-for-patients-with-chronic-lymphocytic-leukemia-in-real-world-settings-results-from-a-multi-center-international-study/2023-08-24T13:03:09+00:00https://lymphoma-stg.clarovantdigital.com/library/differential-efficacy-from-the-addition-of-bortezomib-to-r-chop-in-diffuse-large-b-cell-lymphoma-according-to-the-molecular-subgroup-in-the-remodl-b-study-with-a-5-year-follow-up/2025-12-10T19:50:24+00:00https://lymphoma-stg.clarovantdigital.com/library/an-open-label-single-arm-phase-2-trial-of-valemetostat-for-relapsed-or-refractory-adult-t-cell-leukemia-lymphoma/2023-08-24T13:01:32+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-spectrum-diagnosis-and-treatment-outcome-in-individuals-with-intravascular-large-b-cell-lymphoma-affecting-the-nervous-system-a-case-series/2023-08-24T13:00:42+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-circulating-lymphoma-at-diagnosis-on-outcomes-in-patients-with-diffuse-large-b-cell-lymphoma/2023-08-28T21:04:52+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-plus-bendamustine-and-rituximab-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-r-r-dlbcl-final-results-of-a-phase-ib-ii-randomized-study-and-single-arm-extension-ext-stu/2023-08-28T21:04:17+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-combined-with-chemotherapy-in-newly-diagnosed-early-stage-unfavorable-risk-hodgkin-lymphoma-extended-follow-up-with-evaluation-of-baseline-metabolic-tumor-volume-and-pet2/2023-08-28T19:09:29+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-profiling-of-patients-with-previously-untreated-diffuse-large-b-cell-lymphoma-dlbcl-by-measuring-circulating-tumor-dna-ctdna-results-from-the-polarix-study/2023-08-28T20:26:44+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-of-secondary-hematological-malignancies-in-patients-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-an-analysis-of-seer-database/2025-03-03T20:50:54+00:00https://lymphoma-stg.clarovantdigital.com/library/brexucabtagene-autoleucel-for-relapsed-refractory-mantle-cell-lymphoma-real-world-outcomes-in-the-united-kingdom/2023-08-28T20:25:29+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-related-morbidity-in-patients-with-classical-hodgkin-lymphoma-results-of-the-ongoing-randomized-phase-iii-hd21-trial-by-the-german-hodgkin-study-group/2023-08-28T19:08:12+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-cns-prophylaxis-in-the-frontline-setting-for-patients-with-dlbcl/2023-08-24T12:39:33+00:00https://lymphoma-stg.clarovantdigital.com/library/tumor-intrinsic-resistance-mechanisms-to-car-t-cell-therapy-in-lymphomas/2023-04-06T20:31:46+00:00https://lymphoma-stg.clarovantdigital.com/library/assessment-of-impact-of-human-leukocyte-antigen-type-and-cytokine-type-responses-on-outcomes-after-targeted-therapy-currently-used-to-treat-chronic-lymphocytic-leukemia/2023-08-14T16:04:28+00:00https://lymphoma-stg.clarovantdigital.com/library/sequencing-and-combination-of-current-small-molecule-inhibitors-for-chronic-lymphocytic-leukemia-where-is-the-evidence/2023-08-14T16:02:46+00:00https://lymphoma-stg.clarovantdigital.com/library/simplified-algorithm-for-genetic-subtyping-in-diffuse-large-b-cell-lymphoma/2023-08-14T16:00:38+00:00https://lymphoma-stg.clarovantdigital.com/library/defining-the-role-of-the-gut-microbiome-in-the-pathogenesis-and-treatment-of-lymphoid-malignancies/2023-08-14T16:00:05+00:00https://lymphoma-stg.clarovantdigital.com/library/targeting-myc-driven-lymphoma-lessons-learned-and-future-directions/2023-08-14T19:17:51+00:00https://lymphoma-stg.clarovantdigital.com/library/detection-of-second-primary-lymphoma-in-late-diffuse-large-b-cell-lymphoma-recurrences/2023-04-14T18:40:52+00:00https://lymphoma-stg.clarovantdigital.com/library/long%e2%80%91term-outcomes-of-patients-with-primary-intestinal-follicular-lymphoma-managed-with-watch%e2%80%91and%e2%80%91wait-strategy/2023-04-14T18:46:55+00:00https://lymphoma-stg.clarovantdigital.com/library/baseline-circulating-tumour-dna-and-total-metabolic-tumour-volume-as-early-outcome-predictors-in-aggressive-large-b-cell-lymphoma-a-real-world-112-patient-cohort/2023-08-23T20:43:09+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-relevance-of-sarcopenia-geriatric-and-nutritional-assessments-in-older-patients-with-diffuse-large-b%e2%80%91cell-lymphoma-results-of-a-multicentric-prospective-cohort-study/2023-04-18T21:16:39+00:00https://lymphoma-stg.clarovantdigital.com/library/candidate-germline-biomarkers-of-lenalidomide-efficacy-in-mantle-cell-lymphoma-the-fil-mcl0208-trial/2023-04-18T21:24:02+00:00https://lymphoma-stg.clarovantdigital.com/library/should-treatment-of-hypogammaglobulinemia-with-immunoglobulin-replacement-therapy-igrt-become-standard-of-care-in-patients-with-chronic-lymphocytic-leukemia/2023-08-14T15:53:25+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-treated-with-r-chop-in-a-resource-limited-setting-in-south-africa-a-real-world-study/2023-08-14T15:52:15+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-rituximab-addition-to-first-line-chemotherapy-regimens-in-nodular-lymphocyte-predominant-hodgkin-lymphoma-a-study-by-fondazione-italiana-linfomi/2023-08-14T15:51:10+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-classic-hodgkin-lymphoma-who-relapsed-after-autologous-stem-cell-transplant/2023-08-28T18:44:31+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-can-be-administered-as-a-90-minute-short-duration-infusion-in-patients-with-previously-untreated-follicular-lymphoma-gazelle-end-of-induction-analysis/2023-08-14T15:48:24+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-alone-and-in-combination-with-tislelizumab-for-the-treatment-of-richter-transformation-of-chronic-lymphocytic-leukemia/2025-12-15T21:03:37+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-pulmonary-intravascular-large-b%e2%80%91cell-lymphoma-misdiagnosed-as-pneumonia-four-case-reports-and-a-literature-review/2023-08-24T12:59:39+00:00https://lymphoma-stg.clarovantdigital.com/library/early-lymphocyte-collection-for-anti-cd19-cart-production-improves-t-cell-fitness-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma/2025-12-19T15:14:12+00:00https://lymphoma-stg.clarovantdigital.com/library/transcriptomic-profiles-and-5-year-results-from-the-randomized-cll14-study-of-venetoclax-plus-obinutuzumab-versus-chlorambucil-plus-obinutuzumab-in-chronic-lymphocytic-leukemia/2026-01-14T20:45:31+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-in-the-management-of-follicular-lymphoma-current-perspectives-on-clinical-utility-patient-selection-and-reported-outcomes/2023-08-14T15:22:54+00:00https://lymphoma-stg.clarovantdigital.com/library/biosimilar-rituximab-redditux-added-to-chop-chemotherapy-for-de-novo-diffuse-large-b-cell-lymphoma-patients-real-life-single-center-experience/2023-08-14T15:20:10+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-monotherapy-is-active-and-tolerable-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma/2026-01-14T21:39:44+00:00https://lymphoma-stg.clarovantdigital.com/library/adult-t-cell-leukemia-and-lymphoma-in-french-guiana-a-retrospective-analysis-with-real-life-data-from-2009-to-2019/2023-04-24T20:16:52+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-and-cytogenetic-characterization-and-outcome-of-chronic-lymphocytic-leukemia-patients-in-a-single-tertiary-center-in-saudi-arabia/2023-08-14T15:18:29+00:00https://lymphoma-stg.clarovantdigital.com/library/irf4-rearrangement-may-predict-favorable-prognosis-in-children-and-young-adults-with-primary-head-and-neck-large-b-cell-lymphoma/2023-04-24T20:42:10+00:00https://lymphoma-stg.clarovantdigital.com/library/single-or-tandem-autologous-stem-cell-transplantation-for-treating-chinese-patients-with-refractory-relapsed-classical-hodgkin-lymphoma/2023-04-24T21:17:50+00:00https://lymphoma-stg.clarovantdigital.com/library/risks-of-leukemia-intracranial-tumours-and-lymphomas-in-childhood-and-early-adulthood-after-pediatric-radiation-exposure-from-computed-tomography/2023-04-24T21:24:20+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-host-immune-modulation-following-tisagenlecleucel-administration-in-patients-with-diffuse-large-b-cell-lymphoma-and-b-lineage-acute-lymphoblastic-leukemia/2023-04-24T21:29:29+00:00https://lymphoma-stg.clarovantdigital.com/library/integration-of-molecular-testing-for-the-personalized-management-of-patients-with-diffuse-large-b-cell-lymphoma-and-follicular-lymphoma/2023-10-24T19:00:50+00:00https://lymphoma-stg.clarovantdigital.com/library/myd88l265p-and-myd88other-variants-show-different-molecular-characteristics-and-prognostic-significance-in-diffuse-large-b%e2%80%91cell-lymphoma/2023-08-14T15:15:50+00:00https://lymphoma-stg.clarovantdigital.com/library/transformation-and-survival-in-marginal-zone-lymphoma-a-finnish-nationwide-population-based-study/2023-04-25T14:04:43+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-fixed-duration-oral-targeted-therapies-on-the-economic-burden-of-chronic-lymphocytic-leukemia-in-canada/2023-08-14T15:14:43+00:00https://lymphoma-stg.clarovantdigital.com/library/breast-implant-associated-ebv%e2%80%91positive-diffuse-large-b%e2%80%91cell-lymphoma-an-underrecognized-entity/2026-09-02T16:17:38+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-factors-for-car-t-cell-manufacturing-failure-among-dlbcl-patients-a-nationwide-survey-in-japan/2025-11-18T23:13:25+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-outcome-of-burkitts-lymphoma-in-adolescents-and-adults-a-retrospective-study/2023-04-25T20:15:41+00:00https://lymphoma-stg.clarovantdigital.com/library/overcoming-barriers-to-referral-for-chimeric-antigen-receptor-t-cell-therapy-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma/2026-01-14T22:16:20+00:00https://lymphoma-stg.clarovantdigital.com/library/sugemalimab-monotherapy-for-patients-with-relapsed-or-refractory-extranodal-natural-killer-t-cell-lymphoma-gemstone-201-results-from-a-single-arm-multicenter-phase-ii-study/2023-08-24T12:36:41+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-the-gut-microbiome-in-lymphoma-outcomes/2023-04-28T19:10:38+00:00https://lymphoma-stg.clarovantdigital.com/library/dual-targeted-car-t-cell-therapy-key-updates-from-tct-2023/2026-01-14T22:37:52+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-pirtobrutinib-in-covalent-btk-inhibitor-pre-treated-relapsed-refractory-mantle-cell-lymphoma-additional-patients-and-extended-follow-up-from-the-phase-1-2-bruin-study/2023-08-28T20:23:32+00:00https://lymphoma-stg.clarovantdigital.com/library/tafasitamab-plus-lenalidomide-has-continued-efficacy-and-safety-in-r-r-dlbcl/2023-08-24T12:33:41+00:00https://lymphoma-stg.clarovantdigital.com/library/afm13-exhibits-efficacy-in-cd30-relapsed-refractory-ptcl/2023-08-24T12:32:50+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-phase-iii-trial-evaluating-subcutaneous-rituximab-for-the-first-line-treatment-of-low-tumor-burden-follicular-lymphoma-results-of-a-lysa-study/2023-09-07T18:59:09+00:00https://lymphoma-stg.clarovantdigital.com/library/the-5th-edition-of-the-world-health-organization-classification-of-haematolymphoid-tumours-lymphoid-neoplasms/2023-04-28T19:10:39+00:00https://lymphoma-stg.clarovantdigital.com/library/a-true-travesty-despite-new-data-and-guidance-people-with-hiv-still-lack-access-to-car-t/2023-04-28T19:10:40+00:00https://lymphoma-stg.clarovantdigital.com/library/effect-of-rituximab-on-immune-status-in-children-with-mature-b-cell-non-hodgkin-lymphoma-a-prespecified-secondary-analysis-of-the-inter-b-nhl-ritux-2010-trial/2023-08-23T20:35:06+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-added-to-ifosfamide-carboplatin-and-etoposide-chemotherapy-for-relapsed-or-refractory-classic-hodgkin-lymphoma/2023-08-23T20:34:07+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-effectiveness-and-safety-of-high-dose-chemotherapy-followed-by-autologous-stem-cell-transplantation-in-daily-practice-in-patients-with-diffuse-large-b-cell-lymphoma/2023-05-02T18:32:50+00:00https://lymphoma-stg.clarovantdigital.com/library/a-novel-prednisone-premedication-protocol-significantly-decreases-infusion%e2%80%91related-reactions-of-rituximab-in-newly-diagnosed-diffuse-large-b%e2%80%91cell-lymphoma/2023-08-14T15:12:30+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-and-patterns-of-relapse-in-primary-gastric-diffuse-large-b-cell-lymphoma-treated-with-rchop/2023-08-14T15:11:25+00:00https://lymphoma-stg.clarovantdigital.com/library/reproduction-patterns-among-classical-hodgkin-lymphoma-survivors-treated-with-beacopp-and-abvd-in-sweden-denmark-and-norway/2023-05-02T18:48:35+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-prelymphodepletion-absolute-lymphocyte-counts-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-patients-treated-with-chimeric-antigen-receptor-t-cells/2025-12-19T15:13:20+00:00https://lymphoma-stg.clarovantdigital.com/library/orelabrutinib-for-the-treatment-of-relapsed-or-refractory-mcl-a-phase-1-2-openlabel-multicenter-single-arm-study/2023-08-14T15:09:08+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-targeted-drugs-for-follicular-and-marginal-zone-lymphoma-a-comprehensive-review/2023-05-04T18:47:35+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-study-of-lenalidomide-and-rituximab-r2-combination-in-patients-with-high-risk-refractory-relapsed-diffuse-large-b-cell-lymphoma/2023-08-14T15:08:39+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-and-prognosis-of-double-primary-malignant-neoplasms-in-patients-with-non%e2%80%91hodgkin-lymphoma/2023-05-05T13:40:25+00:00https://lymphoma-stg.clarovantdigital.com/library/humoral-immunity-after-covid-19-vaccination-in-chronic-lymphocytic-leukemia-and-other-indolent-lymphomas-a-single-center-observational-study/2026-01-15T16:29:07+00:00https://lymphoma-stg.clarovantdigital.com/library/radiation-doses-to-mediastinal-organs-at-risk-in-early-stage-unfavorable-hodgkin-lymphoma-a-risk-stratified-analysis-of-the-ghsg-hd17-trial/2023-05-10T14:34:37+00:00https://lymphoma-stg.clarovantdigital.com/library/b-cell-receptor-signaling-is-thought-to-be-a-bridge-between-primary-sjogren-syndrome-and-diffuse-large-b-cell-lymphoma/2023-05-10T14:49:34+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-and-outcome-patterns-of-patients-with-mantle-cell-lymphoma-in-china-a-large-multicenter-retrospective-analysis/2023-08-14T15:01:26+00:00https://lymphoma-stg.clarovantdigital.com/library/pd-l1-expression-predicts-efficacy-in-the-phase-ii-spirel-trial-with-mvp-s-pembrolizumab-and-low-dose-cpa-in-r-r-dlbcl/2023-08-14T15:00:39+00:00https://lymphoma-stg.clarovantdigital.com/library/results-of-ari-0001-cart19-cells-in-patients-with-chronic-lymphocytic-leukemia-and-richters-transformation/2026-01-14T21:39:21+00:00https://lymphoma-stg.clarovantdigital.com/library/surface-trem2-on-circulating-m%e2%80%91mdscs-as-a-novel-prognostic-factor-for-adults-with-treatment%e2%80%91naive-diffuse-large-b%e2%80%91cell-lymphoma/2023-05-10T18:35:59+00:00https://lymphoma-stg.clarovantdigital.com/library/programmed-death-ligand-1-expression-in-diffuse-large-b-cell-lymphoma-correlation-with-clinicopathological-prognostic-factors/2023-05-10T18:45:46+00:00https://lymphoma-stg.clarovantdigital.com/library/increasing-risk-of-lymphoma-over-time-in-crohns-disease-but-not-in-ulcerative-colitis-a-scandinavian-q1-cohort-study/2023-05-10T19:06:03+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-comparative-effectiveness-of-acalabrutinib-and-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia/2023-08-14T14:57:11+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-factors-of-progression-in-low-tumor-burden-follicular-lymphoma-initially-managed-by-watch-and-wait-in-the-era-of-pet-and-rituximab/2023-08-23T20:43:41+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-effector-cell-associated-hemophagocytic-lymphohistiocytosis-like-syndrome/2026-01-14T21:38:53+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-gastrointestinal-follicular-lymphomas-a-prospective-study-of-31-patients-with-long-term-follow-up-registered-in-the-french-gastrointestinal-lymphoma-study-group-geld-of-the-french-federatio/2023-05-16T16:11:17+00:00https://lymphoma-stg.clarovantdigital.com/library/re%e2%80%91mind2-comparative-effectiveness-of-tafasitamab-plus-lenalidomide-versus-polatuzumab-vedotin-bendamustine-rituximab-pola%e2%80%91br-car%e2%80%91t-therapies-and-lenalidomide-rituximab-r/2023-08-14T14:19:39+00:00https://lymphoma-stg.clarovantdigital.com/library/severe-hypersensitivity-reactions-at-biosimilar-versus-originator-rituximab-treatment-initiation-switch-and-over-time-a-cohort-study-on-the-french-national-health-data-system/2023-08-14T14:16:19+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-biosimilar-for-the-treatment-of-diffuse-large-b%e2%80%91cell-lymphoma-a-phase-3-randomized-study-in-india/2023-08-14T14:12:23+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-programmed-cell-death-1-inhibitor-maintenance-therapy-after-combined-treatment-with-programmed-cell-death-1-inhibitors-and-anti%e2%80%90cd19%e2%80%90chimeric-antigen-receptor-t-cells-in-pa/2026-01-14T21:38:29+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-and-rituximab-versus-fludarabine-cyclophosphamide-and-rituximab-for-patients-with-previously-untreated-chronic-lymphocytic-leukaemia-flair-interim-analysis-of-a-multicentre-open-label/2023-08-14T14:02:56+00:00https://lymphoma-stg.clarovantdigital.com/library/how-are-health-technology-assessment-bodies-responding-to-the-assessment-challenges-posed-by-cell-and-gene-therapy/2023-05-16T22:35:12+00:00https://lymphoma-stg.clarovantdigital.com/library/therapy-results-in-pediatric-hodgkin-lymphoma-does-less-mean-better-experience-from-a-single-childrens-oncology-center/2023-05-19T13:59:51+00:00https://lymphoma-stg.clarovantdigital.com/library/marketing-authorisation-and-pricing-of-fda-approved-cancer-drugs-in-brazil/2023-05-19T14:06:07+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-primary-mediastinal-b-cell-lymphoma-with-dose-adjusted-repoch-during-pregnancy/2023-08-14T18:07:23+00:00https://lymphoma-stg.clarovantdigital.com/library/gut-microbiota-and-b-cell-receptor-bcr-inhibitors-for-the-treatment-of-chronic-lymphocytic-leukemia-is-biodiversity-correlated-with-clinical-response-or-immune-related-adverse-event-occurrence-a-c/2026-01-15T16:27:28+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-diffuse-large-b-cell-lymphoma-of-the-bone/2023-05-19T16:04:34+00:00https://lymphoma-stg.clarovantdigital.com/library/feasibility-of-fine-needle-aspiration-for-diagnosis-of-b-cell-lymphoma-of-the-thyroid-a-case-series-and-review-of-the-literature/2023-10-03T11:59:32+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-bendamustine-cytarabine-for-transplant-eligible-patients-with-mantle-cell-lymphoma-a-retrospective-study/2023-05-19T16:25:29+00:00https://lymphoma-stg.clarovantdigital.com/library/relationship-between-bcl2-mutations-and-follicular-lymphoma-outcome-in-the-chemoimmunotherapy-era/2023-08-14T13:58:30+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-rituximab-plus-bendamustine-and-cytarabine-r-bac-in-elderly-patients-with-newly-diagnosed-mcl/2023-08-14T13:53:21+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-as-second-line-therapy-for-large-b-cell-lymphoma-primary-analysis-of-the-phase-3-transform-study/2026-01-14T22:15:51+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-maintenance-following-high-dose-therapy-and-autologous-haematopoietic-stem-cell-transplantation-in-chemo-resistant-or-high-risk-non-hodgkin-lymphoma-a-phase-i-ii-study/2023-09-07T20:15:36+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-venetoclax-combinations-in-chronic-lymphocytic-leukemia/2025-12-15T20:07:27+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-associated-hlh-like-syndrome/2023-05-19T20:11:46+00:00https://lymphoma-stg.clarovantdigital.com/library/a-rare-presentation-of-concomitant-lung-disease-and-hepatitis-after-rituximab-treatment-a-case-report/2023-08-23T20:31:06+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-in-covalent-btk-inhibitor-pre-treated-mantle-cell-lymphoma/2023-05-19T20:11:46+00:00https://lymphoma-stg.clarovantdigital.com/library/a-national-qualitative-study-on-the-impact-of-covid-19-on-cancer-care-and-potential-solutions-to-improve-the-cancer-care-experience-during-the-covid-19-pandemic/2023-08-23T20:28:29+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-perspectives-of-watch-and-wait-for-chronic-haematological-cancers-findings-from-a-qualitative-study/2023-05-23T13:28:04+00:00https://lymphoma-stg.clarovantdigital.com/library/the-characteristics-and-survival-of-second-primary-lung-cancer-after-hodgkins-lymphoma-a-comparison-with-first-primary-lung-cancer-using-the-seer-database/2023-05-23T15:09:19+00:00https://lymphoma-stg.clarovantdigital.com/library/a-new-face-of-fibrin-associated-large-b-cell-lymphoma-epstein-barr-virus-positive-breast-implant-associated-diffuse-large-b-cell-lymphoma/2026-09-02T16:17:06+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-type-2-diabetes-on-mortality-cause-of-death-and-treatment-in-chronic-lymphocytic-leukemia/2023-08-14T13:51:47+00:00https://lymphoma-stg.clarovantdigital.com/library/multiple-primary-malignancies-in-788-chinese-patients-with-diffuse-large-b-cell-lymphoma/2023-05-23T17:36:04+00:00https://lymphoma-stg.clarovantdigital.com/library/a-fixed-duration-immunochemotherapy-approach-in-cll-5-5-year-results-from-the-phase-2-icll-07-filo-trial/2026-01-14T20:45:00+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathological-cytogenetic-and-molecular-profiles-of-primary-cutaneous-diffuse-large-b-cell-lymphomas/2023-05-23T19:08:13+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-chimeric-antigen-receptor-t-cell-therapy-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-with-different-hbv-status-a-retrospective-study-from-a-single-center/2023-05-25T15:24:23+00:00https://lymphoma-stg.clarovantdigital.com/library/quality-adjusted-survival-time-without-symptoms-or-toxicity-of-acalabrutinib-with-or-without-obinutuzumab-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia/2023-08-14T13:36:27+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-in-a-patient-treated-with-azathioprine-for-ulcerative-colitis-a-case-report/2023-05-25T15:35:00+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-after-r-high-chop-chaser-leed-with-auto-pbsct-in-untreated-mantle-cell-lymphoma-final-analysis-of-jcog0406/2023-05-31T18:47:32+00:00https://lymphoma-stg.clarovantdigital.com/library/hhv8-unrelated-primary-effusion-lymphoma-in-a-patient-with-hbv-related-liver-cirrhosis-a-case-successfully-treated-with-rituximab-and-lenalidomide/2023-08-14T14:51:37+00:00https://lymphoma-stg.clarovantdigital.com/library/assessment-of-response-to-immunotherapy-in-patients-with-hodgkin-lymphoma-towards-quantifying-changes-in-tumor-burden-using-fdg-pet-ct/2026-01-15T16:27:01+00:00https://lymphoma-stg.clarovantdigital.com/library/human-immunodeficiency-virus-related-non-hodgkins-lymphoma/2023-05-31T20:25:52+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-diagnosed-with-mantle-cell-lymphoma-with-tumour-lysis-syndrome-case-report-and-literature-review/2023-08-14T13:10:56+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-of-brexucabtagene-autoleucel-for-relapsed-refractory-mantle-cell-lymphoma/2024-07-15T15:37:39+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-colonic-malt-lymphoma-associated-with-crohns-disease-case-report-and-review-of-the-literature/2023-05-31T22:50:46+00:00https://lymphoma-stg.clarovantdigital.com/library/bone-marrow-biopsy-can-be-omitted-in-the-diagnostic-workup-of-cns-lymphoma-of-dlbcl-origin-a-population%e2%80%91based-retrospective-study-in-the-pet%e2%80%91ct-era/2026-01-20T19:45:18+00:00https://lymphoma-stg.clarovantdigital.com/library/infectious-complications-following-car%e2%80%91t-cell-therapy-for-b-cell-non%e2%80%91hodgkin-lymphoma-a-single%e2%80%91center-experience-and-review-of-the-literature/2023-05-31T22:58:31+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-cardiac-lymphoma-a-comprehensive-review/2023-05-31T23:04:02+00:00https://lymphoma-stg.clarovantdigital.com/library/chemotherapy-resistant-burkitt-lymphoma-possible-novel-therapies-including-car-t-cell-infusion/2023-05-31T23:10:16+00:00https://lymphoma-stg.clarovantdigital.com/library/pediatric-autologous-hematopoietic-stem-cell-transplantation-safety-efficacy-and-patient-outcomes-literature-review/2023-05-31T23:16:22+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-outcomes-for-patients-with-relapsed-refractory-aggressive-b-cell-lymphomas-following-receipt-of-high-dose-chemotherapy-autologous-stem-transplantation-and-or-chimeric-antigen-receptor-modifie/2026-01-15T14:12:30+00:00https://lymphoma-stg.clarovantdigital.com/library/a-rare-case-of-recurrent-cutaneous-non-hodgkins-lymphoma-in-the-extremity-long-term-follow-up-and-review-of-the-literature-written-with-the-assistance-of-chatgpt/2023-08-23T20:27:39+00:00https://lymphoma-stg.clarovantdigital.com/library/pancreatic-diffuse-large-b-cell-lymphoma-in-the-us-population/2023-06-09T17:50:01+00:00https://lymphoma-stg.clarovantdigital.com/library/very-long-term-follow-up-of-rituximab-maintenance-in-young-patients-with-mantle-cell-lymphoma-included-in-the-lyma-trial-a-lysa-study/2023-09-07T20:15:12+00:00https://lymphoma-stg.clarovantdigital.com/library/results-of-molto-a-multicenter-open-label-phase-ii-clinical-trial-evaluating-venetoclax-atezolizumab-and-obinutuzumab-combination-in-richter-syndrome/2023-08-28T20:20:48+00:00https://lymphoma-stg.clarovantdigital.com/library/zilovertamab-vedotin-mk-2140-in-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-early-results-from-the-phase-2-waveline-004-study/2023-08-28T20:20:12+00:00https://lymphoma-stg.clarovantdigital.com/library/subgroup-analysis-of-elderly-patients-pts-with-diffuse-large-b-cell-lymphoma-dlbcl-in-the-phase-3-polarix-study/2023-08-28T20:19:33+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-overall-survival-analysis-of-the-phase-3-randomized-zuma-7-study-of-axicabtagene-ciloleucel-versus-standard-of-care-therapy-in-relapsed-refractory-large-b-cell-lymphoma/2023-06-09T17:50:01+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-brexucabtagene-autoleucel-brexu-cel-for-relapsed-or-refractory-r-r-mantle-cell-lymphoma-mcl-a-cibmtr-subgroup-analysis-by-prior-treatment/2023-08-28T20:10:56+00:00https://lymphoma-stg.clarovantdigital.com/library/the-emerging-role-of-mrd-in-the-treatment-of-chronic-lymphocytic-leukemia/2026-01-14T21:06:57+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-r2-regimen-and-responses-in-high-risk-follicular-lymphoma-regardless-of-pod24-status/2026-01-14T22:15:24+00:00https://lymphoma-stg.clarovantdigital.com/library/observation-vs-radiotherapy-in-primary-mediastinal-b-cell-lymphoma-patients-with-complete-response-to-standard-immunochemotherapy-the-ielsg37-randomized-trial/2023-08-28T20:09:18+00:00https://lymphoma-stg.clarovantdigital.com/library/effect-of-follow-up-time-on-the-ability-of-subcutaneous-epcoritamab-to-induce-deep-and-durable-complete-remissions-in-patients-with-relapsed-refractory-large-b-cell-lymphoma-updated-results-from-the/2026-01-14T22:14:53+00:00https://lymphoma-stg.clarovantdigital.com/library/swog-s1826-a-randomized-study-of-nivolumabn-avd-versus-brentuximab-vedotinbv-avd-in-advanced-stage-as-classic-hodgkin-lymphoma-hl/2023-08-28T20:08:07+00:00https://lymphoma-stg.clarovantdigital.com/library/an-international-real-world-analysis-of-relapsed-refractory-lymphoma-occurring-during-pregnancy/2023-06-14T14:53:22+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-front-line-immunochemotherapy-for-transplant-ineligible-mantle-cell-lymphoma-a-network-meta-analysis-of-randomized-controlled-trials/2023-06-14T15:00:43+00:00https://lymphoma-stg.clarovantdigital.com/library/a-fondazione-italiana-linfomi-cohort-study-of-r-comp-vs-r-chop-in-older-patients-with-diffuse-large-b-cell-lymphoma/2023-06-14T15:09:59+00:00https://lymphoma-stg.clarovantdigital.com/library/the-epidemiological-patterns-of-non-hodgkin-lymphoma-global-estimates-of-disease-burden-risk-factors-and-temporal-trends/2023-06-14T15:13:39+00:00https://lymphoma-stg.clarovantdigital.com/library/anal-lymphoma-a-tumor-with-insufficient-attention/2026-09-02T16:16:21+00:00https://lymphoma-stg.clarovantdigital.com/library/health-resource-utilization-and-costs-of-care-for-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-in-the-united-states-a-retrospective-claims-analysis/2023-06-14T15:26:11+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-minimal-residual-disease-on-progression-free-survival-outcomes-after-fixed-duration-ibrutinib-venetoclax-versus-chlorambucil-obinutuzumab-in-the-glow-study/2026-01-14T20:44:39+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-in-patients-with-high-risk-features-after-fixed-duration-ibrutinib-plus-venetoclax-phase-ii-captivate-study-in-first-line-chronic-lymphocytic-leukemia/2026-01-14T20:43:22+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-infection-patterns-on-the-outcomes-of-patients-with-hematological-malignancies-in-southwest-china-a-10-year-retrospective-case-control-study/2023-06-14T15:46:40+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-biology-driven-frontline-treatment-for-chronic-lymphocytic-leukemia-a-network-meta-analysis-of-randomized-clinical-trials/2023-08-14T12:12:51+00:00https://lymphoma-stg.clarovantdigital.com/library/effect-of-cumulative-dose-of-brentuximab-vedotin-maintenance-in-relapsed-refractory-classical-hodgkin-lymphoma-after-autologous-stem-cell-transplant-an-analysis-of-real-world-outcomes/2023-09-07T19:02:29+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t%e2%80%90cell-therapy-in-large-b-cell-lymphoma/2023-08-14T20:08:11+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-agents-in-relapsed-refractory-diffuse-large-b%e2%80%90cell-lymphoma/2023-06-14T18:35:40+00:00https://lymphoma-stg.clarovantdigital.com/library/cd30-expression-in-cutaneous-b-cell-lymphomas/2023-06-14T18:42:16+00:00https://lymphoma-stg.clarovantdigital.com/library/plasmablastic-lymphoma-histopathological-features-and-differential-diagnosis/2023-06-14T18:52:41+00:00https://lymphoma-stg.clarovantdigital.com/library/classical-hodgkin-lymphoma-from-past-to-future-a-comprehensive-review-of-pathophysiology-and-therapeutic-advances/2023-08-28T18:41:25+00:00https://lymphoma-stg.clarovantdigital.com/library/a-population-level-analysis-of-second-hematological-malignancies-in-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-survivors-in-the-era-of-targeted-therapies/2025-03-03T19:41:45+00:00https://lymphoma-stg.clarovantdigital.com/library/management-considerations-for-patients-with-primary-refractory-and-early-relapsed-diffuse-large-b-cell-lymphoma/2023-06-14T19:11:46+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-remedies-of-current-challenges-in-design-injection-infiltration-and-working/2023-08-11T20:37:57+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-treatment-adherence-with-acalabrutinib-in-very-old-80y-and-or-frail-patients-with-chronic-lymphocytic-leukemia-cll-interim-safety-analysis-of-the-ongoing-phase-ii-cll-frail-trial/2023-09-08T21:53:42+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-dose-modifications-for-management-of-cardiac-adverse-events-in-patients-with-b-cell-malignancies-pooled-analysis-of-10-clinical-trials/2023-08-28T20:06:48+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-ctdna-status-and-clinical-outcomes-in-patients-pts-with-previously-untreated-diffuse-large-b-cell-lymphoma-dlbcl-in-the-polarix-study/2023-08-28T20:05:39+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-early-outcomes-of-axicabtagene-ciloleucel-for-relapsed-or-refractory-follicular-lymphoma/2026-01-14T22:14:22+00:00https://lymphoma-stg.clarovantdigital.com/library/longer-follow-up-from-the-pivotal-epcore-nhl-1-trial-reaffirms-subcutaneous-epcoritamab-induces-deep-durable-complete-remissions-in-patients-with-relapsed-refractory-large-b-cell-lymphoma/2026-01-14T18:01:30+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-in-patients-pts-with-waldenstrom-macroglobulinemia-wm-treated-with-zanubrutinib-zanu-vs-ibrutinib-ibr-results-from-the-phase-3-aspen-trial-long-term-follow-up/2023-08-28T20:03:29+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-vs-ibrutinib-in-relapsed-refractory-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-r-r-cll-sll-impact-on-health-related-quality-of-life-hrqol/2025-03-03T20:50:09+00:00https://lymphoma-stg.clarovantdigital.com/library/initial-safety-data-from-the-phase-3-polar-bear-trial-in-elderly-or-frail-patients-with-diffuse-large-cell-lymphoma-comparing-r-pola-mini-chp-and-r-mini-chop/2023-09-08T21:54:28+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-pancreatic-mature-t-cell-lymphoma-as-a-cause-of-obstructive-jaundice-a-case-report-and-review-of-the-literature/2023-08-23T20:24:53+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-obinutuzumab-for-previously-untreated-chronic-lymphocytic-leukemia-6-year-results-of-the-randomized-cll14-study/2023-08-28T20:01:44+00:00https://lymphoma-stg.clarovantdigital.com/library/final-7-year-follow-up-and-retreatment-substudy-analysis-of-murano-venetoclax-rituximab-venr-treated-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-r-r-cll/2026-01-14T21:06:31+00:00https://lymphoma-stg.clarovantdigital.com/library/golidocitinib-in-treating-refractory-or-relapsed-peripheral-t-cell-lymphoma-primary-analysis-of-the-multinational-pivotal-study-results-jackpot8/2023-08-28T19:59:50+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-bv-avd-for-newly-diagnosed-classic-hodgkin-lymphoma-chl-incidence-and-management-of-peripheral-neuropathy-pn-in-a-multi-institution-cohort/2023-08-28T19:59:16+00:00https://lymphoma-stg.clarovantdigital.com/library/toxicities-at-one-year-follow-up-in-patients-with-advanced-stage-classical-hodgkin-lymphoma-results-from-the-randomized-phase-iii-hd21-trial-by-the-german-hodgkin-study-group/2023-08-28T19:58:08+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-nivolumab-doxorubicin-and-dacarbazine-for-early-stage-classical-hodgkin-lymphoma-updated-results-from-an-ongoing-phase-2-study-sgn35-027-part-c/2023-08-28T19:57:21+00:00https://lymphoma-stg.clarovantdigital.com/library/brecadd-is-non-inferior-to-ebeacopp-in-patients-with-advanced-stage-classical-hodgkin-lymphoma-efficacy-results-of-the-ghsg-phase-iii-hd21-trial/2023-08-28T19:56:41+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-versus-placebo-in-patients-with-asymptomatic-treatment-naive-early-stage-chronic-lymphocytic-leukemia-cll-final-results-of-the-phase-3-double-blind-placebo-controlled-cll12-trial/2023-08-28T19:56:02+00:00https://lymphoma-stg.clarovantdigital.com/library/infection-associated-mortality-during-induction-chemotherapy-in-group-b-intermediate-risk-pediatric-burkitts-lymphoma/2026-03-13T19:36:29+00:00https://lymphoma-stg.clarovantdigital.com/library/how-to-treat-newly-diagnosed-dlbcl/2023-06-16T13:59:14+00:00https://lymphoma-stg.clarovantdigital.com/library/pi3k-inhibitor-linperlisib-for-patients-with-relapsed-or-refractory-follicular-lymphoma-subgroup-analysis-of-a-phase-2-trial/2023-08-28T19:55:17+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-with-rituximab-lenalidomide-r2-provides-durable-responses-in-patients-with-high-risk-follicular-lymphoma-regardless-of-pod24-status/2026-01-14T22:13:50+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-bendamustine-rituximab-pola-br-efficacy-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-rrdlbcl-trial-ineligible-patients-an-australian-lymphoma-registry-lardr-study/2023-08-28T19:53:51+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-plus-rituximab-and-lenalidomide-zr2-for-relapsed-and-refractory-diffuse-large-b-cell-lymphoma/2023-08-28T19:52:33+00:00https://lymphoma-stg.clarovantdigital.com/library/high-complete-metabolic-response-rates-with-epcoritamab-r-chop-in-previously-untreated-1l-patients-with-high-risk-diffuse-large-b-cell-lymphoma-including-double-triple-hit-epcore-nhl-2-update/2026-01-14T22:13:03+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-study-of-bortezomib-cytarabine-and-dexamethasone-in-relapsed-or-refractory-mantle-cell-lymphoma/2023-08-28T19:43:30+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-multicenter-single-arm-study-of-parsaclisib-a-pi3k-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-in-china-updated-results-from-the-study/2026-01-15T13:49:56+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-fd-ibrutinib-venetoclax-for-first-line-treatment-of-chronic-lymphocytic-leukemia-cll-small-lymphocytic-lymphoma-sll-4-y-follow-up-from-fd-cohort-of-phase-2-captivate-study/2026-01-14T21:06:02+00:00https://lymphoma-stg.clarovantdigital.com/library/results-of-a-phase-3-study-of-ivo-vs-io-for-previously-untreated-older-patients-pts-with-chronic-lymphocytic-leukemia-cll-and-impact-of-covid-19-alliance/2023-08-28T19:41:23+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-plus-obinutuzumab-versus-obinutuzumab-in-patients-with-relapsed-refractory-follicular-lymphoma-updated-analysis-of-the-rosewood-study/2023-08-28T19:40:26+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-multicenter-phase-ii-trial-of-zanubrutinib-obinutuzumab-and-venetoclax-boven-in-previously-untreated-patients-with-cll-sll/2025-03-03T20:49:15+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-zanu-versus-bendamustine-rituximab-br-in-patients-pts-with-treatment-naive-tn-cll-sll-extended-follow-up-of-the-sequoia-study/2025-03-03T20:48:30+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-efficacy-and-safety-of-zanubrutinib-zanu-in-relapsed-refractory-marginal-zone-lymphoma-r-r-mzl-final-analysis-of-the-magnolia-bgb-3111-214-trial/2023-08-28T19:38:39+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-safety-tolerability-profile-and-comparison-with-ibrutinib-profile-in-b-cell-malignancies-post-hoc-analysis-of-a-large-clinical-trial-safety-database/2023-08-28T19:38:04+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-of-zanubrutinib-in-previously-treated-b-cell-malignancies-intolerant-to-ibrutinib-and-or-acalabrutinib-preliminary-results-for-patients-with-cll-sll/2025-03-03T20:47:34+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-results-of-the-fil-mcl0208-trial-comparing-lenalidomide-maintenance-len-vs-observation-obs-after-autologous-stem-cell-transplantation-asct-in-mantle-cell-lymphoma-mcl/2023-09-07T20:13:24+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-demonstrates-durable-responses-in-patients-with-relapsed-and-or-refractory-follicular-lymphoma-who-have-received-2-prior-therapies-updated-analysis-of-a-pivotal-phase-ii-study/2026-01-14T22:08:29+00:00https://lymphoma-stg.clarovantdigital.com/library/predicting-thrombotic-risk-in-patients-with-hodgkin-lymphoma-a-multicentric-study-of-throly-and-khorana-risk-scores/2023-08-28T19:35:36+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-stem-cell-transplantation-for-nk-t-cell-lymphoma-in-the-era-of-asparaginase-based-chemotherapy-a-retrospective-analysis-of-the-ebmt-lymphoma-working-party/2023-08-28T19:35:02+00:00https://lymphoma-stg.clarovantdigital.com/library/duvelisib-in-patients-with-relapsed-refractory-peripheral-t-cell-lymphoma-from-the-phase-2-primo-trial-expansion-phase-outcomes-by-baseline-histology/2023-08-28T19:33:53+00:00https://lymphoma-stg.clarovantdigital.com/library/orelabrutinib-a-new-generation-bruton-tyrosine-kinase-inhibitor-demonstrates-safety-and-efficacy-in-relapsed-refractory-marginal-zone-lymphoma/2023-08-28T19:33:17+00:00https://lymphoma-stg.clarovantdigital.com/library/orelabrutinib-lenalidomide-rituximab-olr-in-patients-with-untreated-mantle-cell-lymphoma-mcl-a-prospective-multicenter-single-arm-phase-2-polaris-study-in-china/2023-08-28T19:32:39+00:00https://lymphoma-stg.clarovantdigital.com/library/prophylactic-efficacy-of-intrathecal-versus-intravenous-methotrexate-for-cns-relapse-in-high-risk-diffuse-large-b-cell-lymphoma-a-phase-iii-randomized-controlled-study/2023-08-28T19:32:02+00:00https://lymphoma-stg.clarovantdigital.com/library/the-covid-19-pandemic-and-in-person-visit-rate-disruptions-among-patients-with-hematologic-neoplasms-in-the-us-in-2020-to-2021/2023-08-11T20:37:03+00:00https://lymphoma-stg.clarovantdigital.com/library/sars-cov-2-infection-in-patients-with-waldenstroms-macroglobulinemia-a-multicenter-international-cohort-study/2023-08-11T20:36:33+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-restoration-with-ibrutinib-plus-venetoclax-in-first-line-chronic-lymphocytic-leukemia-the-phase-2-captivate-study/2026-03-09T16:01:57+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-in-the-hiv-setting/2025-12-15T20:01:01+00:00https://lymphoma-stg.clarovantdigital.com/library/reproduction-patterns-among-non-hodgkin-lymphoma-survivors-by-subtype-in-sweden-denmark-and-norway-a-population-based-matched-cohort-study/2023-06-20T14:31:30+00:00https://lymphoma-stg.clarovantdigital.com/library/unraveling-the-immune-microenvironment-in-classic-hodgkin-lymphoma-prognostic-and-therapeutic-implications/2023-08-11T20:32:43+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-follow-up-of-keynote-087-pembrolizumab-monotherapy-in-relapsed-refractory-classical-hodgkin-lymphoma/2023-08-11T20:31:23+00:00https://lymphoma-stg.clarovantdigital.com/library/secondary-antibody-deficiency-in-chronic-lymphocytic-leukemia-and-non-hodgkin-lymphoma-recommendations-from-an-international-expert-panel/2023-08-11T20:30:35+00:00https://lymphoma-stg.clarovantdigital.com/library/notch-signaling-in-mantle-cell-lymphoma-biological-and-clinical-implications/2023-08-14T19:16:15+00:00https://lymphoma-stg.clarovantdigital.com/library/zanbrutinib-lenalidomide-plus-r-chop-zr2-chop-as-the-first-line-treatment-for-non-gcb-diffuse-large-b-cell-lymphoma-an-updated-analysis-of-efficacy-and-tolerability/2023-08-28T19:31:25+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-liso-cel-in-r-r-mcl-primary-analysis-results-from-the-mcl-cohort-of-the-single-arm-multicenter-seamless-design-transcend-nhl-001-study/2023-08-28T19:30:40+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-as-second-line-therapy-for-large-b-cell-lymphoma-in-transplant-ineligible-patients-final-analysis-of-alycante-a-phase-2-lysa-study/2026-01-14T22:12:31+00:00https://lymphoma-stg.clarovantdigital.com/library/final-analysis-of-australasian-leukaemia-lymphoma-group-nhl29-a-phase-ii-study-of-ibrutinib-rituximab-and-mini-chop-in-very-elderly-patients-with-newly-diagnosed-dlbcl/2023-09-08T21:55:07+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-monotherapy-in-patients-with-relapsed-refractory-r-r-large-b-cell-lymphoma-lbcl-extended-follow-up-and-landmark-analyses-from-a-pivotal-phase-ii-study/2026-01-14T22:12:02+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-br-or-r-chop-in-previously-treated-patients-with-follicular-or-marginal-zone-lymphoma-the-phase-3-selene-study/2023-08-28T19:27:41+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-of-anbal-cel-novel-anti-cd19-car-t-therapy-with-dual-silencing-of-pd-1-and-tigit-in-relapsed-or-refractory-large-b-cell-lymphoma-interim-analysis-result/2026-01-14T22:11:27+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-ovarian-non-hodgkins-lymphoma-an-18-year-retrospective-institutional-study-and-review-of-literature-from-india/2023-06-23T16:29:39+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-rituximab-and-venetoclax-irv-followed-by-risk-stratified-r-hypercvad-mtx-in-young-patients-with-untreated-mantle-cell-lymphoma-phase-ii-window-2-trial/2023-08-28T19:26:01+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-monotherapy-induces-durable-complete-remissions-and-has-a-manageable-safety-profile-in-patients-with-richters-transformation/2023-08-28T19:25:16+00:00https://lymphoma-stg.clarovantdigital.com/library/initial-results-of-a-multicenter-phase-2-study-of-venetoclax-in-combination-with-r-chop-vr-chop-for-patients-with-richter-syndrome/2023-08-28T19:24:35+00:00https://lymphoma-stg.clarovantdigital.com/library/an-open-label-phase-1-2-study-of-favezelimab-plus-pembrolizumab-in-patients-with-relapsed-refractory-classical-hodgkin-lymphoma-with-without-previous-anti-pd-1-treatment/2023-08-28T19:24:00+00:00https://lymphoma-stg.clarovantdigital.com/library/peripherally-inserted-central-catheter-insertion-and-management-in-hodgkin-and-non-hodgkin-lymphomas-a-13-year-monocentric-experience/2023-06-26T17:50:20+00:00https://lymphoma-stg.clarovantdigital.com/library/how-to-treat-diffuse-large-b-cell-lymphoma-oncologic-and-cardiovascular-considerations/2023-06-26T18:01:21+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-refractoriness-in-chronic-lymphocytic-leukemia-old-and-new-molecular-biomarkers/2023-08-11T20:27:15+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-nodular-lymphocyte-predominant-hodgkin-lymphoma-where-do-we-stand-where-do-we-go/2023-08-14T14:45:41+00:00https://lymphoma-stg.clarovantdigital.com/library/cytopenia-after-car%e2%80%91t-cell-therapy-analysis-of-63-patients-with-relapsed-and-refractory-b%e2%80%91cell-non%e2%80%91hodgkin-lymphoma/2023-06-26T18:27:40+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-plus-doxorubicin-and-dacarbazine-in-nonbulky-limited-stage-classical-hodgkin-lymphoma/2023-08-28T18:40:23+00:00https://lymphoma-stg.clarovantdigital.com/library/btk-mutations-in-patients-with-chronic-lymphocytic-leukemia-cll-receiving-tirabrutinib/2023-08-11T20:25:43+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-for-the-treatment-of-chronic-lymphocytic-leukemia/2023-08-11T20:25:02+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-in-combination-with-rituximab-is-highly-effective-in-treatment-of-chronic-lymphocytic-leukemia-patients-with-steroid-refractory-and-relapsed-autoimmune-cytopenias/2023-08-11T20:23:39+00:00https://lymphoma-stg.clarovantdigital.com/library/effectiveness-of-tisagenlecleucel-versus-real-world-standard-of-care-in-relapsed-refractory-follicular-lymphoma/2023-06-26T18:54:23+00:00https://lymphoma-stg.clarovantdigital.com/library/additional-lesions-identified-by-genomic-microarrays-are-associated-with-an-inferior-outcome-in-low-risk-chronic-lymphocytic-leukaemia-patients/2023-08-11T20:21:36+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-with-idelalisib-in-patients-with-chronic-lymphocytic-leukemia-real-world-data-from-the-registry-of-the-german-cll-study-group/2023-08-11T20:20:37+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-immunochemotherapy-with-r%e2%80%90bendamustine-or-r%e2%80%90chop-for-treatment-naive-advanced%e2%80%90stage-follicular-lymphoma-a-subset-analysis-of-the-foll12-trial-by-fondazione-italiana/2023-06-26T20:40:17+00:00https://lymphoma-stg.clarovantdigital.com/library/mediastinal-gray-zone-lymphoma-still-an-open-issue/2023-07-04T20:48:21+00:00https://lymphoma-stg.clarovantdigital.com/library/subclonal-tp53-mutation-are-frequent-and-predict-resistance-to-radioimmunotherapy-in-follicular-lymphoma/2023-07-04T21:09:23+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-second-primary-cancer-risk-among-chronic-lymphocytic-leukemia-patients-multicenter-study/2023-08-11T20:17:49+00:00https://lymphoma-stg.clarovantdigital.com/library/combination-of-sarcopenia-and-anemia-predicts-worse-outcome-in-elderly-patients-with-diffuse-large-b-cell-lymphoma/2023-07-05T14:44:23+00:00https://lymphoma-stg.clarovantdigital.com/library/association-between-serum-albumin-levels-and-survival-in-elderly-patients-with-diffuse-large-b-cell-lymphoma-a-single-center-retrospective-study/2023-07-05T14:56:29+00:00https://lymphoma-stg.clarovantdigital.com/library/guideline-concordance-of-treatment-and-outcomes-among-adult-non-hodgkin-lymphoma-patients-in-sub-saharan-africa-a-multinational-population-based-cohort/2023-07-05T15:05:39+00:00https://lymphoma-stg.clarovantdigital.com/library/soluble-cd163-predicts-outcome-in-both-chemoimmunotherapy-and-targeted-therapy-treated-mantle-cell-lymphoma/2023-07-05T15:13:00+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-efficacy-and-tolerability-of-venetoclax-plus-rituximab-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-a-real%e2%80%91world-analysis-of-the-polish-adult-leukemia-study/2023-08-11T20:16:21+00:00https://lymphoma-stg.clarovantdigital.com/library/lymphadenopathy-as-a-predictor-of-progression-during-venetoclax-treatment-in-chronic-lymphocytic-leukemia-a-campus-chronic-lymphocytic-leukemia-study/2023-08-11T19:42:33+00:00https://lymphoma-stg.clarovantdigital.com/library/fluid-overload-associated-large-b-cell-lymphoma-a-case-report-and-review-of-literature/2023-07-05T15:37:20+00:00https://lymphoma-stg.clarovantdigital.com/library/robust-prognostic-value-of-histologic-transformation-in-patients-with-early-progression-of-follicular-lymphoma/2023-07-05T15:43:25+00:00https://lymphoma-stg.clarovantdigital.com/library/continuous-venetoclax-in-treatment-naive-tp53-disrupted-patients-with-chronic-lymphocytic-leukemia-a-chronic-lymphocytic-leukemia-campus-study/2023-08-11T19:34:43+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-strategies-and-survival-outcomes-of-primary-mediastinal-large-b-cell-lymphoma/2023-08-14T18:06:20+00:00https://lymphoma-stg.clarovantdigital.com/library/exposure-of-progressive-immune-dysfunction-by-sars-cov-2-mrna-vaccination-in-patients-with-chronic-lymphocytic-leukemia-a-prospective-cohort-study/2026-01-15T16:29:38+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnostic-approach-for-classic-hodgkin-lymphoma-in-small-samples-with-an-emphasis-on-pd-l1-expression-and-ebv-harboring-in-tumor-cells-a-brief-review-from-morphology-to-biology/2023-07-05T16:31:29+00:00https://lymphoma-stg.clarovantdigital.com/library/fulminant-hepatic-failure-as-the-initial-presentation-of-hodgkin-lymphoma-in-4-patients-with-human-immunodeficiency-virus/2023-07-05T17:47:21+00:00https://lymphoma-stg.clarovantdigital.com/library/positron-emission-tomography-adapted-therapy-in-low-risk-diffuse-large-b-cell-lymphoma-results-of-a-randomized-phase-iii-non-inferiority-trial/2023-07-05T18:17:58+00:00https://lymphoma-stg.clarovantdigital.com/library/infections-in-patients-with-chronic-lymphocytic-leukemia/2023-08-11T19:25:18+00:00https://lymphoma-stg.clarovantdigital.com/library/exposure-to-pesticides-and-risk-of-hodgkin-lymphoma-in-an-international-consortium-of-agricultural-cohorts-agricoh/2023-07-10T17:59:03+00:00https://lymphoma-stg.clarovantdigital.com/library/indirect-comparisons-of-efficacy-of-zanubrutinib-versus-orelabrutinib-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-or-relapsed-or-refractory-mantle-c/2025-03-03T19:40:36+00:00https://lymphoma-stg.clarovantdigital.com/library/the-clinical-challenge-of-relapsed-diffuse-large-b-cell-lymphoma-with-disseminated-infection/2023-07-10T18:17:34+00:00https://lymphoma-stg.clarovantdigital.com/library/unresolved-questions-in-selection-of-therapies-for-treatment%e2%80%91naive-chronic-lymphocytic-leukemia/2023-08-11T19:23:07+00:00https://lymphoma-stg.clarovantdigital.com/library/harnessing-the-potential-of-car%e2%80%91t-cell-therapy-progress-challenges-and-future-directions-in-hematological-and-solid-tumor-treatments/2026-01-14T21:37:48+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-survival-of-autologous-stem-cell-transplantation-in-primary-refractory-and-relapsed-hodgkin-lymphoma-in-the-brentuximab-vedotin-era-real%e2%80%91world-data-from-hungary/2023-08-28T18:39:53+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-versus-rituximab-immunochemotherapy-in-previously-untreated-inhl-final-results-from-the-gallium-study/2023-08-11T19:17:57+00:00https://lymphoma-stg.clarovantdigital.com/library/radiation-and-dose-densification-of-r-chop-in-primary-mediastinal-b-cell-lymphoma-subgroup-analysis-of-the-unfolder-trial/2023-07-11T18:41:14+00:00https://lymphoma-stg.clarovantdigital.com/library/radiation-and-dose-densification-of-r-chop-in-aggressive-b-cell-lymphoma-with-intermediate-prognosis-the-unfolder-study/2023-07-11T18:55:44+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b%e2%80%90cell-lymphoma/2023-07-19T23:30:20+00:00https://lymphoma-stg.clarovantdigital.com/library/inferior-outcomes-of-eu-versus-us-patients-treated-with-cd19-car-t-for-relapsed-refractory-large-b-cell-lymphoma-association-with-differences-in-tumor-burden-systemic-inflammation-bridging-therapy/2025-12-19T18:14:36+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-add%e2%80%91on-anti%e2%80%91cd20-monoclonal-antibody-to-bruton-tyrosine-kinase-inhibitor-treatment-for-chronic-lymphocytic-leukemia-a-meta%e2%80%91analysis-2/2023-08-11T19:14:19+00:00https://lymphoma-stg.clarovantdigital.com/library/b-cell-receptor-pathway-mutations-are-infrequent-in-patients-with-chronic-lymphocytic-leukemia-on-continuous-ibrutinib-therapy/2023-08-11T19:01:57+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-intensified-abvd-demonstrates-superior-efficacy-than-pet-adapted-abvd-in-advanced-hodgkin-lymphoma-the-fil-rouge-phase-3-trial-by-the-fondazione-italiana-linfomi/2023-08-28T19:22:55+00:00https://lymphoma-stg.clarovantdigital.com/library/fertility-may-decline-early-in-women-treated-as-children-for-hodgkin-lymphoma-more-successfully-pregnant-at-younger-age/2023-07-21T17:28:41+00:00https://lymphoma-stg.clarovantdigital.com/library/encouraging-complete-responses-crs-with-cdk9-inhibitor-azd4573-in-patients-pts-with-relapsed-refractory-r-r-peripheral-t-cell-lymphoma-ptcl-early-trial-analysis/2023-08-28T19:21:55+00:00https://lymphoma-stg.clarovantdigital.com/library/cd20-car-t-therapy-with-mb-106-for-btk-inhibitor-refractory-waldenstrom-macroglobulinemia-wm-lymphoplasmacytic-lymphoma-lpl/2023-08-28T19:21:20+00:00https://lymphoma-stg.clarovantdigital.com/library/characterization-of-mechanisms-of-resistance-in-previously-treated-chronic-lymphocytic-leukemia-from-a-head-to-head-trial-of-acalabrutinib-versus-ibrutinib/2023-08-23T18:35:33+00:00https://lymphoma-stg.clarovantdigital.com/library/odronextamab-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-dlbcl-results-from-a-prespecified-analysis-of-the-pivotal-phase-ii-study-elm-2/2026-01-14T22:11:00+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-rituximab-and-venetoclax-irv-followed-by-risk-stratified-r-hypercvad-mtx-in-young-patients-with-untreated-mantle-cell-lymphoma/2023-07-21T17:28:42+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-t-cell-vitreoretinal-non-hodgkin-lymphoma-a-case-report-and-literature-review/2023-07-21T17:28:42+00:00https://lymphoma-stg.clarovantdigital.com/library/afm13-in-patients-with-cd30-positive-relapsed-or-refractory-r-r-peripheral-t-cell-lymphoma-ptcl-results-from-the-phase-2-redirect-study/2023-08-28T19:19:23+00:00https://lymphoma-stg.clarovantdigital.com/library/alk-positive-anaplastic-large-cell-lymphoma-associated-with-hemophagocytic-lymphohistiocytosis/2023-07-21T17:28:43+00:00https://lymphoma-stg.clarovantdigital.com/library/synchronous-adenocarcinoma-stomach-with-marginal-zone-lymphoma-a-sporadic-occurrence-and-review-of-literature/2023-07-21T17:28:43+00:00https://lymphoma-stg.clarovantdigital.com/library/a-review-of-hodgkin-lymphoma-in-the-era-of-checkpoint-inhibitors/2023-08-28T19:00:03+00:00https://lymphoma-stg.clarovantdigital.com/library/targeted-treatment-of-adults-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-dlbcl-tafasitamab-in-context-2/2023-08-14T14:23:05+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-in-relapsed-or-refractory-primary-mediastinal-large-b-cell-lymphoma-final-analysis-of-keynote-170/2023-08-11T15:13:49+00:00https://lymphoma-stg.clarovantdigital.com/library/advancements-in-the-treatment-of-cll-the-rise-of-zanubrutinib-as-a-preferred-therapeutic-option/2023-08-11T19:50:56+00:00https://lymphoma-stg.clarovantdigital.com/library/reflect-prospective-multicenter-non-interventional-study-evaluating-the-effectiveness-and-safety-of-sandoz-rituximab-sdz-rtx-rixathon-in-combination-with-chop-for-the-treatment-of-patients-with-pr/2026-01-06T21:09:37+00:00https://lymphoma-stg.clarovantdigital.com/library/time-to-next-treatment-in-patients-with-chronic-lymphocytic-leukemia-initiating-first-line-ibrutinib-or-acalabrutinib/2023-08-11T14:57:06+00:00https://lymphoma-stg.clarovantdigital.com/library/nationwide-assessment-of-patient-trajectories-in-mantle-cell-lymphoma-the-swedish-mclcomplete-project/2023-09-07T19:01:45+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-strategies-and-prognostic-factors-in-secondary-central-nervous-system-lymphoma-a-multicenter-study-of-124-patients/2023-08-14T19:37:27+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-versus-ibrutinib-in-symptomatic-waldenstrom-macroglobulinemia-final-analysis-from-the-randomized-phase-iii-aspen-study/2023-08-06T16:25:26+00:00https://lymphoma-stg.clarovantdigital.com/library/evolving-therapeutic-landscape-of-diffuse-large-b%e2%80%91cell-lymphoma-challenges-and-aspirations/2023-08-06T17:29:41+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcome-of-mantle-cell-lymphoma-patients-with-high-risk-disease-high-risk-mipi-c-or-high-p53-expression/2025-12-15T21:54:26+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-time-to-discontinuation-of-first-line-venetoclax-obinutuzumab-in-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/2025-03-03T19:39:32+00:00https://lymphoma-stg.clarovantdigital.com/library/mutations-associated-with-progression-in-follicular-lymphoma-predict-inferior-outcomes-at-diagnosis-alliance-a151303/2023-08-06T19:12:54+00:00https://lymphoma-stg.clarovantdigital.com/library/successful-anatomy-adapted-therapeutic-management-and-genetic-profiling-of-primary-pituitary-diffuse-large-b-cell-lymphoma/2023-08-06T19:16:58+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-cholesterol-in-chronic-lymphocytic-leukemia-development-and-pathogenesis-2/2023-08-11T14:51:11+00:00https://lymphoma-stg.clarovantdigital.com/library/the-spectrum-of-nodular-lymphocyte-predominant-hodgkin-lymphoma-a-report-of-the-lymphoma-workshop-of-the-20th-meeting-of-the-european-association-for-haematopathology/2026-01-20T19:44:22+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-for-relapsed-refractory-classical-hodgkin-lymphoma-5-year-survival-from-pivotal-phase-2-checkmate-205-study/2023-08-11T14:49:22+00:00https://lymphoma-stg.clarovantdigital.com/library/consolidative-radiotherapy-after-complete-remission-following-r-chop-immunochemotherapy-in-stage-iii-iv-diffuse-large-b-cell-lymphoma-patients-a-systematic-review-and-meta-analysis/2023-08-06T19:51:55+00:00https://lymphoma-stg.clarovantdigital.com/library/work-ability-and-work-status-changes-in-long%e2%80%91term-hodgkin-lymphoma-survivors-with-focus-on-late-adverse-effects/2023-08-06T19:59:38+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-hepatic-burkitt-lymphoma-in-a-child-and-review-of-literature/2023-08-06T20:39:44+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-in-patients-with-chronic-lymphocytic-leukemia-and-tp53-aberration-who-received-first-line-ibrutinib-a-nationwide-registry-study-from-the-italian-medicines-agency/2023-08-11T15:12:31+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-dlbcl-is-infiltrated-with-activated-cd8-t-cells-despite-immune-checkpoint-signaling/2023-08-15T19:07:33+00:00https://lymphoma-stg.clarovantdigital.com/library/bridging-therapy-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2023-08-17T14:39:49+00:00https://lymphoma-stg.clarovantdigital.com/library/histopathological-experience-of-primary-adrenal-lymphoma-from-two-tertiary-hospitals/2023-08-17T14:41:11+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-effectiveness-of-salvage-chemotherapy-regimens-and-chimeric-antigen-t-cell-receptor-therapies-in-relapsed-and-refractory-diffuse-large-b-cell-lymphoma-a-network-meta-analysis-of-clinical/2023-08-17T14:57:07+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-fludarabine-cyclophosphamide-and-rituximab-ifcr-as-initial-treatment-in-chronic-lymphocytic-leukemia/2023-08-17T18:37:04+00:00https://lymphoma-stg.clarovantdigital.com/library/time-to-progression-of-disease-and-outcomes-with-second-line-btk-inhibitors-in-relapsed-refractory-mantle-cell-lymphoma/2023-08-17T19:40:28+00:00https://lymphoma-stg.clarovantdigital.com/library/a-significant-proportion-of-classic-hodgkin-lymphoma-recurrences-represents-clonally-unrelated-second-primary-lymphoma/2023-08-17T20:17:56+00:00https://lymphoma-stg.clarovantdigital.com/library/measurable-residual-disease-in-japanese-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-treated-with-venetoclax/2026-01-14T20:42:46+00:00https://lymphoma-stg.clarovantdigital.com/library/the-progress-of-novel-strategies-on-immune%e2%80%91based-therapy-in-relapsed-or-refractory-diffuse-large-b%e2%80%91cell-lymphoma/2023-08-22T17:48:16+00:00https://lymphoma-stg.clarovantdigital.com/library/peri-car-t-practice-patterns-and-survival-predictors-for-all-car-t-patients-and-post-car-t-failure-in-aggressive-b-nhl/2023-08-22T18:23:26+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-micrornas-in-chronic-lymphocytic-leukemia/2023-08-22T18:31:10+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-subdivisions-of-follicular-lymphoma-defined-by-distinct-coding-and-noncoding-mutation-patterns/2023-08-22T18:40:14+00:00https://lymphoma-stg.clarovantdigital.com/library/skin-involvement-by-hematological-neoplasms-with-blastic-morphology-lymphoblastic-lymphoma-blastoid-variant-of-mantle-cell-lymphoma-and-differential-diagnoses/2023-08-22T18:47:26+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-research-in-chronic-lymphocytic-leukemia-in-pakistan-a-systematic-review/2023-08-22T19:01:30+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-tisagenlecleucel-with-conventional-treatments-for-relapsed-refractory-diffuse-large-b-cell-lymphomas-a-retrospective-external-comparator-study/2023-08-22T19:37:11+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-in-covalent-bruton-tyrosine-kinase-inhibitor-pretreated-mantle-cell-lymphoma/2023-08-22T19:43:13+00:00https://lymphoma-stg.clarovantdigital.com/library/trends-in-non-hodgkin-lymphoma-mortality-rate-in-japan-and-the-united-states-a-population-based-study/2023-08-22T19:54:16+00:00https://lymphoma-stg.clarovantdigital.com/library/sequential-pembrolizumab-and-avd-are-highly-effective-at-any-pd-l1-expression-level-in-untreated-hodgkin-lymphoma/2023-08-22T19:59:41+00:00https://lymphoma-stg.clarovantdigital.com/library/cytokine-profiles-in-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma-il-6-and-il-10-levels-are-associated-with-adverse-clinical-features-and-poor-outcomes/2023-08-22T20:04:39+00:00https://lymphoma-stg.clarovantdigital.com/library/a-rare-entity-of-accelerated-chronic-lymphocytic-leukemia-a-report-of-two-cases-and-review-of-literature/2023-08-22T20:09:10+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-post-treatment-serum-soluble-interleukin-2-receptor-in-newly-diagnosed-diffuse-large-b-cell-lymphoma-patients-who-achieved-complete-metabolic-response-following-r-chop-therapy/2023-08-22T20:18:16+00:00https://lymphoma-stg.clarovantdigital.com/library/classical-hodgkin-lymphoma-following-follicular-lymphoma-a-case-report/2023-08-22T20:25:00+00:00https://lymphoma-stg.clarovantdigital.com/library/multiply-relapsed-secondary-cns-non-germinal-center-diffuse-large-b-cell-lymphoma-successfully-treated-with-cns-centric-therapy/2023-08-22T20:43:35+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-overall-survival-analysis-of-the-phase-3-randomized-zuma%e2%80%917-study-of-axicabtagene-ciloleucel-versus-standard%e2%80%91of%e2%80%91care-therapy-in-relapsed-refractory-large-b-cell-lymphoma/2023-08-28T20:18:35+00:00https://lymphoma-stg.clarovantdigital.com/library/triple-lymphoma-and-transformation-to-diffuse-large-b-cell-lymphoma-finding-at-the-time-of-diagnosis/2023-09-04T12:52:11+00:00https://lymphoma-stg.clarovantdigital.com/library/overcoming-chemotherapy-resistance-in-cutaneous-t-cell-lymphoma-a-successful-case-of-high-dose-radiotherapy-management/2023-09-04T12:53:48+00:00https://lymphoma-stg.clarovantdigital.com/library/a-case-of-hodgkins-lymphoma-diagnosed-by-endobronchial-ultrasound-guided-transbronchial-forceps-biopsies/2023-09-04T12:56:12+00:00https://lymphoma-stg.clarovantdigital.com/library/how-do-we-place-monoclonal-b-cell-lymphocytosis-in-the-context-of-early-asymptomatic-chronic-lymphocytic-leukemia/2023-09-04T12:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/no-sex-differential-in-relative-survivano-sex-differential-in-relative-survival-among-older-patients-with-dlbcl-treated-with-r-chop21-a-population-based-studyl-among-older-patients-with-dlbcl-treated/2023-09-19T14:25:47+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-in-patients-with-diffuse-large-b-cell-lymphoma-undergoing-autologous-stem-cell-transplantation-2/2026-01-14T20:42:27+00:00https://lymphoma-stg.clarovantdigital.com/library/xpo1-mutations-identify-early-stage-cll-characterized-by-shorter-time-to-first-treatment-and-enhanced-bcr-signalling/2023-09-19T17:07:36+00:00https://lymphoma-stg.clarovantdigital.com/library/br-vs-r%e2%80%91minichop-in-unfit-patients-with-b%e2%80%91cell-non%e2%80%91hodgkin-lymphoma-a-randomized-two%e2%80%91center-cohort-study/2023-09-19T17:21:01+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-quality-of-life-data-from-the-phase-3b-venice-ii-trial-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-receiving-venetoclax-monotherapy/2023-09-19T17:42:19+00:00https://lymphoma-stg.clarovantdigital.com/library/factors-determining-whether-diffuse-large-b-cell-lymphoma-samples-are-detected-by-flow-cytometry/2023-09-19T20:27:45+00:00https://lymphoma-stg.clarovantdigital.com/library/selinexor-with-anti-pd-1-antibody-as-a-potentially-effective-regimen-for-patients-with-natural-killer-t-cell-lymphoma-failing-prior-l-asparaginase-and-pd-1-blockade/2023-09-19T21:03:10+00:00https://lymphoma-stg.clarovantdigital.com/library/beyond-brutons-tyrosine-kinase-inhibitors-in-mantle-cell-lymphoma-bispecific-antibodies-antibody-drug-conjugates-car-t%e2%80%91cells-and-novel-agents/2025-12-15T22:32:40+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-comparison-of-first-line-treatment-adherence-between-single-agent-ibrutinib-and-acalabrutinib-in-patients-with-chronic-lymphocytic-leukemia/2023-09-19T21:11:12+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evidence-on-the-clinical-characteristics-and-management-of-patients-with-chronic-lymphocytic-leukemia-in-spain-using-natural-language-processing-the-srealcll-study/2023-09-19T21:21:00+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-in-transplant-eligible-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-after-second-line-salvage-chemotherapy-a-retrospective-study/2023-09-19T21:26:47+00:00https://lymphoma-stg.clarovantdigital.com/library/parsaclisib-a-pi3k%ce%b4-inhibitor-in-relapsed-and-refractory-mantle-cell-lymphoma-citadel-205-a-phase-2-study/2023-09-26T12:34:19+00:00https://lymphoma-stg.clarovantdigital.com/library/a-validated-composite-comorbidity-index-predicts-outcomes-of-car-t-cell-therapy-in-patients-with-diffuse-large-b-cell-lymphoma/2026-01-14T21:37:11+00:00https://lymphoma-stg.clarovantdigital.com/library/myc-overexpression-but-not-myc-bcl2-double-expression-predicts-survival-in-bulky-mass-diffuse-large-b-cell-lymphoma-patients/2023-09-26T13:57:33+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-role-of-red-cell-distribution-width-rdw-in-patients-with-diffuse-large-b-cell-lymphoma/2023-09-26T14:04:59+00:00https://lymphoma-stg.clarovantdigital.com/library/systematic-review-of-perchloroethylene-and-non-hodgkins-lymphoma/2023-09-26T14:25:46+00:00https://lymphoma-stg.clarovantdigital.com/library/subclonal-tp53-mutations-are-frequent-and-predict-resistance-to-radioimmunotherapy-in-follicular-lymphoma/2025-12-15T21:21:52+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-of-polatuzumab-vedotin-bendamustine-rituximab-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2023-09-26T20:46:27+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-myd88-and-tp53-mutations-in-diffuse-large-b-cell-lymphoma/2023-09-26T20:59:26+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-immune-checkpoint-molecule-pd-l1-in-classical-hodgkin-lymphoma-a-clinicopathologic-study-of-120-cases/2023-09-26T21:06:47+00:00https://lymphoma-stg.clarovantdigital.com/library/nine-year-follow-up-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma/2023-09-26T21:15:30+00:00https://lymphoma-stg.clarovantdigital.com/library/from-genetics-to-therapy-unraveling-the-complexities-of-richter-transformation-in-chronic-lymphocytic-leukemia/2023-09-26T21:25:07+00:00https://lymphoma-stg.clarovantdigital.com/library/next%e2%80%91generation-sequencing-optimal-sequencing-of-therapies-in-relapsed-refractory-chronic-lymphocytic-leukemia-cll/2023-09-26T21:32:48+00:00https://lymphoma-stg.clarovantdigital.com/library/differences-in-mutational-signature-of-diffuse-large-b-cell-lymphomas-according-to-the-primary-organ/2023-09-27T14:48:38+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-of-second-line-versus-later-line-zanubrutinib-treatment-in-patients-with-relapsed-refractory-mantle-cell-lymphoma-an-updated-pooled-analysis/2023-09-27T17:11:48+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-survival-benefit-of-anti-pd-1-therapy-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma/2023-09-27T17:31:14+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-checkpoint-inhibition-after-car-t-failure-in-aggressive-b-cell-lymphomas-outcomes-from-15-us-institutions/2025-12-19T18:13:57+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-and-prognostic-factors-of-pediatric-patients-with-hodgkin-lymphoma-a-single%e2%80%91center-experience/2023-09-27T18:05:11+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-in-large-b-cell-lymphoma-ineligible-for-autologous-stem-cell-transplantation-the-phase-2-alycante-trial/2026-01-14T21:36:28+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-eshap-versus-ice-plus-dexamethasone-dice-as-salvage-chemotherapy-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2026-01-15T14:09:42+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-loncastuximab-tesirine-may-be-beneficial-earlier-on-in-r-r-dlbcl-treatment/2023-09-29T14:34:08+00:00https://lymphoma-stg.clarovantdigital.com/library/ctdna-may-play-role-in-large-cell-lymphoma-detection/2023-09-29T14:34:09+00:00https://lymphoma-stg.clarovantdigital.com/library/study-questions-value-of-interim-pet-imaging-to-guide-frontline-hodgkin-treatment/2023-09-29T14:34:09+00:00https://lymphoma-stg.clarovantdigital.com/library/consolidative-autotransplant-achieves-high-cure-rates-in-adverse-risk-large-b-cell-lymphoma/2023-09-29T14:34:09+00:00https://lymphoma-stg.clarovantdigital.com/library/causes-of-death-in-patients-with-diffuse-large-b-cell-lymphoma-in-armenia/2023-09-29T14:34:09+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-multi-hit-vs-single-hit-tp53-mutations-in-chronic-lymphocytic-leukemia/2023-09-29T14:34:09+00:00https://lymphoma-stg.clarovantdigital.com/library/metformin-in-combination-with-the-standard-therapy-in-patients-with-diffuse-large-b-cell-lymphoma-a-randomized-phase-ii-clinical-trial/2023-09-29T14:34:09+00:00https://lymphoma-stg.clarovantdigital.com/library/transcend-fl-phase-ii-study-results-of-lisocabtagene-maraleucel-liso-cel-in-patients-with-r-r-follicular-lymphoma-fl/2026-01-14T22:10:26+00:00https://lymphoma-stg.clarovantdigital.com/library/anti-cd19-chimeric-antigen-receptor-t-cell-therapy-with-tisagenlecleucel-for-secondary-central-nervous-system-lymphoma-a-case-series/2023-09-29T14:34:09+00:00https://lymphoma-stg.clarovantdigital.com/library/rosewood-a-phase-ii-randomized-study-of-zanubrutinib-plus-obinutuzumab-versus-obinutuzumab-monotherapy-in-patients-with-relapsed-or-refractory-follicular-lymphoma/2023-09-29T14:34:10+00:00https://lymphoma-stg.clarovantdigital.com/library/vemurafenib-and-obinutuzumab-as-frontline-therapy-for-hairy-cell-leukemia/2025-07-03T17:23:59+00:00https://lymphoma-stg.clarovantdigital.com/library/incorporation-of-ruxolitinib-in-the-management-of-refractory-relapsed-hodgkin-lymphoma/2023-09-29T14:34:10+00:00https://lymphoma-stg.clarovantdigital.com/library/effectiveness-and-safety-of-pembrolizumab-in-recurrent-and-relapsed-classic-hodgkin-lymphoma-a-systematic-review/2023-09-29T14:34:10+00:00https://lymphoma-stg.clarovantdigital.com/library/combined-therapy-with-ibrutinib-and-bortezomib-followed-by-ibrutinib-maintenance-in-relapsed-or-refractory-mantle-cell-lymphoma-and-high-risk-features-a-phase-1-2-trial-of-the-european-mcl-network-s/2023-09-29T14:34:10+00:00https://lymphoma-stg.clarovantdigital.com/library/composite-classical-hodgkin-lymphoma-and-mantle-cell-lymphoma-a-case-report/2023-09-29T14:34:10+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-after-chimeric-antigen-receptor-car-t-cell-therapy-failure-in-large-b-cell-lymphomas/2023-09-29T14:34:11+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-past-present-and-future/2023-09-29T14:34:11+00:00https://lymphoma-stg.clarovantdigital.com/library/hairy-cell-leukemia-hematological-and-immunophenotypic-profile-of-13-patients/2023-09-29T14:34:11+00:00https://lymphoma-stg.clarovantdigital.com/library/estimating-the-lifetime-treatment-burden-of-patients-with-follicular-lymphoma-a-retrospective-study-using-real-world-multicenter-data/2023-09-29T14:34:11+00:00https://lymphoma-stg.clarovantdigital.com/library/ct-based-body-composition-in-diffuse-large-b-cell-lymphoma-patients-changes-after-treatment-and-association-with-survival/2023-10-17T09:19:00+00:00https://lymphoma-stg.clarovantdigital.com/library/mutations-associated-with-progression-in-follicular-lymphoma-predict-inferior-outcomes-at-diagnosis-alliance-a151303-2/2023-10-17T09:30:36+00:00https://lymphoma-stg.clarovantdigital.com/library/the-eortc-qlq-hl27prospective-international-validation-of-a-quality-of-life-questionnaire-for-hodgkin-lymphoma-patients/2023-10-17T09:38:50+00:00https://lymphoma-stg.clarovantdigital.com/library/patterns-of-pet%e2%80%91positive-residual-tissue-at-interim-restaging-and-risk-of-treatment-failure-in-advanced%e2%80%91stage-hodgkins-lymphoma-an-analysis-of-the-randomized-phase-iii-hd18-t/2023-10-17T11:52:55+00:00https://lymphoma-stg.clarovantdigital.com/library/high-prevalence-of-past-hepatitis-b-virus-infection-in-diffuse-large-b-cell-lymphoma-a-retrospective-study-from-italy/2023-10-17T12:05:31+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukaemia-australasian-consensus-practice-statement/2023-10-17T12:35:03+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-maintenance-following-frontline-treatment-in-patients-with-mantle-cell-lymphoma/2023-10-18T11:50:50+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-adherence-and-discontinuation-among-medicare-beneficiaries-initiating-venetoclax-vs-btkis-in-relapsed-refractory-chronic-lymphocytic-leukemia/2023-10-24T16:57:47+00:00https://lymphoma-stg.clarovantdigital.com/library/loncastuximab-tesirine-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-long-term-efficacy-and-safety-from-the-phase-2-lotis-2-study/2023-10-24T15:45:30+00:00https://lymphoma-stg.clarovantdigital.com/library/targeted-therapy-in-follicular-lymphoma-towards-a-chemotherapy-free-approach/2023-10-24T15:50:49+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-immunotherapy-for-the-treatment-of-cutaneous-t-cell-lymphoma/2025-06-05T21:42:49+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-in-combination-with-chop-in-previously-untreated-dlbcl-safety-and-efficacy-results-from-a-phase-2-study/2026-01-14T21:36:00+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-scholar-1-criteria-on-chimeric-antigen-receptor-t-cell-therapy-efficacy-in-aggressive-b-lymphoma-a-real-world-geltamo-geth-study/2023-10-24T17:28:43+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-subtype-guided-immunochemotherapy-in-diffuse-large-b-cell-lymphoma-the-randomized-guidance-01-trial/2023-10-24T18:51:58+00:00https://lymphoma-stg.clarovantdigital.com/library/scientific-techniques-in-adolescent-and-young-adult-classic-hodgkin-lymphoma/2023-10-24T19:03:55+00:00https://lymphoma-stg.clarovantdigital.com/library/the-car-hematotox-score-identifies-patients-at-high-risk-for-hematological-toxicity-infectious-complications-and-poor-treatment-outcomes-following-brexucabtagene-autoleucel-for-relapsed-or-refractor/2023-10-24T19:38:05+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-survival-of-children-and-adolescents-with-classical-hodgkin-lymphoma-treated-on-a-harmonised-protocol-in-south-africa/2023-10-24T19:44:50+00:00https://lymphoma-stg.clarovantdigital.com/library/post-transplantation-burkitt-lymphoma-a-retrospective-study-of-55-patients/2023-10-24T19:51:59+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-diffuse-large-b-cell-lymphoma-in-the-biosimilar-era/2023-10-24T20:15:45+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-depleted-tumor-microenvironment-is-associated-with-poor-outcomes-and-btk-inhibitor-resistance-in-mantle-cell-lymphoma/2023-10-24T20:31:23+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-expenditures-and-survival-time-after-car-t-treatment-for-large-b-cell-lymphoma-in-switzerland-a-retrospective-study-using-insurance-claims-data/2023-10-24T20:37:17+00:00https://lymphoma-stg.clarovantdigital.com/library/the-evolving-landscape-of-covid-19-and-post-covid-condition-in-patients-with-chronic-lymphocytic-leukemia-a-study-by-eric-the-european-research-initiative-on-cll/2023-10-24T20:44:32+00:00https://lymphoma-stg.clarovantdigital.com/library/the-salvage-role-of-allogeneic-hematopoietic-stem%e2%80%91cell-transplantation-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2023-10-24T20:53:14+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-polatuzumab-vedotin-piiq-therapy-a-review-of-treatment-efficacy-in-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma/2023-10-24T20:58:04+00:00https://lymphoma-stg.clarovantdigital.com/library/marital-status-independently-predicts-the-overall-survival-in-young-adult-patients-with-lymphoma-a-population-based-propensity-matched-study/2023-10-24T21:08:40+00:00https://lymphoma-stg.clarovantdigital.com/library/redefining-efficacy-and-safety-endpoints-for-chronic-lymphocytic-leukemia-in-the-era-of-targeted-therapy/2023-10-24T21:32:16+00:00https://lymphoma-stg.clarovantdigital.com/library/fdg-pet-ct-provides-clues-on-bone-marrow-involvement-in-follicular-lymphoma-and-carries-important-prognostic-information/2025-12-15T22:15:27+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-3-selene-study-ibrutinib-plus-br-r-chop-in-previously-treated-patients-with-follicular-or-marginal-zone-lymphoma/2023-10-25T00:15:14+00:00https://lymphoma-stg.clarovantdigital.com/library/indirect-treatment-comparison-of-brexucabtagene-autoleucel-zuma-2-versus-standard-of-care-scholar-2-in-relapsed-refractory-mantle-cell-lymphoma/2023-10-25T00:20:38+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-effectiveness-between-mosunetuzumab-monotherapy-clinical-trial-and-real-world-data-in-relapsed-refractory-follicular-lymphoma-in-third-or-subsequent-lines-of-systemic-therapy/2023-10-25T00:29:54+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-new%e2%80%91generation-bruton-tyrosine-kinase-inhibitors-in-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-a-systematic-review-and-meta%e2%80%91analysis/2025-03-03T19:35:42+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-adolescents-and-young-adults-with-diffuse-large-b-cell-lymphoma-a-multicenter-retrospective-cohort-study/2023-10-25T14:22:54+00:00https://lymphoma-stg.clarovantdigital.com/library/radiotherapy-for-non-hodgkins-lymphoma-with-cardiac-infiltration-a-case-report/2023-10-25T14:30:43+00:00https://lymphoma-stg.clarovantdigital.com/library/immunochemotherapy-combined-with-novel-agents-for-richter-syndrome-report-of-3-cases/2023-10-25T14:40:27+00:00https://lymphoma-stg.clarovantdigital.com/library/response-adapted-time-limited-venetoclax-umbralisib-ublituximab-for-relapsed-refractory-chronic-lymphocytic-leukemia/2023-10-25T14:50:38+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-discontinuation-and-associated-factors-in-a-real-world-national-sample-of-elderly-medicare-beneficiaries-with-chronic-lymphocytic-leukemia/2025-12-19T18:13:29+00:00https://lymphoma-stg.clarovantdigital.com/library/men-treated-with-beacopp-for-hodgkin-lymphoma-may-be-at-increased-risk-of-testosterone-deficiency/2023-10-25T15:07:39+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-chimeric-antigen-receptor-car-t-cell-therapy-in-patients-with-large-b-cell-lymphoma-lbcl-a-single-institution-experience/2023-10-25T17:28:52+00:00https://lymphoma-stg.clarovantdigital.com/library/hepatitis-b-virus-associated-diffuse-large-b-cell-lymphoma-epidemiology-biology-clinical-features-and-hbv-reactivation/2023-10-25T17:33:26+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-hepatitis-b-virus-and-hepatitis-c-virus-infections-in-patients-with-hodgkins-and-non-hodgkins-lymphoma/2023-10-25T18:21:19+00:00https://lymphoma-stg.clarovantdigital.com/library/second-primary-malignancy-risk-after-hodgkin-lymphoma-treatment-among-hiv-uninfected-and-hiv-infected-survivors/2023-10-25T18:25:45+00:00https://lymphoma-stg.clarovantdigital.com/library/t-cell-engaging-antibodies-in-diffuse-large-b-cell-lymphoma/2023-10-25T18:30:40+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-blastoid-and-pleomorphic-variant-mantle-cell-lymphoma/2023-10-25T18:35:03+00:00https://lymphoma-stg.clarovantdigital.com/library/a-rare-first-presentation-of-hodgkins-lymphoma-symptomatic-pericardial-effusion/2023-10-25T18:53:26+00:00https://lymphoma-stg.clarovantdigital.com/library/cd19-targeted-chimeric-antigen-receptor-t-cell-therapy-for-concomitant-diffuse-large-b-cell-lymphoma-and-multiple-myeloma/2023-10-25T18:53:27+00:00https://lymphoma-stg.clarovantdigital.com/library/developing-cancer-rehabilitation-services-and-research-in-low-income-and-middle-income-countries-the-case-for-zambia-and-key-messages/2023-10-25T18:53:27+00:00https://lymphoma-stg.clarovantdigital.com/library/ctdna-pushes-its-prognostic-role-in-large-cell-lymphomas/2023-10-25T18:53:27+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-and-rituximab-continues-to-best-bendamustine-rituximab-in-relapsed-refractory-cll/2026-01-14T21:05:21+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-sobuzoxane-plus-etoposide-and-rituximab-is-safe-and-effective-in-older-dlbcl-population/2023-10-25T18:53:27+00:00https://lymphoma-stg.clarovantdigital.com/library/consolidative-radio-therapy-in-place-of-autologous-stem-cell-transplant-in-patients-with-low-risk-relapsed-refractory-r-r-classic-hodgkin-lymphoma-chl-treated-with-nivolumab-plus-brentuximab-vedot/2023-10-25T18:53:27+00:00https://lymphoma-stg.clarovantdigital.com/library/importance-of-low-and-moderate-grade-adverse-events-in-patients-treatment-experience-and-treatment-discontinuation-an-analysis-of-the-e1912-trial/2023-10-25T18:53:27+00:00https://lymphoma-stg.clarovantdigital.com/library/high-grade-b-cell-lymphoma-not-otherwise-specified-a-multi-institutional-retrospective-study/2023-10-26T13:59:41+00:00https://lymphoma-stg.clarovantdigital.com/library/antinuclear-antibodies-are-associated-with-an-increased-risk-of-diffuse-large-b-cell-lymphoma/2023-11-02T19:07:18+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-markers-within-the-tumour-microenvironment-in-classical-hodgkin-lymphoma/2023-11-02T20:20:52+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-zanubrutinib-plus-r-chop-in-treatment-of-non-gcb-dlbcl-with-extranodal-involvement/2023-11-02T20:26:06+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathologic-and-mutational-profiles-of-primary-breast-diffuse-large-b-cell-lymphoma-in-a-male-patient-case-report-and-literature-review/2023-11-07T21:18:59+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-and-outcomes-of-primary-breast-diffuse-large-b-cell-lymphoma-a-matched-pair-study/2023-11-02T20:41:24+00:00https://lymphoma-stg.clarovantdigital.com/library/image-based-deep-learning-detection-of-high-grade-b-cell-lymphomas-directly-from-hematoxylin-and-eosin-images/2023-11-03T13:51:30+00:00https://lymphoma-stg.clarovantdigital.com/library/the-shifting-therapeutic-paradigm-for-relapsed-refractory-mantle-cell-lymphoma/2023-11-03T14:00:00+00:00https://lymphoma-stg.clarovantdigital.com/library/overall-survival-and-causes-of-death-in-elderly-patients-with-hodgkin-lymphoma-a-norwegian-population-based-case-control-study/2023-11-03T14:03:39+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnostic-approach-to-pulmonary-b-cell-lymphomas-in-small-biopsies-with-practical-recommendations-to-avoid-misinterpretation/2023-11-03T20:03:44+00:00https://lymphoma-stg.clarovantdigital.com/library/a-population-based-family-case-control-study-of-sun-exposure-and-follicular-lymphoma-risk/2026-05-26T20:42:14+00:00https://lymphoma-stg.clarovantdigital.com/library/importance-of-mrd-in-the-era-of-targeted-therapies-in-cll/2023-11-16T15:58:47+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-classic-hodgkin-lymphoma-on-informal-caregivers-results-from-the-connect-cross%e2%80%91sectional-survey/2023-11-07T21:34:05+00:00https://lymphoma-stg.clarovantdigital.com/library/follow-up-of-the-ghsg-hd16-trial-of-pet-guided-treatment-in-early-stage-favorable-hodgkin-lymphoma/2023-11-07T21:41:09+00:00https://lymphoma-stg.clarovantdigital.com/library/coping-and-perception-of-prognosis-in-patients-with-indolent-non-hodgkins-lymphoma/2025-04-14T21:02:20+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-outcomes-of-single-agent-ibrutinib-therapy-in-chronic-lymphocytic-leukemia-and-relapsed-refractory-mantle-cell-lymphoma/2023-11-08T21:47:15+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-orelabrutinib%e2%80%91based-regimens-in-diffuse-large-b%e2%80%91cell-lymphoma-a-single%e2%80%91center-retrospective-analysis/2023-11-08T22:07:08+00:00https://lymphoma-stg.clarovantdigital.com/library/case-report-of-rare-primary-gastric-large-b-cell-lymphoma/2023-11-09T14:49:41+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-compared-to-standard-of-care-in-swedish-patients-with-large-b-cell-lymphoma-a-cost-effectiveness-analysis-of-the-zuma-7-trial/2023-11-09T15:14:40+00:00https://lymphoma-stg.clarovantdigital.com/library/subcutaneous-epcoritamab-monotherapy-in-japanese-adults-with-relapsed-refractory-diffuse-large-b-cell-lymphoma/2026-01-14T21:35:39+00:00https://lymphoma-stg.clarovantdigital.com/library/functional-drivers-of-resistance-to-anti-cd19-car-t-cell-therapy-in-diffuse-large-b-cell-lymphoma/2023-11-09T15:36:45+00:00https://lymphoma-stg.clarovantdigital.com/library/vitamin-d-insufficiency-and-clinical-outcomes-with-chimeric-antigen-receptor-t-cell-therapy-in-large-b-cell-lymphoma/2023-11-09T15:46:08+00:00https://lymphoma-stg.clarovantdigital.com/library/clonal-relationship-and-mutation-analysis-in-lymphoplasmacytic-lymphoma-waldenstrom-macroglobulinemia-associated-with-diffuse-large-b-cell-lymphoma/2023-11-09T17:00:29+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-absolute-peripheral-blood-nk-cell-count-after-four-cycles-of-r%e2%80%91chop%e2%80%91like-regimen-treatment-in-patients-with-diffuse-large-b-cell-lymphoma/2023-11-09T17:11:21+00:00https://lymphoma-stg.clarovantdigital.com/library/significance-of-e-lesions-in-hodgkin-lymphoma-and-the-creation-of-a-new-consensus-definition-a-report-from-search/2023-11-09T17:20:04+00:00https://lymphoma-stg.clarovantdigital.com/library/secondary-malignancies-among-mantle-cell-lymphoma-patients/2023-11-09T17:20:04+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-the-response-adjusted-therapy-for-advanced-hodgkin-lymphoma-trial/2023-11-09T17:20:05+00:00https://lymphoma-stg.clarovantdigital.com/library/radioimmunotherapy-versus-autologous-hematopoietic-stem-cell-transplantation-in-relapse-refractory-follicular-lymphoma-a-fondazione-italiana-linfomi-multicenter-randomized-phase-3-trial/2023-11-09T17:20:05+00:00https://lymphoma-stg.clarovantdigital.com/library/death-from-mantle-cell-lymphoma-limits-sequential-therapy-particularly-after-first-relapse-patterns-of-care-and-outcomes-in-a-series-from-australia-and-the-united-kingdom/2023-11-09T17:20:05+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnosis-and-management-of-mantle-cell-lymphoma-a-british-society-for-haematology-guideline/2023-11-09T17:20:05+00:00https://lymphoma-stg.clarovantdigital.com/library/evolving-treatment-patterns-and-improved-outcomes-in-relapsed-refractory-mantle-cell-lymphoma-a-prospective-cohort-study/2023-11-16T15:52:59+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-strategy-in-chronic-lymphocytic-leukemia-with-symptomatic-central-nervous-system-involvement-a-case-report/2023-11-16T15:57:29+00:00https://lymphoma-stg.clarovantdigital.com/library/absence-of-btk-bcl2-and-plcg2-mutations-in-chronic-lymphocytic-leukemia-relapsing-after-first-line-treatment-with-fixed-duration-ibrutinib-plus-venetoclax/2023-11-16T16:04:24+00:00https://lymphoma-stg.clarovantdigital.com/library/a-low-total-metabolic-tumor-volume-independently-predicts-for-a-longer-time-to-first-treatment-in-initially-observed-low-tumor-burden-follicular-lymphoma/2023-11-16T19:28:37+00:00https://lymphoma-stg.clarovantdigital.com/library/australian-data-on-the-utilisation-and-duration-on-treatment-of-ibrutinib-with-a-proton-pump-inhibitor-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukaemia/2023-11-16T20:03:07+00:00https://lymphoma-stg.clarovantdigital.com/library/ebf1-myo6-and-calr-expression-levels-predict-therapeutic-response-in-diffuse-large-b-cell-lymphomas/2026-01-15T16:25:43+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-of-bendamustine-for-the-treatment-of-indolent-non-hodgkin-lymphoma-a-uk-real-world-experience/2023-11-17T00:31:27+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-prognostic-factors-for-primary-pediatric-and-adolescent-non%e2%80%91hodgkin-lymphomas-of-the-gastrointestinal-tract-a-population%e2%80%91based-study/2023-11-17T00:37:12+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-frontline-chemotherapy-for-extranodal-natural-killer-t-cell-lymphoma-a-systematic-review-and-network-meta-analysis/2023-11-17T18:39:36+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-in-treating-chinese-patients-with-lymphoma-a-multicenter-real-world-study/2023-11-17T19:31:08+00:00https://lymphoma-stg.clarovantdigital.com/library/a-decade-of-cd4-chimeric-antigen-receptor-t-cell-evolution-in-two-chronic-lymphocytic-leukemia-patients-were-chronic-lymphocytic-leukemia-cells-present/2023-11-17T19:43:46+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-r-pvp-effective-in-older-patients-with-dlbcl/2023-11-17T19:53:53+00:00https://lymphoma-stg.clarovantdigital.com/library/p1081-a-multicenter-observational-study-on-chimeric-antigen-receptor-t-cell-therapy-for-large-b-cell-lbcl-and-mantle-cell-mcl-lymphomas-the-italian-cart-sie-real-life-experience/2023-11-17T19:53:54+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-transformed-diffuse-large-b-cell-lymphoma-dlbcl/2023-11-17T19:53:54+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-and-primary-treatment-outcomes-for-mantle-cell-lymphoma-peruvian-national-cancer-institute/2023-11-17T19:53:54+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-reference-vs-biosimilar-utilization-for-oncology-vs-nononcology-indications/2023-11-17T19:53:54+00:00https://lymphoma-stg.clarovantdigital.com/library/recent-bendamustine-treatment-before-apheresis-has-a-negative-impact-on-outcomes-in-patients-with-large-b-cell-lymphoma-receiving-chimeric-antigen-receptor-t-cell-therapy-2/2023-11-17T19:53:54+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-the-response-adapted-intergroup-eortc-lysa-fil-h10-trial-for-localized-hodgkin-lymphoma/2023-11-17T19:53:54+00:00https://lymphoma-stg.clarovantdigital.com/library/other-malignancies-in-the-history-of-cll-an-international-multicenter-study-conducted-by-eric-the-european-research-initiative-on-cll-in-harmony/2023-11-17T19:53:55+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-hematological-malignancies-from-ct-radiation-exposure-in-children-adolescents-and-young-adults/2023-11-17T19:53:55+00:00https://lymphoma-stg.clarovantdigital.com/library/indirect-treatment-comparisons-of-mosunetuzumab-with-third-and-later-line-treatments-for-relapsed-refractory-follicular-lymphoma/2023-11-21T14:43:25+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-arid1a-and-tp53-mutations-in-pediatric-refractory-or-relapsed-mature-b-cell-lymphoma-treated-with-car-t-cell-therapy/2023-11-21T14:51:49+00:00https://lymphoma-stg.clarovantdigital.com/library/blinatumomab-consolidation-post-autologous-stem-cell-transplantation-in-patients-with-diffuse-large-b-cell-lymphoma/2023-11-21T15:00:28+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-diagnosis-treatment-and-prognostic-factors-of-gastrointestinal-dlbcl/2023-11-21T15:09:02+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-for-classical-hodgkin-lymphoma/2023-11-21T15:24:49+00:00https://lymphoma-stg.clarovantdigital.com/library/pilot-study-of-lung-cancer-screening-for-survivors-of-hodgkin-lymphoma/2023-11-21T15:28:57+00:00https://lymphoma-stg.clarovantdigital.com/library/dual-target-dilemma-navigating-epcoritamab-vs-glofitamab-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2026-01-14T18:14:59+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-in-mantle-cell-lymphoma-management-a-comprehensive-review/2023-11-27T15:35:17+00:00https://lymphoma-stg.clarovantdigital.com/library/revolutionizing-chronic-lymphocytic-leukemia-diagnosis-a-deep-dive-into-the-diverse-applications-of-machine-learning/2023-11-27T15:40:20+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-complete-remission-and-peripheral-biomarkers-in-hodgkin-lymphoma-patients-after-decitabine-plus-camrelizumab-epi-immunotherapy-and-treatment-cessation/2023-11-27T15:49:20+00:00https://lymphoma-stg.clarovantdigital.com/library/salvage-radiotherapy-in-relapsed-refractory-large-b-cell-lymphoma-after-failure-of-car-t-cell-therapy/2025-05-27T12:07:51+00:00https://lymphoma-stg.clarovantdigital.com/library/dlbcl-arising-from-indolent-lymphomas-how-are-they-different/2025-03-04T17:59:48+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-breast-diffuse-large-b-cell-lymphoma-in-the-rituximab-era-a-retrospective-study-of-the-chinese-southwest-oncology-group/2023-11-27T17:41:21+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-potential-of-galectin-9-mrna-expression-in-chronic-lymphocytic-leukemia/2023-11-27T17:48:19+00:00https://lymphoma-stg.clarovantdigital.com/library/three-year-follow-up-analysis-of-axicabtagene-ciloleucel-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-zuma-5/2023-11-27T17:58:01+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-of-patients-with-transformed-follicular-lymphoma-in-the-united-states-a-multiple-cohort-study/2025-12-19T18:13:04+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-sequencing-and-outcome-of-chronic-lymphocytic-leukemia-patients-treated-at-fondazione-policlinico-universitario-agostino-gemelli-irccs-a-thirty-year-single-center-experience/2023-11-27T18:07:49+00:00https://lymphoma-stg.clarovantdigital.com/library/r-chop-treatment-for-patients-with-advanced-follicular-lymphoma-over-15-year-follow-up-of-jcog0203/2023-11-27T18:12:28+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-%c2%b1-obinutuzumab-vs-obinutuzumab-chlorambucil-in-treatment-naive-chronic-lymphocytic-leukemia-6-year-follow-up-of-elevate-tn/2023-12-12T15:24:59+00:00https://lymphoma-stg.clarovantdigital.com/library/cytokine-release-syndrome-in-patients-treated-with-chimeric-antigen-receptor-t-cell-therapy-a-retrospective-study-analyzing-risks-outcomes-and-healthcare-burden/2023-12-14T16:55:54+00:00https://lymphoma-stg.clarovantdigital.com/library/improvements-in-patient-reported-outcomes-in-relapsed-or-refractory-large-b-cell-lymphoma-patients-treated-with-epcoritamab/2026-01-14T19:39:11+00:00https://lymphoma-stg.clarovantdigital.com/library/predictive-value-of-minimal-residual-disease-for-efficacy-of-rituximab-maintenance-in-mantle-cell-lymphoma-results-from-the-european-mantle-cell-lymphoma-elderly-trial/2026-01-14T21:04:53+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-diffuse-large-b-cell-lymphoma-treated-with-r-choplike-therapy-in-an-asian-multi-ethnic-population/2023-12-14T16:55:56+00:00https://lymphoma-stg.clarovantdigital.com/library/unmet-need-in-relapsed-refractory-rr-mantle-cell-lymphoma-mcl-post-bruton-tyrosine-kinase-inhibitor-btki-systematic-literature-review-and-meta-analysis/2023-12-14T16:55:56+00:00https://lymphoma-stg.clarovantdigital.com/library/time-to-lymphoma-treatment-within-24-months-in-watchful-waiting-follicular-lymphoma-defines-patients-at-high-risk-for-progression/2023-12-14T16:55:56+00:00https://lymphoma-stg.clarovantdigital.com/library/extended-follow-up-of-alpine-randomized-phase-3-study-confirms-sustained-superior-progression-free-survival-of-zanubrutinib-versus-ibrutinib-for-treatment-of-relapsed-refractory-chronic-lymphocytic-le/2025-12-15T22:28:22+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-intensity-and-outcomes-in-elderly-patients-with-dlbcl-receiving-first-line-therapy/2023-12-14T16:55:57+00:00https://lymphoma-stg.clarovantdigital.com/library/early-stage-follicular-lymphoma-learnings-from-the-final-analysis-of-the-multicenter-phase-ii-fil-fondazione-italiana-linfomi-miro-trial-combining-local-radiotherapy-and-mrd-driven-immunotherapy/2026-01-14T21:04:04+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-tafasitamab-with-or-without-lenalidomide-added-to-first-line-r-chop-for-dlbcl-the-phase-1b-first-mind-study/2023-12-14T16:55:57+00:00https://lymphoma-stg.clarovantdigital.com/library/endemic-burkitts-lymphoma-the-pathogenic-link-with-malaria-infection-a-systematic-review/2023-12-14T16:55:58+00:00https://lymphoma-stg.clarovantdigital.com/library/smart-stop-lenalidomide-tafasitamab-rituximab-and-acalabrutinib-alone-and-with-combination-chemotherapy-for-the-treatment-of-newly-diagnosed-diffuse-large-b-cell-lymphoma/2023-12-14T16:55:58+00:00https://lymphoma-stg.clarovantdigital.com/library/golidocitinib-in-treating-refractory-or-relapsed-peripheral-t-cell-lymphoma-full-analysis-of-the-multinational-pivotal-study-results-jackpot8/2023-12-14T16:55:58+00:00https://lymphoma-stg.clarovantdigital.com/library/tolerability-and-outcomes-of-bruton-tyrosine-kinase-inhibitors-for-chronic-lymphocytic-leukemia-in-patients-with-severe-renal-dysfunction/2023-12-14T16:55:58+00:00